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The early stages of the genome-wide association study (GWAS) era were dominated 
by studies focusing on single phenotypes, while in recent years there has been 
growing interest in multi-trait GWAS. A wide variety of multi-trait GWAS methods 
have been developed, but publications introducing new methods are highly 
inconsistent in their evaluation of method performance, obscuring their relative merit. 
Facilitated by burgeoning national biobank resources, multi-trait analyses are set to 
become more routinely applied, making understanding their relative performance 
increasingly important. 
 
We develop a simulation framework to model the complex networks underlying 
multivariate genetic epidemiology. We exploit our simulation framework to perform a 
comprehensive comparison study of the leading multi-trait GWAS methods, providing 
a web application and open-source software program implementing our simulation 
framework for further benchmarking of multi-trait GWAS methods. 
 
Motivated by our comparison results, we develop novel methodology and present a 
series of multi-trait analyses. We perform multi-trait genome-wide analyses on 
publicly available GWAS summary statistics on 19 traits – metabolic, anthropometric 
and psychiatric. We develop and apply two summary statistic methods: one that has 
increased power to detect pleiotropic effects on multiple traits, and one that is more 
powerful for detecting heterogeneous genetic effects.  
 
Polygenic risk scores (PRS) are now a commonly used tool for performing phenotype 
prediction from genetics, assessing the genetic aetiology underlying diseases, and 
testing for shared genetic aetiology among traits. Using UK Biobank data, we explore 
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the predictive ability of PRS computed across multiple traits for Major Depressive 
Disorder (MDD). The MDD PRS itself has so far offered modest prediction of MDD 
case/control status; we explore the use of PRS built on traits correlated with MDD to 
improve predictive ability. We build main effect and interaction models, using both 
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Genome-wide association studies (GWAS) traditionally adopt a univariate approach, 
focusing on a single phenotype of interest (Gieger et al., 2011; Teslovich et al., 2010; 
Willer et al., 2008; Morris et al., 2012). In recent years numerous methods have been 
proposed that model multiple phenotypes simultaneously to investigate their joint 
association with single-nucleotide polymorphisms (SNPs) (O’Reilly et al., 2012; van 
der Sluis et al., 2013; Zhu et al., 2015; Ferreira and Purcell, 2009; Klei et al., 2008; 
Aschard et al., 2014; Marchini et al., 2007; Stephens, 2013; Nath and Pavur, 1985; 
Zhou and Stephens, 2014; Korte et al., 2012; Segura et al., 2012; Schifano et al., 
2013) and to increase the statistical power for discovery of susceptibility loci. There 
are also methods that, in addition, model multiple SNPs jointly (Bottolo et al., 2013; 
Servin and Stephens, 2007; Casale et al., 2015) which can lead to increased power 
to detect susceptibility loci due to reduced residual variation. 
 
Methods that model multiple phenotypes jointly could be utilised to uncover 
relationships between phenotypes that do not have established relationships, or 
could be used to modify existing phenotype definitions. The modelling of multiple 
SNPs jointly also allows the exploration of the biological relationships underpinning 
correlated phenotypes. This could highlight genetic pathways important to certain 
groups of phenotypes, and motivate investigation into their shared biology. 
 
So far there has not been an extensive, systematic comparison of multi-trait GWAS 
methods and thus there is no clear overall preference or guidance on when diﬀerent 
multivariate methods should be implemented in order to optimise discovery. 
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Moreover, many of the methods have not been tested under certain scenarios and so 
there is a need for a comprehensive simulation study comparing the relative 
performance of these methods, which may lead to improved methodology. Largely 
due to lack of clarity as to the relative performance of multi-trait GWAS methods 
compared to the univariate approach, there have been few large-scale multi-trait 
GWAS performed (Adhikari et al., 2015, 2016; Kauwe et al., 2014). Producing and 
applying the most powerful method to GWAS will likely lead to new discoveries and 
novel drug targets. 
 
Polygenic risk scores (PRS) (Purcell et al., 2009; Euesden et al., 2015; Dudbridge, 
2013) have so far only been applied to pairs of phenotypes. Often a PRS is built in 
one phenotype then used to predict either itself, to assess the predictive ability of the 
PRS, or to predict another related phenotype to assess the shared genetic aetiology 
between traits. By using PRS built on multiple phenotype predictors that correlate 
with the trait we wish to predict, new insights into the shared biology between 
phenotypes can be gained, as well as informing phenotype stratification. 
 
1.2 Genome-wide association studies 
 
Genome-wide association studies (GWAS) have become a successful tool for 
identifying associations between common genetic variants and many different 
diseases and traits. GWAS test hundreds of thousands of genetic variants, typically 
single nucleotide polymorphisms (SNPs), across the genome for their association 
with a phenotype of interest. Since the emergence of GWAS in 2007 (Burton et al., 
2007), thousands of SNPs have been found to be associated with a range of 
complex traits, under the common disease common variant (CDCV) hypothesis 
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(Reich and Lander, 2001) which states that many frequent, low risk variants 
contribute to diseases with high population prevalence.  
 
The formation of large consortia, such as the PGC (Psychiatric Genomics 
Consortium) and GIANT (Genetic Investigation of ANthropometric Traits) for the 
meta-analysis of multiple data sets has led to increased sample sizes and statistical 
power, and thus even greater discovery of genetic variants using the GWAS 
approach. Psychiatric traits highlight the successes and failures of GWAS. More than 100 genetic variants have been found to be associated with schizophrenia (Figure 1; 
Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014); in 
contrast, for Major Depressive Disorder (MDD) there are few known genetic 
determinants to date (Ripke et al., 2013; Converge Consortium, 2015; Hyde et al., 
2016). This difference in findings could be due to several factors, such as differences 
in the quality of phenotyping, in the statistical power of the studies or due to incorrect 
disease model assumptions. A recently published study using data from the genetic 
testing company 23andMe (Hyde et al., 2016), and meta-analysed with the PGC 
MDD GWAS (Ripke et al., 2013), on 326,113 individuals (84,847 cases) has led to 
the discovery of 4 independent loci associated with MDD. This highlights the need for 
large sample sizes when studying heterogeneous traits in order to provide sufficient 
statistical power to detect causal genetic associations.  
 
Methodology development for increasing the statistical power of genetic association 
studies is extremely important for heterogeneous traits and those with small sample 
size GWAS, in order to maximise the discovery potential and thus provide insights 





Figure 1. Manhattan plot for the latest schizophrenia (SCZ) GWAS from the Psychiatric Genomics 
Consortium (PGC), illustrating the 108 known loci (Schizophrenia Working Group of the Psychiatric 
Genomics Consortium, 2014). 
 
 
1.2.1 Multi-trait GWAS 
 
GWAS are most commonly performed on a single phenotype of interest, or across 
many related traits, such as lipids (Teslovich et al., 2010; Willer et al., 2008), but with 
each trait analysed separately. The association between a SNP and a phenotype is 
typically tested by performing linear regression for continuous traits and logistic 
regression for case/control phenotypes, where each SNP is regressed on the 
phenotype separately. The association is considered significant if the P-value is 
below the genome-wide significance threshold of 5 × 10!!. Although this has been 
the primary method of analysis for most GWAS, it allows only one phenotype to be 
considered at a time, despite the likelihood that SNPs often associate with many 
traits. In recent years, numerous multivariate methods have been proposed; these 
model multiple phenotypes simultaneously to investigate their joint association with a 
SNP. These methods allow shared genetic architecture and correlation between 
phenotypes to be exploited, potentially increasing the power to detect true genotype-
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phenotype associations. There have been some applications of multi-trait GWAS 
methodology in the literature (Kauwe et al., 2014; Adhikari et al., 2015, 2016), 
however they have so far only been applied to relatively small sample sizes, thus 
making it difficult to ascertain the performance gains from current applications. 
However, large multi-trait resources, such as the UK Biobank and planned US 
Biobank, should help to facilitate such analyses. 
 
There are two types of GWAS method that test multiple phenotypes jointly: single 
SNP methods (O’Reilly et al., 2012; van der Sluis et al., 2013; Zhu et al., 2015; 
Bolormaa et al., 2014; Ferreira and Purcell, 2009; Klei et al., 2008; Aschard et al., 
2014; Stephens, 2013; Marchini et al., 2007; Nath and Pavur, 1985; Zhou and 
Stephens, 2014; Korte et al., 2012; Segura et al., 2012; Schifano et al., 2013; Casale 
et al., 2015), which test the joint association of a set of phenotypes SNP-by-SNP, 
and multi-SNP methods (Bottolo et al., 2013; Servin and Stephens, 2007; Zhou and 
Stephens, 2012; Kim et al., 2016; Casale et al., 2015), which test the association 
between multiple phenotypes and multiple SNPs simultaneously. Within the single 
SNP category, there are two further types: those that use summary statistics from 
existing univariate analyses (O’Reilly et al., 2012; van der Sluis et al., 2013; Zhu et 
al., 2015; Bolormaa et al., 2014) and those that use individual-level genotype-
phenotype data (O’Reilly et al., 2012; Ferreira and Purcell, 2009; Aschard et al., 
2014; Stephens, 2013; Marchini et al., 2007; Nath and Pavur, 1985; Klei et al., 2008; 
Zhou and Stephens, 2014; Korte et al., 2012; Segura et al., 2012; Schifano et al., 
2013; Casale et al., 2015). 
 
1.2.2 Summary statistic methods 
 
By applying multi-trait GWAS methods based on summary statistics, previous studies 
on separate phenotypes can be repurposed to conduct a multi-trait study without 
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additional data collection. Furthermore, often much larger sample sizes of summary 
statistics are available than individual-level data. Currently, the most common 
approach to multi-trait GWAS is to perform separate univariate GWAS for each 
phenotype, and adjust the P-values to account for multiple testing (The International 
Consortium for Blood Pressure, 2011), though often this correction is not applied and 
the usual 5 × 10!!  genome-wide significance threshold is applied. A Bonferroni 
correction (Bland and Altman, 1995) can be applied to the P-value threshold 𝛼, to 
obtain a corrected significance threshold of 𝛼!  =  𝛼 𝑁  , for 𝑁 tests. However, this is 
a highly conservative correction as this assumes that all the univariate analyses were 
independent, and thus does not account for the correlation between traits. A simple 
and less conservative way of correcting for multiple testing is to apply a standard 
Šidák (Sidak, 1968) correction to the minimum of the univariate P-values, 
incorporating the effective number of independent tests, which is determined by the 
trait correlations. A formula for the effective number of tests is given by Nyholt 
(Nyholt, 2004), based on the eigen-decomposition of the phenotype correlation 
matrix. The min-𝑃 method (O’Reilly et al., 2012) uses Nyholt’s effective number of 
tests calculation, based on the number of GWAS results being tested and the 
correlation of their results, and then performs a Šidák correction on the minimum P-
value from a set of univariate GWAS results at a SNP. This method was used by the 
authors to benchmark their individual-level based method, MultiPhen (O’Reilly et al. 
2012). 
 
TATES (Trait-based Association Test that uses Extended Simes procedure) (van der 
Sluis et al., 2013) is a method that has been developed exclusively for utilising 
existing summary statistics from univariate analyses. The method requires the 
phenotype correlation matrix and the P-values obtained from univariate analyses on 
each of these phenotypes; so for 𝐾  phenotypes, the method requires the 𝐾 ×
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 𝐾 phenotype correlation matrix and the 𝐾 univariate P-values for each SNP. Rather 
than use the phenotype correlation matrix to deduce the number of independent 
tests, TATES transforms this trait correlation matrix into a corresponding P-value 
correlation matrix via a sixth order polynomial that was determined by simulation, and 
uses the eigen-decomposition of this P-value correlation matrix. The univariate P-
values are weighted according to this eigen-decomposition, and the minimum of 
these weighted P-values is chosen as the corrected P-value for the joint association. 
TATES has been shown to outperform univariate analyses and other multi-trait 
methods that use individual-level data, such as MultiPhen (O’Reilly et al., 2012), in 
certain scenarios (van der Sluis et al., 2013). It is unclear whether this higher power 
is generalisable, or a characteristic of the modelling scenarios imposed in the 
simulations. Summary statistic methods are more easily applied, since complete 
genotype-phenotype data across multiple traits are often not available, and there are 
now growing resources of publicly available summary data. However, by using only 
the P-values from univariate studies, they are not able to fully exploit the correlation 
structure between the phenotypes.  
 
Multi-trait methods have also been developed that use the signed t-values in a meta-
analysis across traits. These methods are able to exploit the correlation between 
phenotypes via the correlation between the t-values. The SHet and SHom methods (Zhu 
et al., 2015) combine the t-values from multiple traits, and across multiple cohorts, in 
a sample size and t-value correlation weighted meta-analysis. The SHom method 
performs a meta-analysis across all traits under study; the SHet method, however, 
meta-analyses subsets of traits, with these subsets being determined by their 
univariate t-values and some user specified threshold. For each SNP, the association 
between the SNP and all traits with an absolute univariate association t-value >  𝑇 for 
some threshold 𝑇 is tested. This analysis is then repeated across a range of different 
thresholds, or is performed for one threshold if specified by the user. The default is to 
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order the traits by their univariate t-values, recursively performing associations 
between subsets of the traits and the SNP, starting with the trait with the largest 
absolute univariate t-value, and progressively adding each trait until all traits are 
included in the association. It has been shown that the SHom method has greater 
power to detect homogenous genetic effects (or pleiotropic genetic effects), but when 
heterogeneous genetic effects exist the SHet method is preferred as subsets of traits 
are tested for their association with the genetic variant (Zhu et al., 2015). Another 
standard approach to meta-analysis across traits has been proposed (Bolormaa et 
al., 2014), which weights the t-values only by their t-value correlations, whereas SHet 
and SHom perform t-value correlation and sample size weighted meta-analyses. This 
method has been identified as performing best under homogenous genetic effects 
due to having a large number of degrees of freedom compared to the other two tests 
(Zhu et al., 2015). 
 
The public release of GWAS summary statistics across multiple traits motivates the 
development of multi-trait GWAS methods for increasing discovery and identifying 
pleiotropic loci. A Bayesian approach to performing multi-trait GWAS on summary 
statistic data has been recently proposed (Zhu and Stephens, 2016), where a 
summary statistic specific likelihood is developed and implemented for the detection 
of genetic variants. Furthermore, the recently published method GWIS (genome-wide 
inferred statistics) (Nieuwboer et al., 2016), can construct summary statistic data for 
compound traits, such as BMI, from the individual component summary statistics, 
expanding the utility of summary data to phenotypes for which there was no 
previously available resource. The utility of summary statistics has been further 
explored in other genetic analysis tools, such as polygenic risk scores (PRS) for 
quantifying genetic risk of disease (Purcell et al., 2009; Euesden et al., 2015; 
Dudbridge, 2013), LD Score regression for calculating the genetic correlation 
between traits (B. Bulik-Sullivan et al., 2015) and for estimating heritability (B. K. 
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Bulik-Sullivan et al., 2015). These tools use summary data in order to gain further 
insight into the genetic aetiology of traits, without the requirement for large resources 
of individual-level data. A review of current summary statistic methodology has 
recently been performed (Pasaniuc and Price, 2016). The authors conclude that, 
although there are certain limitations to using summary data, for example loss of 
accuracy for applications such as imputation, given the large sample sizes of 
available summary data, methods exploiting summary statistics are often preferable 
to their individual-level counterparts. An online resource of GWAS summary statistics 
has recently been developed (Staley et al., 2016), allowing the vast amount of 
summary statistic data to be easily extracted across traits, which will further facilitate 




Figure 2. Genetic correlation ‘atlas’ plot from the application of the LD score regression method (B. K. 
Bulik-Sullivan et al., 2015) to publicly available summary statistic data (B. Bulik-Sullivan et al., 2015). 
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1.2.3 Individual-level methods 
 
Methods that utilise individual-level genotype-phenotype data have been the most 
commonly developed multi-trait method in recent years. Ferreira and Purcell 
(Ferreira and Purcell, 2009) proposed the use of canonical correlation analysis 
(CCA) for modelling multiple phenotypes jointly. The statistical method CCA tests the 
association between two sets of variables, thus could be applied to multiple SNPs, 
but here it is presented as a single-SNP, multi-trait method. This method is 
equivalent in power to MANOVA (Multivariate ANalysis Of VAriance) (Nath and 
Pavur, 1985; O’Reilly et al., 2012). Another method that has been shown to be 
approximately equivalent to CCA and MANOVA for common genetic variants is 
MultiPhen (O’Reilly et al., 2012). MultiPhen reverses the regression of usual 
univariate analyses, treating the SNP as outcome and multiple phenotypes as 
predictors, in an ordinal logistic regression model. What makes CCA and MultiPhen 
differ is the assumed distribution of the outcome; CCA assumes normality of 
residuals, whereas MultiPhen models the genotype as an ordinal random variable. 
Both methods find the linear combination of phenotypes most associated with the 
SNP, and a likelihood ratio test is performed on the full model versus that with no 
phenotype predictors. These methods mostly outperform the univariate approach, 
particularly when the direction of genetic effect is not concordant with the phenotypic 
correlation, however when the direction is the same, their power appears greatly 
reduced compared to the univariate approach (O’Reilly et al., 2012). Aschard et al. 
(Aschard et al., 2014) developed a method that performs a principal components 
analysis (PCA) on the individual-level phenotype data. For 𝐾 phenotypes there are 𝐾 
principal components, which are tested for association with a SNP. For each 
principal component (PC), a univariate analysis is performed with SNP as predictor 
and PC as outcome, resulting in 𝐾 univariate models for each SNP. Since PCs are 
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independent, the chi-squared statistics from each univariate model can be summed, 
resulting in a single P-value representing the joint association between the SNP and 
all the PCs. The combined-PC method was shown to have similar power to 
MultiPhen across the scenarios considered, but MultiPhen had type I error inflation 
when analysing 50 phenotypes (Aschard et al., 2014). The authors suggest that it is 
not always best to consider only the top few PCs, and that the effect of the SNP on 
the phenotype can be spread across all or a subset of the PCs. Disentangling which 
PCs are detecting the genetic effect could lead to a method with more power than 
the proposed combined-PC approach due to a reduction in the degrees of freedom of 
the test. 
 
Bayesian approaches to GWAS have also been proposed for single-SNP, multi-trait 
analyses (Stephens, 2013; Marchini et al., 2007), but have had limited application in 
the field so far due to their computational intensity. The package BIMBAM (Bayesian 
IMputation-Based Association Mapping) (Stephens, 2013; Servin and Stephens, 
2007), performs Bayesian multivariate regression to test for association, partitioning 
the phenotypes according to the effect of the genetic variant, and using Bayes 
factors to assess the association between the groups of phenotypes and a SNP. 
Different association scenarios are modelled, such as separate direct effects 
between the SNP and all traits or indirect effects between the SNP and a subset of 
the traits, captured in a Directed Acyclic Graph (DAG) framework, and the support for 
each model relative to the null hypothesis is computed. The BIMBAM package also 
performs multi-SNP analysis. The software package SNPTEST (Marchini et al., 
2007), for performing SNP association testing in GWAS, now incorporates Bayesian 
association testing for multiple phenotypes, accounting for genotype uncertainty. The 
model implemented is a Bayesian multivariate linear model with a conjugate prior, 
consisting of an inverse Wishart prior on the error covariance matrix, and a matrix 
normal prior on the genetic effect parameters (A. P. Dawid, 1981).  
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Mixed models have also been considered as a way of testing for joint association. 
Zhou and Stephens (Zhou and Stephens, 2014) proposed the use of multivariate 
linear mixed models (mvLMMs), incorporated into the software GEMMA (Genome-
wide Efficient Mixed Model Association) (Zhou et al., 2013; Zhou and Stephens, 
2012), for testing the association between a single SNP and many correlated 
phenotypes, while controlling for population stratification. mvLMMs have previously 
been used to estimate heritability (Zhou and Stephens, 2014; Price et al., 2011), as 
well as studying pleiotropy and genetic correlation (Lee et al., 2012; Zhou and 
Stephens, 2014). mvLMMs are also a useful tool for GWAS as they can adjust for 
population stratification and cryptic relatedness between individuals (Zhou and 
Stephens, 2014). Algorithms for fitting mvLMMs can be highly computationally 
intensive, such as in GCTA (Genome-wide Complex Trait Analysis) (Yang et al., 
2011) and therefore they are not practical for conducting likelihood ratio tests (LRTs) 
in a GWAS setting (Zhou and Stephens, 2014). GEMMA, however, is able to fit 
mvLMMs and perform LRTs in GWAS by extending existing univariate linear mixed 
model (LMM) methods, (Zhou and Stephens, 2012; Lippert et al., 2011; Pirinen et al., 
2013), and applying them in a multivariate context. Although GEMMA provides a 
more computationally efficient alternative, it is still only practical genome-wide for no 
more than 10  phenotypes, and sample sizes up to 50,000  (Zhou and Stephens, 
2014). Segura et al. (Segura et al., 2012) proposed a mixed-model approach that 
performs multi-locus association testing, for use in structured populations. It uses 
stepwise mixed-model regression, and the authors explore two model selection 
criteria: an extended Bayesian information criterion (EBIC) and a multiple Bonferroni 
criterion (mBonf). It was shown that this method performed better than alternatives 
for structured samples and when studying phenotypes for which several SNPs have 
moderate to large effect sizes (Segura et al., 2012). Schifano et al. (Schifano et al., 
2013) proposed a scaled marginal model (SMM) for both testing and estimating the 
effect of a SNP on many phenotypes in case/control studies. The authors found that 
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their method, SMAT (Scaled Multiple-phenotype Association Test), has higher power 
than univariate analyses, as well as higher power than other multi-trait methods 
when the phenotypes are positively correlated and when they capture an underlying 
trait in the same direction (Schifano et al., 2013).  
 
1.2.4 Multi-SNP methods 
 
Many methods have been proposed in the literature for testing the association of 
multiple phenotypes accounting for the trait correlation structure, but in most cases 
correlated sets of traits are tested for association SNP-by-SNP. Multi-SNP methods 
aim to increase power by reducing the residual variance by including other genetic 
variants as predictors in the model. The correlation structure between genetic 
variants across the genome is highly spatial, in that SNPs physically close are often 
highly correlated, whereas distant SNPs tend to be uncorrelated due to genetic 
linkage (The International HapMap 3 Consortium, 2010). The correlation structure 
between genetic variants is measured by linkage disequilibrium (LD) (Reich et al., 
2001). By modelling multiple SNPs jointly, and controlling for this correlation 
structure, multi-SNP methods may have increased power to identify susceptibility 
loci. Most multi-SNP methods adopt a Bayesian approach; in a review of Bayesian 
approaches to genetic association testing (Stephens and Balding, 2009), Stephens 
and Balding discuss the use of Bayes factors over P-values, as well as the choice of 
prior distribution. GUESS (Graphical Unit Evolutionary Stochastic Search Algorithm) 
(Bottolo et al., 2013) is one such multi-SNP Bayesian method. This method is an 
amalgamation of Bayesian variable selection (BVS) (Guan and Stephens, 2011) 
procedures, to extend single-SNP GWAS analyses, and multi-trait modelling 
methods. GUESS uses linear regression to test for association, with SNP predictors 
and phenotype outcomes, along with an evolutionary stochastic search algorithm 
(Bottolo and Richardson, 2010) that searches genome-wide for subsets of SNPs 
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associated with multiple phenotypes in order to reduce dimensionality. GUESS was 
shown to outperform the Bayesian multi-trait association testing of SNPTEST in both 
single-phenotype and multi-phenotype simulations (Bottolo et al., 2013), but GUESS 
is highly computationally intensive, partly due to the stochastic search algorithm 
component of the method. The multi-SNP methods can also be utilised for single-
SNP analyses. CCA, MultiPhen, SNPTEST and BIMBAM have similar power for the 
modelling scenarios considered in a recent comparison study (Galesloot et al., 
2014).  
 
A common misconception in the field of multi-trait GWAS is that there must exist 
pleiotropic effects between the genetic variant and most or all of the phenotypes 
under study for a gain in power to be achieved by the multivariate approach. 
However, gains in power can be achieved even if only one of the traits exhibits a 
causal relationship with the genetic variant (O’Reilly et al., 2012; Zhou and Stephens, 
2014). A multivariate model assesses the overall association between the SNP and 
the phenotypes in the model, as compared to a model with none of the phenotypes 
included, and thus conclusions about the effects on the individual phenotypes cannot 
be made directly. Including additional phenotypes that correlate with the associated 
phenotype can reduce the residual variance because the correlated phenotypes 
likely share a high proportion of risk factor effects. Thus, the association between the 
variant and the one associated phenotype explains a high fraction of remaining 
residual variance, resulting in high statistical power.  
 
Zhou and Stephens (Zhou and Stephens, 2014) state that there is no one most 
powerful method, reiterated in a recent comparison study (Galesloot et al., 2014), but 
that instead the different methods should be viewed as complementary. This 
highlights the importance of gaining a deeper understanding into the performance of 
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these methods to identify the scenarios in which each method should be adopted in 
order to maximise discovery potential. 
 
1.3 Assessing genetic aetiology 
 
It has been established that most common diseases and traits are polygenic whereby 
hundreds or even thousands of genetic variants have small contributing effects 
across the genome (Wood et al., 2014; Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014; Global Lipids Genetics Consortium, 2013). 
Larger sample sizes are sought when performing GWAS on such traits in order to 
detect the small genetic effects that associate with the disease/trait outcome. This is 
particularly pertinent for traits such as Major Depressive Disorder (MDD), in which 
high heterogeneity in the phenotype contributes further to produce low power of 
discovery. Methods have been developed to exploit the polygenicity of complex traits 
to optimise phenotype prediction from genetics and to gain understanding of their 
genetic architecture. Polygenic risk scores (PRS) are one such tool that aggregate 
information on genetic risk across the genome (Purcell et al., 2009; Euesden et al., 
2015; Dudbridge, 2013). In addition, the LD Score regression method (B. Bulik-
Sullivan et al., 2015) allows the genetic correlation between traits to be determined, 
providing information about the genetic overlap between traits, and methods such as 
GCTA (Yang et al., 2011) and LD Score regression (B. K. Bulik-Sullivan et al., 2015) 
allow the heritability and co-heritability of traits to be estimated. Furthermore, the 
identification of pleiotropic SNPs (SNPs that effect more than one phenotype) is likely 
to become an increasingly important area of research as we seek to further our 






The term pleiotropy historically refers to a single gene influencing multiple, very 
different, traits (Solovieff et al., 2013). In the context of complex disorders, which are 
influenced by many small genetic effects across the genome (Visscher et al., 2012), 
we can also consider pleiotropy at the SNP level, and so the term has evolved to 
also consider effects on multiple, related traits. Therefore, in the context of 
investigating complex disorders, for which SNP effects are unlikely to be unique to 
particular traits, SNPs are considered pleiotropic even when influencing similar traits, 
such as LDL and triglycerides. Identifying pleiotropic SNPs can lead to greater 
understanding of the underlying biological network between traits, and identify 
biological pathways enriched for effects on clusters of traits for further investigation. 
 
A recent review paper on the topic of pleiotropy (Solovieff et al., 2013) considered 
how different types of pleiotropy can arise, and noted the importance of 
distinguishing between them in order to gain biologically meaningful conclusions as 
to the shared biological mechanisms between traits. Solovieff et al. highlight what 
they classify as ‘cross-phenotype’ associations, where a SNP expresses an 
association with more than one phenotype, and the important distinction with 
pleiotropic SNPs. For a SNP to be pleiotropic, they state, it must have a genuine 
effect on more than one trait, rather than merely having an observed association with 
multiple traits. Previous studies have supported the existence of pleiotropic SNPs 
through the identification of loci that affect more than one trait, such as the TYK2 
locus in Crohn’s disease and psoriasis (Franke et al., 2010; Genetic Analysis of 
Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, 2010 in 
Solovieff et al., 2013). In addition, polygenic risk score and LD score regression 
analyses have established shared genetic aetiology between a huge range of traits 
(Power et al., 2015; Bulik-Sullivan et al., 2015; Krapohl et al., 2015), for example 
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between schizophrenia and bipolar disorder (Purcell et al., 2009), as well as type 2 
diabetes and hypertension (Lee et al., 2012 in Solovieff et al., 2013). 
Pleiotropy can arise in many forms, and distinguishing between them is important for 
understanding the biological implications. Figure 3 shows a graphical representation 
of the different forms of pleiotropy (Solovieff et al., 2013).  
 
Figure 3. A visual representation of the different forms of pleiotropy as illustrated in a recent review 
paper (Solovieff et al., 2013). 
 
Pleiotropy can refer to a single causal variant with effects on both traits, P1 and P2 
(Figure 3a), but can also refer to two causal variants that are in the same gene or 
locus that are tagged by the same genetic variant (Figure 3b). However, two causal 
variants in the same gene or locus that are tagged by two separate genetic variants 
can also be classified as pleiotropic SNPs (Figure 3c). These three types of 
pleiotropy are classified as biological pleiotropy, where the causal variant(s) are 
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having direct effects on the phenotypes of interest.  The other type of pleiotropy is 
mediated pleiotropy, whereby a causal variant, tagged by a genetic variant, has an 
effect on one phenotype P1, which then has a downstream effect on another 
phenotype P2; we say that the genetic effect on P2 is mediated by P1 (Figure 3d). 
While biological and mediated pleiotropy have different biological implications, they 
can be difficult to differentiate using GWAS results alone. The final two 
representations of pleiotropy in Figure 3 refer to spurious pleiotropy, where there 
appears to be a pleiotropic effect when one does not exist. Spurious pleiotropy can 
arise through misclassification of phenotypes or ascertainment bias (Figure 3e), or, 
when in a region of high linkage disequilibrium, there is a single genetic variant 
tagging two causal variants in different genes (Figure 3f).  
 
The main challenge in the analysis of pleiotropic genetic variants is in distinguishing 
between the different types, and translating this knowledge into meaningful biological 
findings. Mendelian randomisation is a technique that aims to identify whether there 
exists direct effects from the genetic variant to each phenotype, or whether there 
exists an intermediate effect on one phenotype that has a downstream effect on 
another (Davey Smith and Hemani, 2014). This method therefore attempts to 
distinguish between biological and mediated pleiotropy, as illustrated in Figure 3 
above (Solovieff et al., 2013). Another approach to further characterising pleiotropy is 
the PRIMe pleiotropy index (Huang et al., 2011). This method is able to first detect 
regions where there exist multiple associations from published GWAS, and then 
define a pleiotropy index based on the number of traits with which the region is 
associated. While this approach does not make any distinction between pleiotropy 
types, it provides a way of quantifying the degree of pleiotropy and highlighting 
pleiotropic ‘hotspots’ for further follow up analysis. In the context of multi-trait GWAS, 
while most methods are not optimised for the detection of pleiotropic variants, nor do 
they require a pleiotropic effect to gain power over the univariate approach, they do 
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have the potential to further describe the effect of a genetic variant on multiple traits. 
However, most of those described in this thesis (with the notable exception of mv-
BIMBAM (Stephens, 2013)) are focused on increasing statistical power for detecting 
variants affecting some number of the traits, and not on establishing the type effect 
or form of pleiotropy. The study of pleiotropic variants, while challenging, is likely to 
be instrumental in both increasing our knowledge of related diseases and traits, and 
in the development of effective treatments. 
 
1.3.2 Polygenic risk scores 
 
A polygenic risk score (PRS) is an effect-size weighted sum of risk alleles present 
across the genome of an individual, and thus quantifies the genetic load of disease 
for an individual (Purcell et al., 2009; Euesden et al., 2015; Dudbridge, 2013). PRS 
are calculated according to a number of P-value thresholds, which determine the 
number of SNPs to be included in the score based on the univariate GWAS P-values 
for each SNP. The most predictive score of the studied trait among those calculated 
at different thresholds is typically chosen for subsequent analyses. PRS provide a 
useful tool for assessing how at risk an individual is for a particular disease, as well 
as for determining the polygenicity of traits. They were originally presented in the 
psychiatric genetics field (Purcell et al., 2009), but have since been applied across 
numerous human traits (Krapohl et al., 2015; Selzam et al., 2016; Power et al., 2015; 
Hung et al., 2015; Vassos et al., 2016). They are particularly useful as a way of 
leveraging the results of an underpowered GWAS. In the first study to investigate the 
concept of polygenic risk, the authors found that the PRS for schizophrenia (SCZ) 
both significantly predicts SCZ case/control status and also case/control status of 
Bipolar Disorder (BPD) (Purcell et al., 2009). Since then, PRS have been commonly 
applied to assess shared genetic aetiology across traits, and phenome-wide PRS 
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approaches have been adopted by performing such analyses systematically across 
many traits (Krapohl et al., 2015).  
 
PRS method development has also been an active area of research interest in the 
field; the software PRSice calculates high-resolution PRS at hundreds of P-value 
thresholds in order to find the most predictive threshold, while the AVENGEME 
software exploits theory developed in Dudbridge 2013 (Dudbridge, 2013) to estimate 
heritability, co-heritability and the proportion of causal variants from polygenic risk 
scores (Palla and Dudbridge, 2015). 
 
 
Figure 4. Bar plot from the high-resolution polygenic risk score (PRS) method PRSice; the PRS for SCZ 
at the 𝑃!  =  0.0265 threshold is most predictive of SCZ case/control status (Euesden et al., 2015). 
 
Despite PRS now being routinely applied across traits to assess shared genetic 
aetiology, this has been performed on a pairwise basis where a PRS built on one trait 
is used to predict another trait. A multivariate approach, whereby PRS for multiple 
traits are used to predict disease outcomes, has yet to be explored. The genetics of 
one trait do not act independently of the genetics of another, and given that the 
biological network underlying multiple traits is a highly connected network, interaction  
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between genetic markers occurs. Genetic interaction is most commonly tested 
statistically between a small number of SNPs or genes, rather than across the whole 
genome, due to the computational complexity of modelling such a large number of 
interactions. The interaction between PRS could thus provide broad insight into the 
genetic interaction influencing common traits.  
 
1.3.3 Major Depressive Disorder  
 
Major Depressive Disorder (MDD) is a debilitating psychiatric disorder estimated to 
affect more than 350 million people worldwide (‘WHO | Depression’, Fact Sheet; 
Whiteford et al., 2013). Given the high heritability (ℎ! = 37%) (Sullivan et al., 2000), 
there have been intense research efforts to establish the genetic underpinnings of 
this common, complex disorder. 
 
Most GWAS performed on MDD to date have had limited success. The first genetic 
loci found to be associated with MDD was the result of whole-genome sequencing of 
around 5,000 Chinese women with recurrent MDD (Converge Consortium, 2015). 
This population was chosen due to under-diagnosis of MDD in China, thus, in 
addition to restricting to only recurrent cases of MDD, provided a more homogenous 
phenotype. There has also been a study into the trade-off between sample size and 
read depth in whole-genome sequencing; it was found that larger sample sizes at 
lower read depth provide greater statistical power (Pasaniuc et al., 2012), which was 
the approach adopted in this study. More recently, the largest study of MDD to date 
(Hyde et al., 2016) identified 4 independent loci from a GWAS on 326,113 individuals 
(84,847 cases). The study was performed using data from the consumer genetic 
testing company 23andMe, and was meta-analysed with the PGC MDD GWAS 
(Ripke et al., 2013). The MDD phenotype obtained from 23andMe is likely to be more 
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heterogeneous than provided by a clinical sample, due to MDD diagnoses being 
determined by a simple online question with no confirmation of diagnosis; this 
heterogeneity, however, is likely to be at least somewhat negated by the large 
sample size.  
 
Due to the limited success of MDD GWAS to date, PRS have been frequently 
applied, though the predictive ability of the MDD PRS is limited (Ripke et al., 2013). 
The heterogeneity of MDD suggests that there exist many MDD subtypes, which 
would explain why there has been limited success to date using the dichotomous 
MDD definition, as defined by the DSM-IV criteria. PRS have been used to assess 
the shared genetic aetiology between MDD and associated outcomes such as 
childhood trauma and stressful life events (Mullins et al., 2016). In addition, this 
approach has been adopted in an attempt to identify subtypes of MDD by analysing 
symptomatic data (Milaneschi et al., 2016; Levine et al., 2014; Okbay et al., 2016). 
Multiple PRS on sub-types or on correlated traits have not, however, been used to 
simultaneously predict MDD case-control status. The multi-dimensionality of MDD 
suggests that there are multiple contributing factors (both genetic and 
environmental), and that interaction between these factors across the genome could 
associate with disease status. Chapter 5 investigates prediction models of MDD 
based on PRS computed from multiple MDD relevant traits. 
 
1.3.4 Phenotype stratification 
 
Many complex disorders are heterogeneous, meaning that within individuals defined 
as cases, there is variability in the exhibited phenotype(s). A recent paper, for 
example, examined the polygenicity of MDD and two known clinical subtypes: typical 
and atypical, in order to gain a greater understanding into the MDD phenotype 
(Milaneschi et al., 2016). By grouping individuals only by their case/control status, we 
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potentially introduce noise into the data, and over-simplify the disorder, reducing 
information, by considering it as a binary trait.  Phenotype stratification, where a 
phenotype considered to be one disorder is dissected into its more elementary 
components, is a particularly important objective of personalised medicine. In MDD, 
for example, some individuals experience no success with many different types of 
anti-depressant. One contributing factor could be that there are many underlying 
forms of MDD, and that currently available anti-depressants are not targeting these 
subtypes specifically. If we are able to stratify complex disorders into more 
fundamental components, this may lead to novel drug targets specific to these 
subtypes and greatly improve the prognosis of complex traits. Multi-trait analyses 
could hold the key to stratifying complex disorders, by assessing the shared genetic 
aetiology between correlated traits, and by performing multi-trait analyses on endo-







1.4 Chapter Outline 
 
In Chapter 2 we develop and present a multivariate simulation framework for 
modelling the effect of a SNP on multiple correlated traits in the context of multi-trait 
GWAS. We construct a large range of modelling scenarios that aim to capture 
different aspects of genotype-phenotype associations, by considering the extra 
modelling challenges of multi-trait GWAS. The simulation framework is provided as a 
command-line software package with associated R shiny web application for 
simulation of multivariate genetic datasets, and for the testing and development of 
multi-trait GWAS methodology. 
 
Chapter 3 utilises the simulation framework built in Chapter 2 to perform a 
comprehensive comparison of the leading multi-trait GWAS methods. We compare 
methods that utilise univariate GWAS summary statistics, as well as those methods 
that exploit individual-level genotype-phenotype data directly. Our findings expose 
the similarities and differences across different approaches to multi-trait GWAS and 
act as a guide to other researchers involved in the genetic analysis of multiple traits. 
Furthermore, our findings highlight areas for potential improvement in the 
development of novel methodology. 
 
Motivated by our findings of Chapter 3, in Chapter 4 we perform multi-trait GWAS 
on a variety of traits (both quantitative and binary) using publicly available GWAS 
summary statistics. We develop and apply two summary statistic GWAS methods 
based on our findings of Chapter 3, and to allow quantitative and binary traits to be 
analysed jointly. We identify novel genetic variants through multi-trait analyses, 
highlighting the utility of summary data for gaining further insight into the genetic 
aetiology of correlated traits. 
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In Chapter 5 we further explore the utility of summary statistic data across multiple 
correlated phenotypes by building multivariate predictive models of MDD using PRS 
predictors in the UK Biobank, in addition to environmental (phenotypic) predictors. 
We build both main effect and interaction models, and use variable selection 
procedures for identifying the best fitting model. This study indicates that we can 
explain more variance in MDD case/control status by considering multiple predictors, 







2.  Multivariate simulation framework for 
genetic epidemiology 
 
In this first chapter we develop a multivariate simulation framework suitable for 
genetic epidemiology, motivated by recent advances in multivariate genome-wide 
association study (GWAS) methodology. Although the standard approach to GWAS 
is to perform univariate analyses for each trait under study, the focus is switching to 
multi-trait analyses, facilitated by large national resources of data across a wide 
variety of phenotypes. The relative performance of current methodology, however, 
remains unclear; the aim of this chapter is to develop a simulation framework to act 
as a platform for the comparison of multi-trait GWAS methodology in order to 




The early stages of the GWAS era were dominated by studies with a single 
phenotype as outcome (Burton et al., 2007; The International Consortium for Blood 
Pressure, 2011; Teslovich et al., 2010), while in recent years multi-trait analyses 
have become popular (B. Bulik-Sullivan et al., 2015; Kauwe et al., 2014; Cross-
Disorder Group of the Psychiatric Genomics Consortium and Genetic Risk Outcome 
of Psychosis (GROUP) Consortium, 2013). Multivariate methods have been 
developed to increase statistical power and identify pleiotropic loci in GWAS (Bottolo 
et al., 2013; Zhou and Stephens, 2012; O’Reilly et al., 2012; van der Sluis et al., 
2013; Zhu et al., 2015; Ferreira and Purcell, 2009; Klei et al., 2008; Aschard et al., 
2014; Stephens, 2013; Marchini et al., 2007; Bolormaa et al., 2014; Casale et al., 
2015; Huang et al., 2011; Zhang et al., 2014; Kim et al., 2016), while polygenic risk 
score and co-heritability estimation methods are now routinely applied to GWAS data 
to assess shared genetic aetiology across multiple traits (Purcell et al., 2009; 
Euesden et al., 2015; Dudbridge, 2013; Yang et al., 2011; B. K. Bulik-Sullivan et al., 
2015; Krapohl et al., 2015; Vattikuti et al., 2012; Cross-Disorder Group of the 
Psychiatric Genomics Consortium, 2013). However, these methods have been 
developed and applied in the absence of a dedicated simulation framework for 
generating data that reflects the complexity of multivariate data, where causal 
relationships are known.  
 
Here we present a simulation framework designed to capture as much of the 
multivariate data landscape as possible, allowing researchers to benchmark methods 
across a range of simulation scenarios of genetic variants affecting multiple traits. 
We also incorporate real data so that simulated genetic effects and phenotypic 
correlations reflect reality. We provide a web application implementing our simulation 
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framework (www.MultiTraitGWAS.kcl.ac.uk). A built-in tool generates simple 
multivariate genetic data sets instantaneously, while a downloadable command-line 
program can be used to simulate larger, more complex multivariate data that can be 
used to test a range of multivariate methods under a variety of parameter settings. In 
Chapter 3, we use our simulation framework to perform a comparison study of the 
leading multi-trait GWAS methods (van der Sluis et al., 2013; O’Reilly et al., 2012; 
Zhu et al., 2015; Nath and Pavur, 1985; Ferreira and Purcell, 2009; Aschard et al., 
2014; Stephens, 2013; Marchini et al., 2007). Finally, our web application provides a 
power calculator for multivariate GWAS, which should aid with optimal method 
selection given available data and in budgeting proposed studies. Our simulation 
framework and associated software should help to guide the future development and 
direction of multivariate methodology in genetic epidemiology. 
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2.2 Multivariate simulation framework 
 
We construct a simulation framework to model the multivariate network that exists 
between a single nucleotide polymorphism (SNP) and 𝐾  observed quantitative 
phenotypes (case/control phenotypes are modelled below), with internal and external 
risk factors and confounders (Figure 5). In Chapter 3, we exploit this simulation 
framework to test the relative performance of the leading multi-trait GWAS methods, 
and so this chapter acts as both a description of the study design for that comparison 
study and as an outline to our simulation software (www.MultiTraitGWAS.kcl.ac.uk) 
and its default settings, which can be changed according to user choice. 
 
Figure 5.  A biological network illustrating a genetic variant (G) influencing a set of biological entities, 
such as enzymes, metabolites and disease outcomes. Most are unmeasured internal (light blue) or 


















Figure 6. With no loss in generality, observed phenotype data from a biological network such as that 
represented in Figure 5 (assuming no indirect genetic effects on observed phenotypes via other 
observed phenotypes) can be depicted and parameterised by 𝒗 and 𝒄 as shown. Values of 𝒗 and 𝒄 
differ from their marginal values when observed risk factors are controlled for. 
 
With no loss in generality in the context of multi-trait GWAS, this complex network 
collapses down to a simplified model consisting of a single genetic variant having 
direct effects on multiple correlated phenotypes (Figure 6), and can be modelled with 
two sets of parameters: 
 𝒗 = 𝑣!𝑣!..𝑣!   
   
 𝒄 = 1 ⋯ 𝑐!,!⋮ ⋱ ⋮𝑐!,! ⋯ 1  
 
 
where 𝒗 is the genetic effect vector of the variance in each of the 𝐾 phenotypes 
explained by the genetic variant, and 𝒄 models the phenotypic correlation matrix such 
G





that 𝒄!,! is the approximate (see below) correlation (Pearson’s correlation coefficient, 𝑟) between phenotype 𝑠 and phenotype 𝑡.  
 
The SNP genotypes 𝐺!  ∈ 0, 1, 2  are generated according to Hardy-Weinberg 
Equilibrium (HWE) in the proportions {𝑝!, 2𝑝𝑞, 𝑞!}  where 𝑝  is the major allele 
frequency and 𝑞  is the minor allele frequency, with 𝑞 = 1 − 𝑝 . The genotype-
phenotype data are simulated according to the model: 
 
 𝑌!  =  𝑓 𝒗 ∙ 𝐺!  +  𝜀!   (1) 
 
where 𝑌!   =  {𝑌!,!,… ,𝑌!,!}  denotes the phenotype data corresponding to 𝐾 
phenotypes for an individual 𝑖, 𝑓(𝒗) denotes the regression coefficient corresponding 
to 𝒗 phenotypic variance in 𝑌!  explained by the SNP genotypes 𝐺! , and 𝜀! is the 
residual variance drawn from the multivariate normal distribution 𝑁(𝟎, 𝒄) (thus 𝒄 is not 
the exact phenotypic correlation matrix but given small genotype effect sizes is 
approximately equivalent; henceforth we describe 𝒄 as the phenotypic correlation 
matrix). The regression coefficient 𝑓 𝒗  is determined according to the following 
equation, under the assumption of additive genetic effects: 
 
𝑓 𝒗 =  𝑣2𝑝𝑞 
 
where 𝑣 is the transformed phenotypic variance explained by the SNP, determined 
by: 
𝑣 = 𝑣1 − 𝑣 
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to ensure that the genetic variant explains 𝑣% of the phenotypic variance given that 
the residual variance is 1. 
As default, we generate data corresponding to a sample of 5,000  individuals 
and 10,000 SNP replicates with minor allele frequency (𝑀𝐴𝐹)  =  0.3. While this, our 
main data-generating model, does not consider indirect effects of genetic variants on 
tested traits via other tested traits, nor case/control phenotype data, we also simulate 
and investigate these (see below).  
By varying the values that 𝒗 and 𝒄 take, genotype-phenotype data consistent with a 
wide range of underlying biological networks (Figure 5) and set of observed 
phenotypes can be generated. However, since there are infinite values that 𝒗 and 𝒄 
can take, a systematic search through the parameter space is required. Our 
simulation framework aims to capture as much of the parameter space as possible 
via four modelling scenarios:  
 
(S1)  𝒗 and 𝒄 are varied in a structured way 
(S2) 𝒗 and 𝒄 sampled from uniform distributions 
(S3)  𝒗 and 𝒄 reflect each other 
(S4)  𝒗 and 𝒄 informed by real data 
 
While the simulation framework is sufficiently general that it should be useful outside 
of genetic epidemiology, we exploit it in Chapter 3 to compare multi-trait GWAS 
methods, and thus the simulation scenarios chosen here reflect this. 
 
Table 1 provides a summary of the multi-trait GWAS methods included in the 
comparison study. The methods are described in more detail in Chapter 3. 
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 min-P Univariate P-values 
Adjusts univariate P-values in a standard 
Šidák correction, using the effective 
number of tests of Nyholt 
TATES Univariate P-values 
Adjusts univariate P-values using the P-
value correlation matrix as determined by 











SHom Univariate t-values 
Performs a meta-analysis across traits 
weighted by the t-value correlations and 
the univariate study sample sizes 
SHet Univariate t-values 
Performs a test similar to SHom but for 
subsets of traits (determined by varying a 





















MANOVA Normally distributed 
Test equivalent to multiple linear 
regression with phenotype predictors and 
genotype outcome 
CCA (mv-PLINK) Normally distributed 
Performs multiple linear regression with 
phenotype predictors and genotype 
outcome 
MultiPhen Ordinal variable 
Performs ordinal logistic regression with 
phenotype predictors and ordinal  
genotype outcome 
Combined-PC Normally distributed 
Performs a test equivalent to multiple 
linear regression with PC predictors and 
genotype outcome 
mv-BIMBAM Normally distributed 
Performs Bayesian multivariate 
regression, sub-setting the traits according 
to their SNP effect: direct, indirect or no 
effect 
mv-SNPTEST Normally distributed 
Performs Bayesian multivariate regression 
using a conjugate prior (Wishart on the 
covariance matrix, matrix normal on the 
genetic effects) 






2.3 Simulation scenarios 
 
The simulation scenarios implemented in our simulation framework, and incorporated 
into our simulation software, are described below. 
 
2.3.1 S1: Structured genetic effects and phenotypic correlations 
 
In this scenario the genetic effects, 𝒗, and phenotypic correlations, 𝒄, are varied in a 
structured way. First we consider a case with only two phenotypes and three genetic 
effect vectors: 
 𝒗𝟏 = 0.50.5   
   
 𝒗𝟐 = 0.50.1   
   
 𝒗𝟑 = 0.50   
 
such that 𝒗𝟐 corresponds to a SNP that explains 0.5% variance in trait 1 and 0.1% 
variance in trait 2. The phenotypic correlations are varied between an 𝑟 of −0.9 and 0.9  in increments of 0.1 . Data corresponding to 5,000  individuals are simulated 
according to Equation 1 under each of the three effect vectors across the range of 
correlations. 10,000  such replicates of genotype-phenotype data are simulated. 
Statistical power is measured as the proportion of results with a multivariate 
association P-value <  5 × 10!!  or a log!"  Bayes factor > 6  for the Bayesian 
methods tested, corresponding, respectively, to the well established genome-wide 
significance P-value threshold and the Bayes factor for declaring a discovery 
proposed by Stephens and Balding (Stephens and Balding, 2009). 
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While the number of qualitatively different genetic effect vectors is only three for two 
phenotypes (equal effects, different effects, one effect and one with no effect), the 
number increases exponentially as more traits are considered. In scenario S1 we 
consider 2, 4, 8, 20 and 48 phenotypes, and for those with four or more we apply 10 genetic effect vectors, defined in Table 2. These effect vectors are chosen to 
cover a large proportion of qualitatively different combinations of genetic effects as 





st 𝟏𝟒 of traits 2nd 𝟏𝟒 of traits 3rd 𝟏𝟒 of traits 4th 𝟏𝟒 of traits 𝒗𝟏 0.5 0.5 0.5 0.5 𝒗𝟐 0.5 0.5 0.5 0 𝒗𝟑 0.5 0.5 0 0 𝒗𝟒 0.5 0 0 0 𝒗𝟓 0.5 0.5 0.5 0.1 𝒗𝟔 0.5 0.5 0.1 0.1 𝒗𝟕 0.5 0.1 0.1 0.1 𝒗𝟖 0.5 0.5 0.1 0 𝒗𝟗 0.5 0.1 0.1 0 𝒗𝟏𝟎 0.5 0.1 0 0 
 
Table 2. Description of the 10 genetic effect vectors used in the simulations of 4 or more phenotypes. 
For 8 phenotypes, 𝒗𝟓 corresponds to the genetic variant explaining 0.5% variance in 6 of the traits and 0.1% in 2 of the traits, while for 20 phenotypes 𝒗𝟖 corresponds to the genetic variant explaining 0.5% 
variance in 10 traits, 0.1% variance in 5 traits and having no effect on 5 traits. 
 
For two phenotypes we consider pairwise phenotypic correlations ranging between −0.9 and 0.9 in increments of 0.1. When we simulate four phenotypes, the correlation 
range is reduced to between −0.3 and 0.9, as the corresponding correlation matrices 
with pairwise phenotypic correlations less than −0.3 are not positive definite. For the 
same reason, the correlation range for eight phenotypes is between −0.1 and 0.9, 
and for 20 and 48 phenotypes the correlation range is between 0 and 0.9. 
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The simulations of scenario S1 consider only genetic effects in the same direction 
(i.e. positive genetic effects), although the phenotypic correlations can be negative, 
but in Chapter 3 we explicitly consider the situation where one allele of the genetic 
variant increases the value of one trait but decreases the value of the other. 
 
2.3.1.1 Modelling indirect effects 
Our main data-generating model (Equation 1) does not consider indirect genetic 
effects, whereby the genetic variant has an effect on one of the tested phenotypes 
via its effect on another (a downstream or mediated effect). Here we perform 
simulations that model such an effect on two phenotypes. We simulate the genetic 
variant as explaining 0.5% variance in the first phenotype, and the first phenotype 
explaining 1%, 5%, 10% and 20% variance in the second phenotype. 
 
We simulate and evaluate indirect genetic effects for scenario S1. We model an 
indirect genetic effect from a SNP 𝐺! to a phenotype 𝑌!,! by simulating a direct effect 
on a phenotype 𝑌!,! and a direct effect from 𝑌!,! to 𝑌!,!. Data are generated according 
to the following equations: 
 𝑌!,! =  𝑓 𝒗 ∙ 𝐺!  +  𝜀!,!  
 𝑌!,!  =  𝑔(𝒗!) ∙ 𝑌!,!  +  𝜀!,!   
 
where 𝑓 𝒗  denotes the regression coefficient corresponding to 𝒗  phenotypic 
variance in 𝑌!,!  explained by the SNP, 𝑔(𝒗!)  denotes the regression coefficient 
corresponding to 𝒗! phenotypic variance in 𝑌!,! explained by 𝑌!,!, and 𝜀 ~ Ν(𝟎, 𝒄). We 
only simulate downstream effects for two phenotypes, but the simulations can be 




2.3.1.2 Modelling case/control data 
We simulate and evaluate case/control data for scenario S1. We first simulate 
quantitative phenotype data as in Equation 1, and then apply a liability threshold 
model (Falconer, 1960) of disease to generate case/control phenotype data 
according to the prevalence of the disease: 
 
 𝑌!,! =  1 𝑌!,! ≥ 𝑞𝑛𝑜𝑟𝑚(1 − 𝑝𝑟𝑒𝑣!) 0 𝑌!,! < 𝑞𝑛𝑜𝑟𝑚(1 − 𝑝𝑟𝑒𝑣!)  
 
where 𝑝𝑟𝑒𝑣! is the prevalence of the 𝑘!! phenotype. In Chapter 3, simulations of two 
case/control phenotypes are performed, as well as a mixture of one case/control 
phenotype and one quantitative trait. 
 
2.3.2 S2: Uniform genetic effects and phenotypic correlations 
 
In contrast to the structure of the first simulation scenario, here we choose genetic 
effects and phenotypic correlations uniformly, where every value is assumed to be 
equally likely. The instances of genetic effects and phenotypic correlations simulated 
in the first scenario are highly structured, which allows us to more easily infer 
continuous power curves across the full correlation range for given genetic effects, 
than from an unrelated set of point estimates in high-dimensional model space. 
However, this may result in simulating unrealistic data, such as a SNP explaining 0.5% variance in 10 traits that all have pairwise correlations of 0.1. By sampling 
parameters uniformly, we eradicate the structure in our choices and allow the 
parameters to take any values within a prescribed range. In this way, the power 
estimates we achieve in this scenario should act as an average of other more 
structured scenarios, and provide a more general indication of the performance of 
the methods. 
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We sample the genetic effects from the uniform distribution: 
 𝑈(0, 0.005) 
 
such that the genetic effects can take any value between 0% variance explained and 0.5% variance explained. We sample the pairwise phenotypic correlations from the 
uniform distribution: 𝑈(−0.9, 0.9) 
 
such that the pairwise phenotypic correlations can take any value between −0.9 and 0.9 . We perform this sampling for each pair of phenotypes, and construct the 
corresponding phenotypic correlation matrix. This matrix is required to be positive 
definite, and so the matrix is resampled if the previous sampling of pairwise 
phenotypic correlations did not result in a positive definite matrix, but otherwise each 
of the 10,000  genotype-phenotype simulated datasets relate to a random 
combination of genetic effects and phenotypic correlations. 
 
While this scenario simulates a random and diverse set of effects and correlations 
and thus may be vulnerable to simulating unrealistic combinations of genetic effects 
and phenotypic correlations, the aim here is to generate unrestricted parameter 
values in contrast to the first scenario; by doing so, we hope to gain an overall picture 







2.3.3 S3: Genetic effects reflective of phenotypic correlations 
 
Since most causal genetic variants explain < 1% of phenotypic variance (Park et al., 
2010; Visscher et al., 2012), their effects on a set of phenotypes do not induce 
phenotypic correlations reflecting their relative sizes. However, it may be likely that 
genetic effects are on average more reflective of the corresponding phenotypic 
correlations than not. Here we simulate data such that the phenotypic correlations 
reflect the relative sizes of the genetic effects. Phenotypic correlations are chosen to 
reflect the genetic effect vectors described in scenario S1 (three effect vectors for 
two traits, and 10 for four or more traits) in the following way: if the variant has equal 
effects on two traits then the corresponding phenotypic correlation is set to be 0.6, for 
different effect sizes the correlation is 0.2, and if the variant affects one phenotype 
but not the other then their pairwise correlation is set as 0.05.  
 
In this way, we align the phenotypic and genetic correlations so that they are 
concordant, which leads to simulation of potentially more realistic genotype-
phenotype data and avoids modelling scenarios that are highly unlikely to occur in 
biological data. As in scenario S1, the power of the methods will be a function of the 
phenotypic correlations modelled, the impact of which can be further explored using 
our simulation tool. 
 
2.3.4 S4: Real data informed genetic effects and phenotypic 
correlations 
 
The final simulation scenario exploits real data from published GWAS results, and 
from the individual-level genotype-phenotype data of the Northern Finland Birth 
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Cohort 1966 (NFBC1966) on 4,772 individuals, to simulate realistic values for the 
genetic effect and phenotype correlation parameters. This scenario is in two parts:  
 
 (a)  Real data informed phenotype correlations 
 (b)  Real data informed genetic effects and phenotype correlations 
 
2.3.4.1 (a) Real data informed phenotype correlations 
Here we fit a mixture Gaussian distribution to the observed Northern Finland Birth 
Cohort 1966 (NFBC1966) phenotype correlations of 16 metabolic traits. We used this 
set of metabolic traits, which include BMI, systolic and diastolic blood pressure, HDL 
and LDL, because they represent a large number of well-measured quantitative 
phenotypes with diverse pairwise correlations. We fit a theoretical distribution to this 
in order to sample uniquely from it repeatedly; the fitted mixture Gaussian distribution 
is given by: 
  120  Ν −0.23, 0.045! +  910Ν 0.21, 0.175! +  120Ν(0.74, 0.07!)   (2) 
 
The observed NFBC1966 and fitted probability density functions are shown in Figure 
7. Genotype-phenotype data are generated as in scenario S1 but by sampling the 
pairwise phenotypic correlations from this fitted density, discarding sampled non-
positive definite correlation matrices. This scenario is similar to scenarios S1 and S2 
in that the genetic effect vectors are independent of the phenotypic correlations. 
However, the phenotypic correlations are based on real data here and so these data 
should be more reflective of epidemiological data. 
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Figure 7. Phenotypic correlation density based on 16 metabolic traits from the NFBC1966, and fitted 
mixture Gaussian density as given in Equation 2. Pairwise phenotypic correlations are sampled from 
this fitted density for simulations of scenario S4a. 
 
2.3.4.2 (b) Real data informed genetic effects and phenotype correlations 
Here we sample genetic effect sizes directly from reported genotype-phenotype 
associations from publicly released GWAS on 12 phenotypes: height (Wood et al., 
2014), BMI (Yang et al., 2012), systolic and diastolic blood pressure (The 
International Consortium for Blood Pressure, 2011), Triglycerides, HDL, LDL and 
total cholesterol (Global Lipids Genetics Consortium, 2013), fasting-glucose, fasting-
insulin, HOMA-B and HOMA-IR (Dupuis et al., 2010). We compiled a list of all SNPs 
with a reported genome-wide significant association in the largest available GWAS 
on each trait, and recorded the corresponding genetic effect size for each SNP 
across all 12 traits. Across the 12 phenotypes under study there are a total of 237 
unique SNP-phenotype associations with complete summary data across all traits, 
and thus 237 SNPs eligible for inclusion in the multi-trait analyses. From this set of 
SNPs, for traits with 20 or fewer genome-wide significant associations, all associated 
SNPs are taken forward for analysis. Of the remaining traits, 20 SNPs are sampled 




















from the larger set of associated SNPs in order to reduce bias toward traits with a 
larger number of genome-wide significant findings. This approach is applied for the 
analysis of all 12 phenotypes, as well as for the subsets of 2, 4 and 8 phenotypes. 
 
We use the 𝛽 (SNP effect size) estimates from these published GWAS to inform the 
simulation of genetic effects. For a given SNP 𝐺! we take the absolute effect size 
estimates across 𝐾 phenotypes, say 𝛽!,… ,𝛽!, and apply a transformation so that the 
maximum effect size is 0.5% of phenotypic variance, while maintaining the relative 
effect sizes. The transformation factor, 𝑑!, for SNP 𝐺! is defined as follows: 
 
𝑑! = 𝛽!𝛽!! 
where 
 𝛽! = 0.0052𝑝𝑞  
 
 
where 𝑝 = 1 −𝑀𝐴𝐹 , 𝑞 = 1 − 𝑝 , 𝛽!  is the beta coefficient that corresponds to the 
maximum effect size of 0.5% variance explained, and 𝛽!! is the maximum beta for a 
given SNP 𝐺!  across all 𝐾 phenotypes. The real data obtained beta coefficients for 
SNP 𝐺!  are then multiplied by 𝑑! to generate the beta coefficients used to simulate 
the phenotype data according to Equation 1. 
 
The real effect sizes are transformed so that the largest effect is equivalent to 0.5% 
of phenotypic variance so that the results of scenario S4b can be directly compared 
to those of the other scenarios, since power is a function of effect size. The relative 
effect sizes of the set of SNP-phenotype associations remain the same after the 
transformation.  
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We then simulate 10,000 replicates of genotype-phenotype data corresponding to 5,000 individuals by sampling from these genetic effect vectors and directly (not from 
the fitted density of Figure 7) from the phenotypic correlations estimated in the 
NFBC1966 data on those traits. As well as simulations based on all 12 phenotypes, 
we repeat this scenario for 2 , 4  and 8  phenotypes by iterating through all 𝐶!.!"  
combinations of the 12 phenotypes, forming the corresponding genetic effect vectors 
and phenotype correlation matrices to simulate the data. 
 
2.4 Comparison with previous multivariate genetic 
simulations  
 
We designed the simulation settings implemented in this framework to be as 
comprehensive as possible by considering a variety of different simulation scenarios, 
including those that likely closely match reality. Previous simulation efforts, while 
seemingly considering a range of scenarios, have not fully explored the available 
model space and have thus provided an incomplete picture of the performance of 
multi-trait methods. 
 
2.4.1 van der Sluis et al. 2013: TATES: Efficient Multivariate Genotype-
Phenotype Analysis for Genome-Wide Association Studies 
 
Publications of novel methodology are often accompanied by simulation studies 
showing that the novel method is preferable to existing methodology in terms of 
statistical power. An example is the publication of the TATES method (van der Sluis 
et al., 2013), which produces an omnibus P-value for the association of each SNP 
with a group of phenotypes from a set of corresponding univariate P-values from 
published GWAS. The authors considered a series of different network models to 
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assess the performance of their method. One type of model considered is a single 
factor network where a genetic variant has an effect on a single factor, which then 
affects a series of traits (Figure 8a), or the genetic variant effects a trait directly, 
which is correlated with other traits via a single factor (Figure 8b).  
 
  
Figure 8. Single factor biological networks where (a) the genetic variant has a direct effect on a 
mediating factor, which has effects on multiple phenotypes, and (b) the genetic variant has a direct 
effect on one phenotype, which is correlated with other modelled phenotypes via a single factor. 
 
Multi-factorial models are also considered where the genetic variant has an effect on 
a single factor, which then affects a series of traits, with a correlation between this 
factor and other factor(s) (Figure 9a), or the genetic variant affects a trait directly, 














Figure 9. Multi-factorial biological networks where (a) the genetic variant has a direct effect on a 
mediating factor, which is correlated with another factor, both of which have effects on phenotypes, and 
(b) the genetic variant has a direct effect on one phenotype, which has a correlation structure with the 
other modelled phenotypes via the two factors. 
 
The single factor models correspond directly to the model used in our simulation 
framework to simulate direct genetic effects. Simulations of the factor model given by 
Figure 8a can be achieved by our simulation framework; the impact of the genetic 
effects going via a mediating factor are that the genetic effects on the traits are 
diminished. However, by choosing appropriate values for the genetic effect from the 
variant to the factor and from the factor to the traits, the whole model space can be 
explored using our framework. Here the phenotypic correlation is induced by the 
mediating factor, but in our model we can stipulate the phenotypic correlations 
explicitly. The factor model of Figure 8b corresponds to a special case of the one 
factor model, where the genetic variant affects only one trait, and is correlated with 
other traits via some factor. In our simulation framework the two one-factor models 
are considered to be the same modelling scenario where we can achieve the model 
of Figure 8a by simulating genetic effects on all correlated traits, and Figure 8b by 
simulating only one trait to be affected by the genetic variant, and inducing a 
phenotypic correlation between the traits.  
 
The modelling scenarios of the multi-factorial models can also be achieved using our 
simulation framework via appropriate choice of the genetic effects and phenotypic 
.  .  .
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correlations. In both Figure 9a and Figure 9b, the two factor models induce a 
correlation structure in the phenotypes due to the two groupings of factors and 
phenotypes, which can be achieved in our simulation framework by appropriate 
choice of the phenotypic correlation matrix i.e. by having sub-matrices that 
correspond to the two groups of phenotypes. In Figure 9a the genetic variant (𝐺) is 
affecting one factor (𝐹!), which is correlated with the other factor (𝐹!). This means 
that the genetic effect on traits 𝑃! to 𝑃!  is mediated by 𝐹! and thus diminished, while 
the genetic effects on phenotypes 𝑃! to 𝑃! are further diminished according to the 
correlation between the two factors. Like in Figure 8, the scenario represented by 
Figure 9b is a special case of the two-factor model of Figure 9a, where only one trait 
is affected by the genetic variant, and there exists a correlation structure between the 
traits. Again, in our simulations these are considered to be one modelling scenario, 
where both Figure 9a and Figure 9b can be achieved by choosing the genetic 
effects appropriately, and setting up the phenotypic correlation matrix to induce the 
correlation structure of a two-factor model. 
 
Finally, a network model is considered where the genetic variant affects a trait, with 





Figure 10. Network model where a genetic variant (𝐺) affects a single phenotype 𝑃! which is part of an 
interconnected network of phenotypes with effects between phenotypes. 
 
The network model of Figure 10 is the most different to the other models considered. 
Here a genetic variant (𝐺) affects a single phenotype 𝑃!, which is in a larger network 
of phenotypes, where there exists not only correlations between the phenotypes but 
also causal effects between them. This type of model can be achieved in our 
downstream analyses of scenario S1, where downstream effects between traits exist. 
While we only directly consider two traits for the purposes of our comparison, more 
traits could easily be incorporated.  
 
In the context of assessing the performance of multi-trait GWAS methods, the key 
factors are the sample size, the magnitude of genetic effects on the traits being 
analysed, and how the traits are correlated, meaning that the results pertaining to 
these various factor models can be obtained by varying the genetic effects and 
phenotypic correlations in our framework appropriately. By varying these two sets of 
parameters systematically across a wide range of possible values we can gain 
insight into the performance of multi-trait GWAS methods across different modelling 







In the paper presenting the TATES method (van der Sluis et al., 2013) a mixture of 
different sizes of genetic effect is not considered in these factor and network models. 
Although data are simulated for genetic effects between 0%  and 1% variance 
explained in increments of 0.1, varying the effect size equally across all traits is 
equivalent to simply varying the sample size, and there is no exploration of the effect 
of mixed genetic effects. Continuous, binary and ordinal traits are simulated and 
methods are applied to a mixture of different types of phenotype, as well as to just 
continuous traits, with up to 20 traits simulated. However, the correlations of these 
traits – or correlations between different groupings of the traits in the case of the 
multi-factorial models – are not varied systematically, rather specific point values of 
the correlations are chosen and these chosen correlations are all positive. 
 
2.4.2 Galesloot et al. 2014: A Comparison of Multivariate Genome-Wide 
Association Methods 
 
Galesloot and colleagues (Galesloot et al., 2014) performed a comparison study of 
multi-trait GWAS methods using simulated data on just three traits, with three 
scenarios of genetic effect: the genetic variant affects only one trait, the genetic 
variant affects two traits, and the genetic variant affects all three traits (genetic 
effects fixed at 0.1%). While these genetic effects will capture a pleiotropic effect of 
the genetic variant on the traits, as well as only a single trait being affected, a mixture 
of genetic effect sizes is not considered here, and the small number of traits 
analysed limits the model space dramatically. Only three levels of phenotypic 
correlation (0, 0.3 and 0.7) were simulated rather than exploring the full correlation 
range, meaning that only a snapshot of the performance of the methods is provided, 
and no negative phenotypic correlations are considered. The other parameter that is 
varied is the minor allele frequency (𝑀𝐴𝐹). However, this corresponds to varying the 
 74 
effect size in terms of statistical power, and so does not provide additional insight into 
the relative performance of the methodology and does not make clear by how much 
the effect size has changed in terms of phenotypic variance explained.  
 
Positive and negative genetic correlations are also considered, where there exists a 
positive correlation when the genetic effects are in the same direction, and a 
negative correlation when the genetic effects are in opposite directions. This involves 
the determination of the sign of the beta coefficient of the SNP effect on the traits. If, 
for two traits, the signs are the same then this will induce a positive genetic 
correlation; if the signs are opposite then the traits will be negatively genetically 
correlated. We would expect the results obtained by simulating negative genetic 
correlations to correspond to those with a positive genetic correlation but where a 
negative phenotypic correlation is simulated, which we consider in our simulations of 
scenario S1, the results of which are presented in Chapter 3.  
 
While the simulation scenarios used in this comparison study did provide some 
indication of the performance of multi-trait GWAS methods, they only captured a 
limited snapshot of the possible modelling scenarios, and so we cannot construct the 
full picture of the performance of the methods from these results alone. Other 
important factors for the performance of multi-trait GWAS methods were not 
considered, such as modelling large numbers of traits, a mixture in genetic effect 









We have presented a simulation framework for generating data relating genetic 
variants with multiple phenotypes. The framework incorporates a range of simulation 
scenarios to explore the vast model space relevant to multivariate genetic data, thus 
providing a consistent platform for benchmarking multivariate methods, of sufficient 
rigor to expose their differences and similarities and to demystify user choice.  
 
The motivation behind this simulation framework was to construct simulation 
scenarios relevant to multi-trait GWAS methods, in order to facilitate a 
comprehensive comparison between them. We focus on the modelling challenges of 
single-SNP, multi-trait methods, but there are methods that also model multiple 
SNPs jointly (Bottolo et al., 2013; Zhou and Stephens, 2012; Kim et al., 2016). 
Modifications could be made to the simulation framework presented here to make it 
applicable to this type of method, by generating correlated SNP data and simulating 
groups of SNPs with effects on sets of correlated phenotypes. While we consider a 
wide range of possible modelling scenarios, due to the infinite combinations of 
genetic effect and phenotypic correlations, we inevitably had to restrict to a feasible, 
yet broad, set of parameters. However, our simulation software will facilitate the 
exploration of many more simulation scenarios by varying the simulated causal 
relationships between genetic variants and correlated sets of phenotypes. 
 
While we go on to exploit the simulation framework for a multi-trait GWAS methods 
comparison, our framework and accompanying simulator should have wide 
application across genetic epidemiology. Moreover, with minor modifications, such as 
modelling a normally distributed risk factor such as a polygenic risk score (PRS), the 
simulation framework could be exploited to model any network of correlated variables 
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for which a subset are influenced by a common factor. Thus our simulation 
framework, implemented as a web application and open-source software program 
(www.MultiTraitGWAS.kcl.ac.uk) has potential utility across the life sciences, 





3.  Comparison and investigation of the 
performance of multi-trait GWAS 
methods 
 
In Chapter 2 we presented the multivariate simulation framework that forms the 
basis and motivation for the analyses in this chapter. While our simulation framework 
and associated software will be useful for multivariate methodology development and 
applications across genetic epidemiology, we exploit it here specifically to perform a 
comprehensive comparison of multi-trait GWAS methods and to investigate the 





Burgeoning availability of genome-wide association study (GWAS) results and 
national biobank data has led to growing interest in performing multi-trait genetic 
analyses. Numerous multi-trait GWAS methods that exploit either summary statistics 
or individual-level data have been developed (O’Reilly et al., 2012; van der Sluis et 
al., 2013; Zhu et al., 2015; Ferreira and Purcell, 2009; Klei et al., 2008; Aschard et 
al., 2014; Stephens, 2013; Marchini et al., 2007; Bolormaa et al., 2014; Casale et al., 
2015; Zhang et al., 2014; Kim et al., 2016), but their relative performance is unclear. 
Here we exploit the simulation framework presented in Chapter 2 to perform a 
comprehensive comparison of the leading single-SNP multi-trait methods, both those 
that use individual-level genotype-phenotype data: MANOVA (Nath and Pavur, 
1985), CCA (mv-PLINK) (Ferreira and Purcell, 2009), Combined-PC (Aschard et al., 
2014), MultiPhen (O’Reilly et al., 2012), mv-BIMBAM (Stephens, 2013) and mv-
SNPTEST (Marchini et al., 2007), and those that exploit GWAS summary statistics: 
min-P (O’Reilly et al., 2012), TATES (van der Sluis et al., 2013), SHom and SHet (Zhu 
et al., 2015). These methods cover several approaches to testing the association of 
genetic variants with multiple phenotypes, including multiple linear regression 
techniques (Ferreira and Purcell, 2009; Aschard et al., 2014), a reversed (ordinal) 
regression with SNP as outcome (O’Reilly et al., 2012), simple (O’Reilly et al., 2012) 
and complex (van der Sluis et al., 2013) adjustments of summary statistic results, 
across trait meta-analysis techniques (Zhu et al., 2015) and Bayesian methods 
(Stephens, 2013; Marchini et al., 2007).  
 
The simulation framework was developed to provide a thorough and consistent 
platform on which to compare and benchmark these different methods. We illustrate 
statistical power across a variety of combinations of genetic effects and phenotype 
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correlations for up to 48 phenotypes, which we believe represents the clearest way to 
expose differences in method performance. In addition, we provide insight into the 
behaviour of the different approaches to multi-trait GWAS, and shed light on when 
methods should be implemented in order to optimise discovery power. Our findings 
provide the clearest picture to date of the relative performance of multi-
trait GWAS methods and act as a guide for method selection in the field. 
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3.2 Material and Methods 
 
3.2.1 Multivariate simulation framework 
 
The simulation framework utilised in this comparison of the leading multi-trait GWAS 
methods was presented in Chapter 2. Table 3 provides a summary of the simulation 
scenarios considered. 
 
Scenario Phenotypes Genetic Effects Phenotypic Correlations 
S1 2, 4, 8, 20 and 48 Fixed genetic effects defined by 𝒗𝟏 −  𝒗𝟑 for 2 traits and  
Table 2 for 4 or more 
traits 
Pairwise phenotypic 
correlations range between -0.9 
and 0.9 in increments of 0.1 
S2 2, 4 and 8 Genetic effects sampled uniformly between 0% and 0.5% phenotypic 
variance explained 
Phenotypic correlations 
sampled uniformly, ensuring 
the resulting correlation matrix 
is positive definite 
S3 2, 4, 8, 20 and 48 Genetic effects chosen to reflect the phenotypic 
correlations 
Pairwise phenotypic 
correlations chosen according 
to the genetic effects 
S4a 2, 4 and 8 Fixed genetic effects defined by 𝒗𝟏 −  𝒗𝟑 for 2 traits and  
Table 2 for 4 or more 
traits 
Phenotypic correlations 
sampled from a fitted mixture 
Gaussian distribution based on 
NFBC1966 data 
S4b 2, 4, 8 and 12 Genetic effects based on univariate GWAS 
summary statistics 
Phenotypic correlations 
obtained directly from the 
NFBC1966 on the phenotypes 
for which the genetic effects 
were obtained 
Table 3. Summary of the simulation scenarios that comprise the simulation framework presented in 






3.2.2 Multi-trait GWAS methods 
 
The 10 methods included in the comparison study are briefly described below. These 
methods were chosen due to a combination of them being highly cited and 
representing a diverse set of approaches to multi-trait GWAS. While methods exist 
that simultaneously model multiple SNPs and multiple traits (Bottolo et al., 2013; 
Zhou and Stephens, 2012; Kim et al., 2016) we focus on the more common single-
SNP methods here to isolate the methodological advances responsible for the 
greatest increases in power when modelling multiple phenotypes. 
 
3.2.2.1 Univariate adjustments 
We include two methods in our comparison study that perform adjustments to 
univariate P-values to obtain a joint-association P-value across traits. These methods 
do not, however, explicitly model the phenotypes jointly. The minimum joint P-value 
for a SNP obtained by these methods is determined by the minimum P-value at that 
SNP across all traits under study. Thus, these methods cannot identify novel 
findings, but are included here as a comparison to the univariate approach. 
 
min-P: This test was proposed in O’Reilly et al. (O’Reilly et al., 2012) as a way of 
comparing MultiPhen to a simple multi-trait approach that exploits only existing 
GWAS univariate summary statistics. First, the minimum P-value from the group of 𝐾 
P-values corresponding to the 𝐾 phenotypes under study is recorded for every SNP, 
using the published univariate GWAS results. Next the effective number of 
independent tests represented by the results on the 𝐾 phenotypes is estimated using 
the correlation matrix of the phenotypes according to Nyholt (Nyholt, 2004), and then 
the recorded minimum P-value is adjusted according to this number of tests in a 
standard Šidák correction (Sidak, 1971).  
 82 
TATES: This test is similar to that of min-P but performs a more sophisticated 
correction for multiple testing across the different phenotype results (van der Sluis et 
al., 2013). Here the results are ranked according to P-value and then the extended 
SIMES procedure of Li et al. (Li et al., 2011) is performed – on multiple traits rather 
than variants – by progressively re-ordering the minimum P-value according to a 
scaling that is a function of the effective number of independent P-values.  
 
3.2.2.2 Summary statistic GWAS methods 
We include two methods that use summary statistics (beta and standard error 
estimates) from univariate GWAS to perform multi-trait analyses. These methods 
perform meta-analyses across traits and cohorts. 
 
SHom: This test combines Wald test statistics from univariate GWAS summary 
statistics relating to a SNP across both multiple cohorts and multiple phenotypes in a 
meta-analysis (Zhu et al., 2015). Heterogeneity in effect size and statistical power 
across cohorts is accounted for, as is the correlation among the test statistics, while 
the overall test statistic has optimal power when the genetic effect is homogeneous 
across traits and cohorts. Of the 10 tests considered here, SHom is that which can be 
most considered a ‘test for pleiotropy’, being equivalent to a meta-analysis of effect 
sizes across traits and cohorts with optimal power under fixed effects. 
 
SHet: This test is derived from SHom but is designed to detect genetic variants that only 
affect a subset of the total number of traits under study (Zhu et al., 2015). Only those 
traits with a corresponding Wald test statistic above some threshold are included in 
the calculation of a statistic equivalent to that of SHom. This is then recalculated 
across the range of possible threshold values with the maximum value obtained 
being the test statistic SHet. Since this SHet statistic does not follow a standard 
theoretical distribution, P-values are computed via simulation.  
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3.2.2.3 Individual-level GWAS methods 
Included in our comparison study are a range of different approaches to performing 
multi-trait GWAS that exploit individual-level genotype-phenotype data. The 
development of individual-level methods has been an active area of research in 
genetic epidemiology, which is reflected in the diverse approaches developed here. 
 
MANOVA: The standard Multivariate Analysis of Variance statistical test (Nath and 
Pavur, 1985), which is the multivariate extension of ANOVA, and equivalent to a 
reversed multivariate linear regression with genetic variant as outcome (O’Reilly et 
al., 2012). 
 
CCA (mv-PLINK): Canonical Correlation Analysis (CCA) refers to a statistical 
procedure for identifying and testing the association of linear combinations of two 
sets of variables that maximise their correlation. While this approach could 
theoretically be applied to test for association between multiple genetic variants and 
traits jointly, in the context of multi-trait, single-SNP analyses, as incorporated into 
PLINK (Ferreira and Purcell, 2009), this test is equivalent to a reversed multivariate 
linear regression with a single genetic variant as outcome (O’Reilly et al., 2012). This 
method is equivalent to MANOVA, and has been shown to be approximately 
equivalent to MultiPhen (see below) for common SNPs (O’Reilly et al., 2012). 
 
Combined-PC: This test performs a principal components analysis (PCA) on the 
phenotype data (Aschard et al., 2014). Separate univariate linear regressions are 
performed each with a different PC as outcome and SNP as predictor, and then the 
chi-squared statistics corresponding to the SNP-PC association from each 
regression are summed. Since the PCs are orthogonal to each other these tests are 
independent and their results can thus be summed in this way. Given small genetic 
effect sizes, the simple linear regressions of PC on SNP are approximately 
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equivalent to reverse regressions of SNP on PC; the sum of these individual 
regressions is then equivalent to a multiple linear regression with PC predictors. 
Since all PCs are included as predictors, this is equivalent to a multiple linear 
regression with phenotype predictors and SNP as outcome, and thus overall the 
Combined-PC method is approximately equivalent to CCA (mv-PLINK) (Ferreira and 
Purcell, 2009). 
 
MultiPhen: This test performs a ‘reversed regression’, with multiple phenotype 
predictors and genetic variant as outcome (O’Reilly et al., 2012). Since genotypes of 
SNPs (and other genetic variants) correspond to ordinal data, an ordinal regression 
is performed here.  This test has been shown to be equivalent to MANOVA and CCA 
for common SNPs (O’Reilly et al., 2012). 
 
mv-BIMBAM: This test (Stephens, 2013) performs Bayesian multivariate regression 
by partitioning the phenotypes according to the effect of the genetic variant on them: 
direct, indirect or no effect. Statistical power is assessed using a log!" Bayes factor 
threshold of 6, following Stephens and Balding (Stephens and Balding, 2009) and 
Shim et al. (Shim et al., 2015).  
 
mv-SNPTEST: This test performs Bayesian multivariate regression using an inverse 
Wishart distribution and matrix normal priors (Marchini et al., 2007). The fit of the full 
model is compared to that of the null model, and a log!" Bayes factor quantifies the 




3.3 Multi-trait GWAS method comparison study 
 
The illustration of method performance in the literature is often challenging to 
interpret and is highly inconsistent across publications. Researchers are thus left with 
a perplexing choice between competing methods. Our dedicated simulation 
framework enables a systematic and rigorous search across the multivariate model 
space. We present results across a range of genetic effects and phenotypic 
correlations, from which a clear picture of the relative performance of the methods 
emerges. Our findings can guide the design of future GWAS, in particular those 
utilising the rich multivariate data becoming available from large-scale biobanks such 
as the UK Biobank, German National Cohort and planned US Biobank.  
 
3.2.3 S1: Structured genetic effects and phenotypic correlations  
 
In this scenario the genetic effects, 𝒗, and phenotypic correlations, 𝒄, are varied in a 
structured way; for simulations of two phenotypes we consider three genetic effect 
vectors: 𝒗𝟏 = 0.50.5  
 𝒗𝟐 = 0.50.1  
 𝒗𝟑 = 0.50  
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The phenotypic correlations are varied between −0.9 and 0.9 in increments of 0.1. 




Figure 11. (a) The genetic variant explains 0.5% variance in two traits (𝒗𝟏). (b) The genetic variant 
explains 0.5% variance in one trait and 0.1% in the other (𝒗𝟐). (c) The genetic variant explains 0.5% 
variance in one trait and has no effect on the other (𝒗𝟑). 
 
Figure 11 shows that the methods fall in to one of two distinct groups in terms of 
their power curves, except for SHom, which has a different pattern in Figure 11b and 
Figure 11c. The min-P and TATES methods – which have almost identical power – 
have lower power across much of the parameter space. In Figure 11a, we observe a 
decrease in power for min-P and TATES across the correlation range. Both methods 
perform univariate tests for association with each trait before correcting the smallest 
P-value to account for the number of tests performed. When the traits are highly 
positively correlated the variability in the univariate P-values is small, resulting in 
similar P-values for each test. In contrast, when the traits are uncorrelated the two 
tests are independent and the variability in the univariate P-values is greater, 
increasing the probability that one is small. For negative phenotypic correlations, this 
variability is even greater, resulting in higher power. However, in Figure 11b and 
Figure 11c, since the genetic effect on the second trait is very small or zero, then the 
minimum P-value will almost certainly derive from the SNP with large effect and is 
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(a)  (b)   (c) 
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The group of methods that follow a different pattern gain power via reducing the 
residual variance in analysing the traits jointly. When the genetic variant affects both 
traits equally and the traits are highly correlated (Figure 11a), these methods lose 
power due to the limited additional residual variance explained for the same degrees 
of freedom penalty. When only one trait is affected by the genetic variant and the 
phenotypes are uncorrelated (Figure 11c) then there is no gain in residual variance 
explained by including the unaffected trait. The methods gain power when there is 
discordance between the genetic effects and the phenotypic correlations, due to the 
potential increase in explained residual variance. Figure 11c shows that while the 
SHet method follows the same pattern as the other methods in this group, it has lower 
power for high positive and negative correlations. This is due to the trait sub-setting 
procedure of SHet, which incurs a relatively strong, multiple testing penalty. However, 
as a summary statistic method SHet can be applied to large publicly available GWAS 
results and thus may have a substantial boost in power for certain traits. 
 
In Figure 11 the SHom method, which performs a meta-analysis on the traits, 
generally performs best in pleiotropic scenarios. In Figure 11c only one trait is 
affected by the genetic variant and when the traits are uncorrelated there is no gain 
in power by including the unaffected trait; SHom loses power over min-P and TATES 
here due to it relating to the average rather than maximum association. For highly 
positively correlated traits, the addition of the unaffected trait in the meta-analysis 
reduces the average effect size and thus power, but for highly negatively correlated 
traits the individual effect sizes are augmented, leading to increased power. While a 
standard meta-analysis would produce a different power curve to that of SHom in this 
scenario, the latter explicitly adjusts for the trait correlations, which provides a well-
behaved statistic under the null. The same explanation applies to Figure 11b, 
although here the loss in power for SHom is less pronounced due to the small genetic 
effect on the second trait. 
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For four or more traits, we use the 10  genetic effect vectors defined in  
Table 2 of Chapter 2. Figure 12 illustrates the results corresponding to 𝒗𝟏, 𝒗𝟒, 𝒗𝟖 
and 𝒗𝟏𝟎 in relation to four phenotypes. 
 
 
Figure 12. Power comparisons from simulations of scenario S1, based on (a) 𝒗𝟏, (b) 𝒗𝟒, (c) 𝒗𝟖 and (d) 𝒗𝟏𝟎 (see Table 2 of Chapter 2) applied to data on four phenotypes. For all scenario S1 results the 
correlations between all phenotypes are the same. Correlations <  −0.3 are not possible across four 
phenotypes, hence the truncation in these – and subsequent - results across the correlation range. Full 
results for scenario S1 are shown in Figures 13 – 16. 
 
Figures 13 – 16 show the results for the remaining genetic effect vectors for 4 

























































Figure 13. Power comparisons from simulations of scenario S1, based on (a) 𝒗𝟐, (b) 𝒗𝟑, (c) 𝒗𝟓, (d) 𝒗𝟔, 
(e) 𝒗𝟕  and (f) 𝒗𝟗  (see Table 2 of Chapter 2) applied to data on four phenotypes. The pairwise 
phenotypic correlations are the same for all phenotypes. Correlations < −0.3 are not possible across 













































































Figure 14. Power comparisons from simulations of scenario S1, based on 𝒗𝟏  – 𝒗𝟏𝟎  (see  
Table 2 of Chapter 2) applied to data on eight phenotypes, (a) – (j) respectively. The pairwise 
phenotypic correlations are the same for all phenotypes. Correlations < −0.1 are not possible across 
















































































































 TATES    min−P    SHet    SHom    CCA    MANOVA    MultiPhen    Combined−PC    mv−BIMBAM    mv−SNPTEST   
  (a) (b) 
  (c) 
  (e) 
  (g) 







Figure 15. Power comparisons from simulations of scenario S1, based on 𝒗𝟏  – 𝒗𝟏𝟎  (see  
Table 2 of Chapter 2) applied to data on 20 phenotypes, (a) – (j) respectively. The pairwise phenotypic 
correlations are the same for all phenotypes. Correlations < 0 are not possible across 20 phenotypes, 
hence the truncation in these results across the correlation range. mv-BIMBAM and mv-SNPTEST are 
not computationally feasible for 20 or more phenotypes and so are excluded here. SHet is excluded, as a 
















































































































 TATES    min−P    SHom    CCA    MANOVA    MultiPhen    Combined−PC   
 (a) (b) 
 (c) (d) 
 (e) (f) 
 (g) (h) 
 (i) (j) 
 92 
 
Figure 16. Power comparisons from simulations of scenario S1, based on 𝒗𝟏  – 𝒗𝟏𝟎  (see  
Table 2 of Chapter 2) applied to data on 48 phenotypes, (a) – (j) respectively. The pairwise phenotypic 
correlations are the same for all phenotypes. Correlations < 0 are not possible across 48 phenotypes, 
hence the truncation in these results across the correlation range. mv-BIMBAM and mv-SNPTEST are 
not computationally feasible for 20 or more phenotypes and so are excluded here. SHet is excluded, as a 
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 (a) (b) 
 (c) (d) 
 (e) (f) 
 (g) (h) 
 (i) (j) 
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A clear pattern emerges across these results. The individual-level methods form a 
‘leading group’ in terms of power across much of the parameter space, in contrast to 
the lower performing pair of methods min-P and TATES, while SHom and SHet tend 
towards this leading group the more pleiotropic the scenario (e.g. 𝒗𝟏 ). SHet has 
markedly higher power than the other summary statistic methods in most scenarios 
and often similar to the individual-level data methods. In the most pleiotropic 
scenario, 𝒗𝟏, SHom performs best and min-P and TATES outperform the individual- 
level methods under high, positive phenotypic correlations (e.g. Figure 11a); 
otherwise SHom performs poorly. These differences in power between the methods 
increase with a greater number of phenotypes (see Figures 12 - 16). 
 
Figure 17 shows the behaviour of the methods under the null hypothesis of no direct 
genetic effects on all phenotypes. While the methods generally perform as expected 
under the null, there is mild inflation for min-P and TATES under high phenotypic 
correlations for ≤  8 phenotypes and for MultiPhen for 48 phenotypes, and strong 
deflation for min-P, TATES and SHom for 48 phenotypes. Therefore, use of these 
methods in these scenarios should either be avoided or else their statistics should be 












Figure 17. Simulations of scenario S1 under the null hypothesis of no genetic effect, applied to data on 
(a) 2, (b) 4, (c) 8, (d) 20 and (e) 48 phenotypes, based on 10,000 replicates. The pairwise phenotypic 
correlations are the same for all phenotypes, and the genetic variants are simulated to explain zero 
variance in all phenotypes. SHet is excluded for 20 and 48 phenotypes, as a gamma distribution could 
not be estimated for these correlation matrices. 
 
 
3.2.3.1 Downstream genetic effects 
In addition, we perform simulations to test the performance of the multi-trait methods 
in the presence of indirect genetic effects, whereby the genetic variant has an effect 
on one of the tested phenotypes via its effect on another (a downstream or mediated 
effect). Here we perform simulations that model such an effect across two 
phenotypes (see Chapter 2). The results from these simulations (Figure 18) closely 














































or a small direct effect on the other. Given that a genetic effect on a trait will be 
sharply attenuated when it is only exerted via its effect on another tested trait, then 
unless the phenotypes are highly similar we expect our results on direct effects to 
capture the vast majority of those relating to indirect effects as well. One exception is 
the Combined-PC test, the results of which depart from the other individual-level data 
methods over some of the parameter space when the first trait has a very large effect 
on the second (see Figure 18d). Large differences in results between the Combined-
PC test and the other individual-level data methods on real data may thus indicate 




Figure 18. Power comparisons from simulations of scenario S1 applied to data on two phenotypes with 
simulated downstream genetic effects. Phenotypic variance explained by the genetic variant in trait 1 is 0.5% in all cases, and in trait 2 is (a) 1%, (b) 5%, (c) 10% and (d) 20%. The pairwise phenotypic 
correlations are the same for all phenotypes. 
 
Figure 19 indicates that the behaviour of the methods under the null in the context of 


















































Figure 19. Simulations of scenario S1 with downstream effects under the null hypothesis of no genetic 
effect, applied to data on two phenotypes based on 10,000  replicates. The pairwise phenotypic 
correlations are the same for all phenotypes, and the genetic variants are simulated to explain zero 
variance in the first phenotype, which has a downstream effect on the second phenotype. 
 
3.3.1.2 Case-control phenotypes 
Most of our simulation scenarios relate to quantitative traits, since the majority of the 
methods tested here are designed for the analysis of continuous variables. In 
scenario S1, we also simulate case/control phenotypes (see Chapter 2). Figure 20 
shows the results for the seven multivariate methods that can be applied to 
case/control data. The results show a similar pattern to those on quantitative traits 
only, with the individual-level data methods having similar power and greater than 
that of the summary statistic methods, apart from when the genetic effects reflect the 
phenotypic correlations. Min-P and TATES appear to perform relatively better when 
applied to case/control data in general but worse when the genetic variant affects 
both phenotypes equally, while SHom performs poorly when there is an effect on only 


















Figure 20. Power comparisons for the simulations of scenario S1 involving two case/control phenotypes  
(top panel), and one case/control phenotype and a quantitative phenotype (bottom panel). The genetic 
variant either has (a) the same effect on both phenotypes, (b) a larger effect on the first phenotype, or 
(c) an effect on the first phenotype and no effect on the second – in the mixed phenotype scenarios the 
first phenotype is the quantitative phenotype (see Chapter 2 for details of these simulations). For all 
simulations, the case/control phenotypes have a simulated prevalence of 1% according to a liability 
threshold model. 
 
3.3.1.3 Dissection of the Combined-PC method 
The Combined-PC method (Aschard et al., 2014) performs a principal components 
analysis (PCA) on the phenotype data, and uses all PCs to test for association with 
the SNP. However, in other settings, such as controlling for population structure in 
GWAS, the top few PCs are often selected because they explain most variation in 
the data. This led us to investigate whether using just the top PC(s) may improve 
power. We performed simulations for two traits in scenario S1 and tested the 
Combined-PC method, as well as each PC separately. For the separate PC 
analyses, a linear regression was performed with the SNP as predictor and the PC 
as outcome. The same genetic effect vectors as in the earlier simulations of scenario 




































































 TATES    min−P    SHet    SHom    CCA    MANOVA    MultiPhen   
(a)  (b)   (c) 
(a)  (b)   (c) 
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(a) Same genetic effect on both phenotypes 
When the genetic variant affects both phenotypes equally and there is a negative 
phenotypic correlation, the second PC has highest power, mirroring the Combined-
PC method (see Figure 21). For positive phenotypic correlations, we observe the 
opposite. Here PC1, which is in the direction of the positive phenotypic correlation, 
has optimal power to detect the genetic effect. The Combined-PC method performs 
as an average of both PCs here, in that it has high power for negative phenotypic 
correlations as a result of PC2, yet additionally exploits the power of PC1 for positive 
phenotypic correlations. However, this approach is worse than applying only the first 




Figure 21. Power of the Combined-PC method, as well as the PCs individually under simulation of 
scenario S1 for two traits, where the genetic variant explains 0.5% variance in both traits. 
 
Figure 22 illustrates pictorially why we observe this pattern of power of the two PCs 
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is in that direction whereas PC2 is in the direction of the 𝑌 =  𝑋 line. Since there is a 
positive genetic correlation between the phenotypes in this scenario, the genetic 
effect is in the direction of the 𝑌 =  𝑋 line and is thus aligned to PC2, explaining its 
greater power for negative phenotypic correlations. When there is a positive 
phenotypic correlation (Figure 22b), PC1 is in the direction of the 𝑌 =  𝑋 line and is 
thus aligned to the direction of the genetic effect, resulting in greater power for PC1. 
 
  
Figure 22. Illustration of the direction of the principal components (PC) and the genetic correlation (G) 
for two phenotypes where both phenotypes are affected by the genetic variant with the same 
magnitude. 
 
(b) Different magnitudes of genetic effect 
When the genetic variant affects both traits but with different magnitudes, again the 
first PC has minimal power to detect the causal association for negative phenotypic 





































































Figure 23. Power of the Combined-PC method, as well as the individual PCs under simulation of 
scenario S1 for two traits, where the genetic variant explains 0.5% variance in the first trait and 0.1% 
variance in the second trait. 
 
For positive phenotypic correlations, however, PC1 largely has higher power than 
PC2. In this scenario a pictorial explanation for this pattern is complicated due to the 
different genetic effects on the phenotypes, and how the direction of the genetic 
effect compares to that of the PCs is challenging to explain intuitively. Thus, we 
consider the extreme scenario where only one trait is affected by the genetic variant 
(see below) to aid with the explanation of this scenario. 
 
(c) Only one phenotype affected by the genetic variant 
When the genetic variant affects only one of the two traits, the first PC has minimal 
power to detect the association between the SNP and the phenotype, whereas the 
power of the second PC follows a similar U-shaped pattern as the Combined-PC 
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Figure 24. Power of the Combined-PC method, as well as the individual PCs under simulation of 
scenario S1 for two traits, where the genetic variant explains 0.5% variance in the first trait, and has no 
effect on the second trait. 
 
Under this simulation setting, the genetic correlation between the traits is zero. If we 
imagine the extreme situation where the traits are perfectly correlated, such that their 
residual correlation is 1, the direction of this correlation would be completely aligned 
with PC1 on the line 𝑌 = 𝑋. However, one phenotype is affected by the genetic 
variant and there is no association between the genetic variant and the second 
phenotype. This additional genetic effect on the first phenotype leads to deviation 
from the perfect residual correlation, thus inducing spread around the 𝑌 = 𝑋 line, and 
so the genetic effect must be acting in the direction of the line 𝑌 =  −𝑋, which is the 
direction of PC2. Therefore, there is almost no power for PC1 and high power for 
PC2 here, which in this scenario has power equivalent to the Combined-PC method 
as the second PC is optimal. When the phenotypic correlation is weaker, this in itself 
induces spread around the 𝑌 = 𝑋 line, and so the power of PC2 decreases because 
the partial contribution of the genetic variant to the residual variance ensures that it is 
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When there is a perfect negative correlation between the traits, such that their 
residual correlation is −1, the direction of the phenotypic correlation is aligned with 
the 𝑌 = −𝑋 line, and so for the same reason as above, the genetic effect is aligned 
with 𝑌 = 𝑋, which is the direction of PC2 here. Given that when there are weaker 
levels of correlation between the phenotypes the direction of genetic effect does not 
align perfectly as in these extremes, the Combined-PC approach has optimum power 
by taking both PCs into account. 
 
The scenario where there are effects on both phenotypes of different magnitudes, 
see section (b) above, is a less extreme version of the one considered here, where 
instead there is a small genetic effect on the second trait. In this situation we would 
observe that the genetic variant causes further deviation by its effect on the second 
phenotype, thus making the relationship between the PCs and the genetic variant 
even more complicated. Broadly we see that the power curves of Figure 23 are 
similar to those of Figure 21, where the genetic variant has the same magnitude of 
effect on both traits, but in Figure 23 we observe reduced power due to the 
diminished genetic effect on the second trait. 
 
This investigation illustrates that the power of each PC is dependent on the genetic 
effects and phenotypic correlations, with one often being distinctly more powerful in a 
specific scenario. However, since the genetic effects are usually unknown, it is 
generally not possible to pre-select the most appropriate PC. As a general guide, 
when the genetic correlation aligns with the phenotypic correlation (both positive or 
both negative), the first PC has higher power. When the genetic and phenotypic 
correlations are not concordant, the second PC is preferable. However, when there 
exists weak genetic correlation, as in Figure 23, neither PC optimises power and the 
Combined-PC method is optimal. When more than two traits are analysed, the 
choice of the optimal PC becomes even more complex. Given that it is highly likely 
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that the traits to be analysed by such a method will contain a mixture of genetic 
effects of different magnitudes, the Combined-PC method will most likely, in general, 
optimise statistical power, as postulated in Aschard et al., 2014. 
 
3.2.3.2 Investigating the effect of negative genetic correlations  
In the previous simulations of scenario S1, while the magnitude of the simulated 
genetic effects was varied, the direction remained the same. Here we investigate the 
impact that a negative genetic correlation has on the power of the methods for 
simulations of scenario S1 with two traits, and for the genetic effect vectors defined 
earlier for this scenario. A negative genetic correlation in this scenario would be 
where the genetic variant increases the value of the first phenotype and decreases 
the value of the second phenotype (in the case of quantitative phenotypes), or vice 
versa. In terms of the data generating model as presented in Equation 1 of Chapter 
2, this corresponds to a positive beta 𝛽! for the first phenotype and a negative beta 𝛽! for the second, or vice versa. A reduced set of methods are used here as the 
findings for positive genetic correlations suggested two groups of method according 
to their performance – the univariate adjusted methods, here represented by min-P, 
and the individual-level data methods, here represented by CCA (mv-PLINK). In 
addition, SHom and SHet expressed performance similar to the individual-level 
methods, but with performance differences in certain scenarios, hence why they are 
both included here. Further exploration of the effects of negative genetic correlations 
can be performed using our simulation tool. 
 
(a) Same genetic effect on both phenotypes 
The general effect on the power of the methods when there is negative genetic 
correlation is that the power curves of the positive genetic correlation simulations are 
reflected about a phenotypic correlation of zero (see Figure 25). 
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Figure 25. Power of the methods under simulation of scenario S1 for two traits, where the genetic 
variant explains 0.5% variance in both traits, but where the genetic effects are in opposite directions. 
The min-P method represents the performance of the univariate-adjusted methods; CCA (mv-PLINK) 
represents the performance of the individual-level methods. 
 
However, the SHom method is an exception, producing zero power across the whole 
correlation range. As this method performs a meta-analysis of the traits, and the 
univariate t-values analysed are signed, the method has no power in the case of the 
same magnitude of genetic effects as these equal but opposite effects cancel each 
other out. This is not the case when the genetic effects have the same direction and 
thus the same direction of t-values. 
 
(b) Different magnitudes of genetic effect 
When the genetic correlation is negative - with genetic effects in opposite directions - 
and the magnitude of the genetic effects differ, the performance of all methods 
except SHom behave as expected (Figure 26), with the power curves a reflection of 
the ones observed above for positive genetic correlations. Unlike when the effects 
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Figure 26. Power of the methods under simulation of scenario S1 for two traits, where the genetic 
variant explains 0.5% variance in the first trait and 0.1% variance in the second trait, but where the 
genetic effects are in opposite directions. 
 
These observations provide an important consideration when performing multi-trait 
GWAS. It may be important to consider the direction of genetic effects before 
analysing multiple traits jointly, to avoid losing substantial power. In the application of 
GWAS summary statistics, we can observe the direction of effect of each SNP on 
each trait and could use this to guide which method to apply and which group of traits 
to analyse jointly. 
 
We have shown that in some scenarios SHom has optimal power for detecting causal 
associations, but the results from the simulation of negative genetic correlations 
suggests that this method can also perform poorly. Therefore, we investigated ways 
in which to improve upon this loss of power by, for example, taking the absolute 
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when absolute t-values are used for the SHom and SHet methods is shown in Figure 27 
for two traits under scenario S1, as well as the min-P and CCA methods for 
comparison. Figure 27a shows the results for the simulation of the same magnitude 
of genetic effect and Figure 27b shows the results when the magnitude of the 
genetic effects are different. 
 
 
Figure 27. Power of the methods under the simulation of scenario S1 with two traits, where absolute t-
values are analysed for the SHom and SHet methods. (a) The genetic variant explains 0.5% variance in 
both traits. (b) The genetic variant explains 0.5% in one trait and 0.1% in the other trait. In both cases, 
the genetic effects are in opposite directions. 
 
By taking the absolute of the t-values, we see that in both Figure 27a and Figure 
27b the power of the SHom and SHet methods are as expected; we observe the same 
pattern of power as in the case of positive genetic correlation, but here the curves 
are reflected about a phenotypic correlation of zero due to the opposite genetic and 
phenotypic correlations. However, when we perform null simulations by simulating no 
causal effect on both traits, this modification has led to the inflation of the SHom 
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Figure 28. Power of the methods under the null simulation of scenario S1 with two traits, where 
absolute t-values are analysed for the SHom and SHet methods. 
 
Both the SHom and SHet methods use the correlations between the t-values across 
traits as a proxy for the phenotypic correlations, and perform a t-value correlation and 
sample size weighted meta-analysis. Using the absolute t-values changes this t-
value correlation, and since SHom follows a chi-squared distribution (with 1 degree of 
freedom), taking the absolute value results in its distribution departing from a chi-
squared, leading to the observed inflation. SHet, however, does not follow a standard 
distribution; instead a Gamma distribution is estimated via simulation.  
 
The SHom method performs a test that is equivalent to one of the many tests 
performed in the SHet procedure. SHet tests subsets of the traits based on their 
univariate test statistics, including testing all traits given a specified threshold, 
whereas SHom only performs a meta-analysis on all traits. Taking the absolute t- 
values lead to deviation from the chi-squared distribution of the SHom statistic, thus we 
instead propose performing a version of the SHet method where we specify the 
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not appear to be affected by negative genetic correlations, we use the signed t-




Figure 29. Power of the methods under the simulation of scenario S1 with two traits in which we replace 
the SHom method with a version of SHet where we force all traits to be analysed jointly. (a) The genetic 
variant explains 0.5% variance in both traits. (b) The genetic variant explains 0.5% in one trait and 0.1% 
in the other trait. (c) The genetic variant explains 0.5% in one trait and has no effect on the other. (d) 
Null simulation where no genetic effects are simulated. In cases (a) and (b) the genetic effects are in 
opposite directions. 
 
The power curves in Figure 29a and Figure 29b are as expected for negative 
genetic correlations and we see that SHom has equivalent power to when we simulate 
positive genetic correlations, reflected about a phenotypic correlation of zero as 
described above. We also performed simulations where the genetic variant affects 
only one of the traits (see Figure 29c). Here negative genetic correlations are not 
possible, but we are interested to find out how the new SHom approach performs for 
this combination of genetic effects. We observe that the power of this modified 
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this can be explained by the gain in power for the SHet method by analysing subsets 
of traits when heterogeneous genetic effects exist.  
 
The null simulation results under these settings are shown in Figure 29d, and we 
observe no inflation for the new SHom approach. These simulations suggest that, 
given that genetic effects are likely to be in different directions across the genome, 
this new SHom approach should be adopted in order to optimise the discovery power. 
In Chapter 4 we utilise and develop this approach further, applying it to the latest 
GWAS summary statistics, but for the purpose of this comparison of published 
methods we revert back to applying the original SHom method for the remainder of the 
study. 
 
3.2.4 S2: Genetic effects and phenotypic correlations sampled 
uniformly 
 
In contrast to the structure of the S1 simulations, here we simulate data with genetic 
effects and phenotypic correlations sampled from uniform distributions, for 2, 4 and 8 
phenotypes. Figure 30 indicates that the individual-level data methods, as well as 
SHet and SHom, have almost identical power and distinctly higher than that of min-P 
and TATES, with the difference larger for a greater number of traits. These results 
are in broad agreement with those of scenario S1, where this leading group of 




Figure 30. Power comparisons for the simulations of scenario S2 involving 2, 4 and 8 phenotypes. In 
this scenario the phenotypic correlations are chosen uniformly such that the correlation matrix is positive 
definite, and the effect sizes are sampled uniformly between 0%  and 0.5%  phenotypic variance 
explained. 
 
3.2.5 S3: Genetic effects that reflect phenotypic correlations  
 
In this simulation scenario we simulate genetic effects that are reflective of the 
phenotypic correlations, since it seems likely that on average the genetic correlations 
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Figure 31. Power comparisons for the simulations of scenario S3 involving (a) 2, (b) 4, (c) 8, (d) 20 and 
(e) 48 phenotypes. In this scenario the phenotypic correlations are chosen to reflect the relative genetic 
effect sizes, as defined in Chapter 2. mv-BIMBAM and mv-SNPTEST are not computationally feasible 
for 20 or more phenotypes and so are excluded here for 20 and 48 phenotypes. SHet is excluded for 48 
phenotypes, as a gamma distribution could not be estimated for these correlation matrices. 
 
While the results for two phenotypes are mostly similar across all methods (see 
Figure 31a), the summary statistic methods generally outperform the individual-level 
data methods more as the number of traits increases. The results of SHom, however, 
are sensitive to the genetic effect vector, being the best or worst performing 
summary statistic method depending on the vector, while the power of SHet and the 
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Figure 31e) traits. These results are in broad agreement with those of scenario S1 in 
which the genetic effects and phenotypic correlations are concordant.  
 
3.2.6 S4: Real data informed simulations  
 
This final simulation scenario derives the simulation parameters (genetic effects and 
phenotypic correlations) from published GWAS results, in order to generate data 
reflective of reality. This scenario is in two parts:  
 
 (a)  Real data informed phenotype correlations 
 (b)  Real data informed genetic effects and phenotype correlations 
 
(a) Real data informed phenotype correlations 
In this simulation scenario, we use the same fixed genetic effect vectors as in 
scenarios S1 and S3 (three for simulations of two phenotypes, and 10 for simulations 
of four or more phenotypes). Here, however, we sample pairwise phenotypic 
correlations from a multiple-Gaussian distribution that was fitted to a real correlation 
density based on NFBC1966 data (see Chapter 2).  
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Figure 32. Power comparisons for the simulations of scenario S4a involving (a) 2, (b) 4 and (c) 8 
phenotypes. In this scenario the phenotypic correlations are sampled from a fitted mixture Gaussian 
density (see Chapter 2), and genetic effect sizes are defined in Table 2 of Chapter 2. 
 
Figure 32 reveals that the individual-level methods and SHet have markedly higher 
power than min-P and TATES for the majority of the genetic effect vectors. The 
performance of SHom is, again, highly dependent on the genetic effect vector, with 
greatest performance under pleiotropic effects. The results from this scenario are 
similar to those of scenario S2; in both cases the genetic effect vectors are 
independent of the phenotypic correlations, which optimises the statistical power of 
the individual-level data methods and SHet. 
 
(b) Real data informed genetic effects and phenotype correlations 
In this simulation scenario we sample the genetic effects from real data, by utilising 
genetic effect estimates from published univariate GWAS (see Chapter 2). We 
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Figure 33. Power comparisons for the real data informed simulations of scenario S4b involving (a) 2, (b) 4 , (c) 8  and (d) 12  phenotypes. For 12  phenotypes, all traits are analysed jointly. For 2 , 4  and 8 
phenotypes, data is simulated for all combinations of 𝐾 phenotypes using the corresponding genetic 
effects and phenotypic correlations drawn directly from real data; the power results shown correspond to 
the average of the power estimates from all combinations. 
 
These results, shown in Figure 33 for 2, 4, 8 and 12 traits, may provide the most 
informative overall comparison of method performance given their basis on real 
combinations of effects and correlations. For two phenotypes, the individual-level 
methods substantially outperform min-P, TATES and SHom, while SHet has similar 
power (see Figure 33a). As the number of phenotypes increases the power of the 
summary statistic methods decreases, with SHet and SHom having the most dramatic 
decreases in power. For 12 phenotypes, SHet has similar power to min-P and TATES, 
while SHom performs particularly badly in this scenario. From the results on 12 
phenotypes we would expect the individual-level data methods to yield approximately 
twice the discovery of genetic variants than the summary data methods when applied 
to real data studies of the same sample size. However, for studies that can utilise 
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summary statistic method may optimise statistical power. To explore this, we 
simulated genotype-phenotype data relating to 10,000  individuals and performed 
simulations using the best performing summary statistic method, SHet, to evaluate the 
potential power gains. The results, shown in Table 4, indicate that SHet has 
substantially higher power than the individual-level data methods at this increased 
sample size, although its advantage reduces with more traits. The expected power of 
the methods in studies exploiting individual-level or summary data of different sizes 
can be further estimated by our web application and software program that 

















2 0.366 0.947 0.382 148% 
4 0.382 0.94 0.439 114% 
8 0.31 0.894 0.432 107% 
12 0.21 0.835 0.432 93% 
 
Table 4. Power estimates for the SHet method under simulation scenario S4b with simulated data on 5,000 and 10,000 samples. The maximum power achieved by any individual-level data method for 5,000 
samples is shown, as well as the percentage increase in power for the SHet method on 10,000 samples 
compared to this individual-level data method on 5,000. 
 
We also performed computation time calculations for each of the 10 methods in order 
to assess and compare feasibility of applying these methods. The results can be 







Method 2 traits 4 traits 8 traits 12 traits 
min-P 0.001 0.001 0.001 0.001 
TATES 0.072 0.118 0.228 0.438 
SHet 4.612 8.127 15.437 26.497 
SHom 0.006 0.008 0.007 0.008 
CCA 0.967 1.211 1.534 2.156 
MANOVA 1.257 1.468 2.127 2.979 
MultiPhen 49.036 55.135 72.09 108.078 
Combined-PC 3.421 5.922 11.567 20.912 
mv-BIMBAM 6.72 16.763 1186.968 57050.64 
mv-SNPTEST 25.779 39.421 68.478 120.066 
 
Table 5. Computation time estimates (in seconds) for the 10 methods for 2, 4, 8 and 12 phenotypes. We 
assessed the computation time for all 10 methods on a machine with a 2.7 GHz Intel Core i5 processor 
and 8 GB 1600 MHz DDR3 RAM. We simulated data for 5,000 samples, 100 SNP replicates with MAF 0.3, genetic variance explained of 0.5% for all phenotypes, and pairwise phenotypic correlations of 0. 
 
As expected, the univariate adjusted method of min-P has the smallest computation 
time, as this method involves taking the smallest P-value and applying an adjustment 
for multiple testing, rather than directly performing a joint analysis. The computation 
time also does not increase much with the number of traits, making it scalable to 
large sets of phenotypes. The more complicated procedure of TATES does, 
however, incur additional computational burden with more phenotypes, and is 
consistently slower than min-P. Given the very similar performance between these 
two methods, min-P should be the preferred method for ease of implementation, as 
well as for the computational efficiency and scalability. Of the methods that utilise 
GWAS effect size estimates, SHet is significantly slower than SHom due to the 
computationally intensive sub-setting procedure of the SHet method. Since these 
methods have different optimal uses, one should not select one over the other. 
However, it could be the case that applying a manual sub-setting procedure, by 
choosing phenotypes to analyse jointly that are likely to exhibit homogenous genetic 
effects, and then applying the SHom method multiple times, is quicker than direct 
application of the SHet method. Additionally, the computational load of SHet 
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increases with more phenotypes, suggesting that the procedure described above 
could be a more feasible alternative for larger numbers of traits. While the individual-
level method of mv-BIMBAM provides the greatest overall power in the real data 
simulations of scenario S4b for 12 phenotypes, and is computationally feasible for 
small numbers of traits, it has the largest computational time by more than two orders 
of magnitude in the case of just 12 phenotypes. The most computationally efficient 
individual-level method is CCA, and given the scalability of this method to more 
phenotypes and the similar performance to the other individual-level methods, CCA 
could be considered the individual-level method of choice given its ease of 
implementation. Computational feasibility considerations will become increasingly 
important when applying these methods to large multivariate panels, such as the UK 
Biobank. These computation time calculations were performed on 5,000 samples of 
100 SNP replicates; for large panels of SNP data in population-wide cohorts, the 
computation time of these methods will be further compounded, making the choice of 
method based on computation time an important consideration. In the case of the 
biobank model, given we have observed that the summary statistic methods can 
replicate the power of the more computationally intensive individual-level methods in 
certain scenarios, it may be worth considering whether, for minimal loss in power, it 
would be more computationally efficient to perform univariate GWAS on the traits of 
interest before applying one of the summary statistic methods. Furthermore, by first 
obtaining the univariate summary statistic data, genetic correlation analyses can be 
performed in order to inform future joint analyses by establishing traits that are likely 
to exhibit pleiotropic effects, as well as enabling additional analyses such as 
polygenic risk scores. 
 
Table 6 provides a summary of the performance, both statistical and computational, 
of the multi-trait GWAS methods in this comparison study.  
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Method Performs well  when… 
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Genetic effects and 
phenotypic correlations 
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Moderate for few 








effects and phenotypic 
correlations, and larger 
numbers of traits 
Comparatively 
slow for small 
numbers of traits 
Table 6. Summary of the performance and computational speed of the multi-trait GWAS methods 




Here we exploited the multivariate simulation framework presented in Chapter 2 to 
perform a comprehensive comparison of the leading multi-trait GWAS methods. 
Development of multi-trait GWAS methodology has been an active area of research 
in recent years (Bottolo et al., 2013; Zhou and Stephens, 2012; O’Reilly et al., 2012; 
van der Sluis et al., 2013; Zhu et al., 2015; Ferreira and Purcell, 2009; Klei et al., 
2008; Aschard et al., 2014; Stephens, 2013; Marchini et al., 2007; Bolormaa et al., 
2014; Casale et al., 2015; Huang et al., 2011; Zhang et al., 2014; Kim et al., 2016). 
However, publications introducing new methods are highly inconsistent in their 
evaluation of method performance, thus obscuring their relative merit. Across the 
range of simulation scenarios implemented, we were able to sufficiently expose the 
similarities and differences between the varying approaches, and provide insight into 
their performance. As well as acting as a guide to researchers performing multi-trait 
analyses, our findings will help to guide the future development of multi-trait GWAS 
methodology by highlighting areas where they are power gains to be made. 
 
In the structured simulations of scenario S1, the individual-level data methods and 
the meta-analysis approaches of SHet and SHom mostly outperform the univariate 
approaches of min-P and TATES. However, such a structured search of the model 
space may lead to testing unrealistic data, such as a genetic variant affecting only 12 
of 48 traits, whose pairwise correlations are all 0.9. Therefore, some observed power 
differences may apply only to particular groups of traits or in settings outside genetic 
epidemiology. We also observed that when the genetic effects on the traits are in 
opposite directions (a negative genetic correlation), the meta-analysis approach of 
SHom loses a considerable amount of power. This highlights the importance of 
investigating the performance of different approaches so that optimal power can be 
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achieved by implementing the most appropriate method. When genetic effects and 
phenotypic correlations are sampled from uniform distributions (S2), SHet, SHom and 
the individual-level data methods show markedly higher power than TATES and min-
P. This is consistent with a general tendency for the individual-level data methods to 
have greatest relative power when the genetic effects and phenotypic correlations 
are discordant. This is further supported by the results from scenario S3, where the 
genetic effects and phenotypic correlations reflect each other. Here the summary 
statistic methods tend to perform best, especially SHom in the scenarios that are most 
pleiotropic. In the final scenario (S4b), genetic effects and phenotypic correlations 
are based on real data, and in the results relating to 12 traits the individual-level 
methods provide twice the discovery of genetic variants over the summary statistic 
methods.  
 
Overall our results suggest that for a given sample size, the individual-level methods 
tested here are likely to optimise the discovery of genotype-phenotype associations. 
However, it should be noted that a summary statistic method with the same 
underlying assumptions as an individual-level method could be developed in the 
future, and thus reduce the gap in power between the two types of method. The 
choice of which individual-level method to use depends, in part, on the computational 
feasibility for the number of traits being analysed (see Table 5). For example, mv-
BIMBAM has highest power in scenario S4b on 12  traits, but becomes 
computationally infeasible for a large number of traits (≥  10). Other individual-level 
methods, in particular CCA, are preferable for a larger number of traits in terms of 
computation time (Table 5). The mv-BIMBAM method also provides additional 
interpretation by assigning probabilities to the combinations of direct, indirect and no 
effect of a SNP on the traits analysed, which provides insights into the genetic 
aetiology underlying multiple traits. If summary statistics are available on a sample 
that is markedly larger in size than that of available individual-level data then it is 
 121 
highly likely that applying SHet, in particular, will yield greatest power (Table 4). SHom 
is the best choice if the objective is to identify genetic variants with highly pleiotropic 
effects across all phenotypes under study. 
 
In addition to providing a comprehensive guide to method choice in multi-trait GWAS, 
the extensive array of scenarios considered here expose several issues relating to 
the methods, not established in previous publications: (i) despite the sophisticated 
adjustment of univariate P-values performed by TATES, its power is approximately 
equivalent to simply adjusting the minimum P-value of the univariate tests by the 
effective number of independent tests (min-P); (ii) while the Combined-PC method 
shows almost equivalent power to the other individual-level data methods 
throughout, it has a marked departure in power for indirect genetic effects on the 
tested traits - this could provide a simple method for distinguishing direct and indirect 
effects; (iii) in many scenarios, SHet and SHom have similar power to the individual-
level data methods, demonstrating the potential for summary statistics to provide as 
much information as individual-level multivariate data; (iv) when genetic effects in 
opposite directions exist, however, SHom loses a considerable amount of power; (v) 
most multi-trait methods are not optimised for identifying pleiotropic variants 
(Solovieff et al., 2013), despite common reference to pleiotropy in publications that 
apply them; and (vi) SHom, which is tailored to detect pleiotropic variants, performs 
poorly in the real data informed simulations relating to 12 traits, suggesting that tests 
for pleiotropic variants may not produce novel findings unless applied to phenotypes 
that have prior knowledge of shared genetic aetiology. 
 
While we have assessed the performance of many of the leading multi-trait GWAS 
methods across a range of different scenarios, we acknowledge that there are many 
scenarios not considered here. For example, we did not consider the situation where 
only one of many traits is affected by the genetic variant; in this setting we may 
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expect min-P and TATES to perform relatively well, despite our overall findings that 
these methods appear to have sub-optimal power. However, such simulations are 
easily performed using our simulation software, which implements the scenarios 
considered here and allows flexibility in user choice over parameters such as the 
number of traits, genetic effects and phenotypic correlations in order to simulate new 
scenarios. The results of this highly non-pleiotropic scenario, where we simulate 48 
traits with only one causal association, are presented in Figure 34.  
 
 
Figure 34. Power comparisons from simulations of scenario S1 for 48 traits, where only one trait is 
affected by the genetic variant. The genetic variant is simulated to explain 0.5% variance in the affected 
trait. The pairwise phenotypic correlations are the same for all phenotypes. Correlations < 0 are not 
possible across 48 phenotypes, hence the truncation in these results across the correlation range. mv-
BIMBAM and mv-SNPTEST are not computationally feasible for 20 or more phenotypes and so are 
excluded here. SHet is excluded, as a gamma distribution could not be estimated for these correlation 
matrices. 
 
Min-P and TATES do indeed perform relatively well in this scenario, although the 
individual-level methods have greater power for higher phenotypic correlations. We 
also recognise that there are other multivariate approaches to genetic association 
studies that have not been considered here, such as linear mixed models (Zhou and 
Stephens, 2012), generalised estimating equations (Zhang et al., 2014) and adaptive 
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2013; Zhou and Stephens, 2012; Kim et al., 2016). It is possible that under some 
assumptions these methods are preferred over those considered here, though our 
results suggest that the power of most multivariate methods converge to some 
optimal value for a large part of the model space. Additional methods can be easily 
incorporated into our simulation software, allowing further methods to be 
benchmarked under a wide range of simulation settings. 
 
Multivariate genetic analyses are likely to expand dramatically in future as an 
increasing number of GWAS results are released publicly and as individual-level 
multivariate panels are compiled by population-wide biobank studies. This makes our 
study extremely timely, and designing studies guided by its findings should lead to 
greater discovery of genuine associations. This could be especially significant for 
underpowered but extremely important phenotypes, such as depression (Hyman, 
2014; Ripke et al., 2013; Converge Consortium, 2015; Hyde et al., 2016), for which 
few genetic associations have been discovered. Multivariate methods may leverage 
the power of GWAS on such phenotypes, providing vital targets for drug 
development in diseases and disorders with few biological leads. In addition to the 
direct benefits of increasing the number of known genetic associations for any 
phenotype, without cost, this will also produce higher-powered downstream 
analyses, such as pathway analyses and polygenic risk scoring.  
 
While our results provide a present snapshot of multi-trait GWAS method 
performance, our simulation framework offers a consistent platform from which future 
methods can be easily benchmarked via our web application and open-source 
software program. This should save researcher time and avoid repetition by guiding 
the development, application and publication of only those methods demonstrated as 
outperforming the alternatives. We believe that this study highlights the importance of 
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systematic and comprehensive comparisons of competing methods of analysis, 
easily reproduced and extended via open-source software. 
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4.  Identifying novel loci from multi-trait 
GWAS on summary statistics 
 
 
In Chapter 3, we observed that multi-trait summary statistic GWAS methods could 
achieve equivalent power to individual-level methods, and even greater power when 
taking into account that larger resources of summary data are now available. These 
findings provide the motivation for this chapter, where we perform a series of multi-
trait GWAS using publicly available summary data on 19 quantitative and binary 
phenotypes. We develop and apply different approaches to multi-trait summary 
statistic GWAS, which aim to capture both homogenous and heterogeneous genetic 
effects on sets of correlated traits. While one aim of this study is to confirm the 
results of our simulations, showing that novel findings can be achieved by 
repurposing existing summary data in multi-trait analyses, we also aim to make new 
discoveries from real data that can provide insights for both the study of specific 




Genome-wide association studies (GWAS) have been performed across hundreds of 
phenotypes leading to the identification of thousands of SNPs associated with human 
phenotypes. These results and those from the application of methods for estimating 
genetic correlation between traits, such as bivariate GCTA, LD Score regression and 
others (Yang et al., 2011; B. Bulik-Sullivan et al., 2015; B. K. Bulik-Sullivan et al., 
2015; Han et al., 2016; Pickrell et al., 2016) have demonstrated a substantial 
enrichment of variants affecting multiple traits (see: A plethora of pleiotropy across 
complex traits (Visscher and Yang, 2016)). Therefore, performing GWAS on 
phenotypes jointly could increase the discovery of susceptibility variants and provide 
insights into pleiotropic aetiology, yet GWAS to date have typically analysed 
phenotypes independently. However, the public release of large-scale GWAS 
summary statistics across a large and growing number of phenotypes motivates the 
development and application of multi-trait GWAS methods that exploit summary data. 
 
Summary statistic methodology development is an emerging area of research in 
statistical genetics, with many studies now seeking to exploit univariate GWAS 
summary statistics to gain further insight into the genetic aetiology of complex 
disorders. An already highly popular method, known as LD Score regression (B. K. 
Bulik-Sullivan et al., 2015), has been used to produce an ‘atlas’ of genetic 
correlations among a range of phenotypes with publicly available GWAS data (B. 
Bulik-Sullivan et al., 2015). Another recent study investigated the shared genetic 
aetiology of 42 traits by performing a genome-wide scan to detect genetic variants 
that affect pairs of traits, assessing the causal relationship between these traits 
(Pickrell et al., 2016). Moreover, a review into the advancement of summary statistic 
methodology has recently been undertaken, highlighting that for many applications 
 127 
summary statistic approaches may be preferred over the individual-level approach 
due to the gains in sample size and thus power (Pasaniuc and Price, 2016). 
 
Here we develop highly-powered multi-trait GWAS methods that utilise summary 
statistics, and that are appropriate for a mixture of binary and continuous traits. We 
perform simulations to compare their relative performance against other summary 
statistic GWAS methods and to the individual-level multi-trait approach. We apply 
these methods to GWAS summary statistic data on a range of traits, including 
anthropometric, metabolic and psychiatric traits. We identify novel findings from our 
multi-trait analyses, which can provide further insights into pleiotropy and the biology 
underlying correlated traits. 
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4.2 Materials and Methods 
 
4.2.1 Multi-trait GWAS methods 
 
In order to compare the performance of the different summary statistic approaches, 
we perform simulations utilising the simulation framework presented in Chapter 2. 
We compare MetaHom, MetaHet, developed here, and the ‘Cattle method’ 
(Bolormaa et al., 2014), to min-P (O’Reilly et al., 2012) and TATES (van der Sluis et 
al., 2013), which both adjust univariate P-values to obtain a joint association P-value. 
The final two methods do not explicitly model the traits jointly as they only correct the 
univariate P-values, and by definition they cannot identify novel findings, but we 
include them here to compare to the univariate approach and to act as a benchmark 
for the joint multi-trait methods. Furthermore, we include the individual-level multi-trait 
method CCA (mv-PLINK) (Ferreira and Purcell, 2009), chosen here as a 
representation of individual-level method performance.  
 
4.2.1.1 MetaHom  
This test extends the SHom statistic introduced by Zhu et al. (Zhu et al., 2015), 
making it applicable to a mixture of binary and continuous phenotypes (see 4.2.2).  
The SHom test statistic is given by: 
𝑆!"# =  𝑒! 𝑅𝑊 !!𝑆(𝑒! 𝑅𝑊 !!𝑆)!𝑒!(𝑊𝑅𝑊)!!𝑒   
where 𝑆 is the matrix of summary statistics, 𝑅 is the correlation matrix between the 
summary statistics, 𝑊 is the diagonal matrix of weights for each phenotype under 
study, where 𝑤!" =  𝑛!   for sample size 𝑛!  of the 𝑖!!  cohort, and 𝑒  is the identity 
vector of length 𝑖 × 𝑗. SHom follows a chi-squared distribution with one degree of 
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freedom. 
SHom combines Wald test statistics from univariate GWAS relating to a SNP across 
both multiple cohorts and multiple phenotypes in a meta-analysis. Heterogeneity in 
effect size and statistical power across cohorts is accounted for, as is the correlation 
among the test statistics, while the overall test statistic has optimal power when the 
genetic effect is homogeneous across traits and cohorts. Of the tests considered 
here, SHom is that which can be most considered a ‘test for pleiotropy’, being 
equivalent to a meta-analysis of effect sizes across traits and cohorts with optimal 
power under fixed effects.  
As identified in Chapter 3, when the direction of genetic effects of a SNP on multiple 
traits are in opposite directions, the power of SHom is greatly reduced due to the 
effective ‘cancelling-out’ of the genetic effects in the meta-analysis. However, we do 
not consider it appropriate to make this fixed effects assumption in a multi-trait 
GWAS setting, because we seek to identify any SNP that has a non-null association 
on a group of traits irrespective of the direction of any effects on those traits. Thus, 
our MetaHom method is in fact a special case of MetaHet (see below), which does 
not make a fixed effects assumption but searches for SNPs with a similar absolute 
effect on the set of phenotypes.  
4.2.1.2 MetaHet 
This test extends the SHet statistic introduced by Zhu et al. (Zhu et al., 2015) making 
it applicable to a mixture of binary and continuous phenotypes (see 4.2.2). This test 
is derived from SHom but is designed to detect genetic variants that only affect a 
subset of the total number of traits under study. In addition, the signs of the 
weightings are adjusted to take into account the direction of genetic effect such that 
the effects add rather than cancel out as in the SHom meta-analysis.  
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For each subset of traits, the SHet method performs a meta-analysis similar to that of 
SHom, but with signed weightings so that the absolute effect sizes are considered. 
For each subset, determined by the summary statistic threshold for inclusion 𝜏, the 
corresponding statistic is given by: 
𝑆!"#(𝜏) =  𝑒! 𝑅(𝜏)𝑊(𝜏) !!𝑆(𝜏)(𝑒! 𝑅(𝜏)𝑊(𝜏) !!𝑆(𝜏))!𝑒!(𝑊(𝜏)𝑅(𝜏)𝑊(𝜏))!!𝑒  
where 𝑆(𝜏) is the sub-matrix of summary statistics, 𝑅(𝜏) is the sub-matrix of the 
summary statistic correlation matrix 𝑅, 𝑊(𝜏) is the diagonal matrix of weights for the 
subset of phenotypes under study, where 𝑤!" =  𝑛!  × 𝑠𝑖𝑔𝑛(𝑆!") for sample size 𝑛! of 
the 𝑖!! cohort and summary statistic 𝑆!" for the 𝑗!! phenotype in the 𝑖!! cohort, and 𝑒 
is the identity vector of length 𝑖 × 𝑗 . For each summary statistic threshold 𝜏 the 
phenotypes satisfying 𝑆!" > 𝜏 are selected for joint analysis.  
The maximum value of 𝑆!"# 𝜏  across all analysed subsets is then taken to be the 
SHet test statistic: 
𝑆!"# = max!!! 𝑆!"#(𝜏) 
As the SHet test statistic does not follow a standard distribution, P-values are 
computed via simulation of an empirical gamma distribution. 
In the MetaHet implementation of the SHet method here, we use the default option 
for the sub-setting procedure: the traits are ordered according to the absolute value 
of their Wald test statistics, then for each SNP the association with subsets of the 
traits is tested recursively, starting with the trait with the largest absolute t-statistic, 
and progressively adding in one trait at a time until the SNP is tested for association 
with all traits. Both SHet and SHom are unaffected by sample overlap among meta-
analysed studies (Zhu et al., 2015).  
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The software implementation of the SHet method allows for the sub-setting 
procedure to be bypassed, thus for all traits to be analysed jointly as in the SHom 
procedure. Simulation results presented in Chapter 3 demonstrated that the SHom 
method loses power when applied in real data scenarios due to the cancellation of 
opposite genetic effects in the meta-analysis. We showed that implementing the 
SHet method with the sub-setting procedure disabled replicates the power of the 
SHom method, and is unaffected by oppositely signed genetic effects due to the 
signed weightings. Hence, we propose this modification to the SHet method to 
perform a test similar to that of SHom that does not lose power when jointly 
analysing traits with negative genetic correlations. The MetaHom method 
implemented here is a special case of MetaHet, where all traits are analysed jointly. 
 
4.2.1.3 Cattle 
The ‘Cattle’ summary statistic method (Bolormaa et al., 2014) performs a t-value 
correlation weighted meta-analysis, and has the following test statistic: 
 𝑆!"##$% = 𝑆 (𝑐𝑜𝑟 𝑆 )!! 𝑆! 
 
where 𝑆 is the matrix of t-values from univariate GWAS. This test statistic follows a 
chi-squared distribution with 𝐾 degrees of freedom, where 𝐾 is the number of traits. 
This method was compared to the SHet and SHom methods, and was noted to perform 
poorly for heterogeneous genetic effects, whereby a SNP affects a subset of the 
traits under study, due to the large number of degrees of freedom of the test-statistic 
(Zhu et al., 2015). This method has thus far not been applied to human traits, with 
the publication presenting this method performing analyses of Cattle specific traits 
(Bolormaa et al., 2014). 
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4.2.1.4 Comparison methods 
We compare the performance of the three summary statistic methods detailed above 
to three additional approaches to multi-trait GWAS, which were described in more 
detail in Chapter 3. Min-P (O’Reilly et al., 2012) performs an adjustment of the 
univariate P-values to obtain a joint multi-trait P-value. Since only the univariate P-
values are adjusted, and the phenotypes aren’t explicitly modelled jointly, by 
definition this method cannot produce novel findings. Similarly, the TATES method 
(van der Sluis et al., 2013) adjusts univariate P-values using the eigen-
decomposition of the phenotype correlation matrix, but like min-P cannot identify 
novel findings. CCA (mv-PLINK) (Ferreira and Purcell, 2009) is an individual-level 
multi-trait GWAS method, that is equivalent to a reversed multiple linear regression 
with a single genetic variant as outcome (O’Reilly et al., 2012). The performance of 
the CCA method in the simulations represents the performance of the individual-level 
multi-trait GWAS methods. 
 
4.2.2 Effective sample size for case/control studies 
 
Both the MetaHet and MetaHom methods use, in addition to the correlation between 
the t-values, the sample sizes of the univariate studies to weight the t-values as a 
way of quantifying the certainty in the beta estimates. We use the following formula 
to convert sample sizes from case/control studies into quantitative trait equivalents: 
 
 𝑁!"" ∶= 41𝑁!"#$# + 1𝑁!"#$%"&'  (3) 
 
where 𝑁!""  is the effective quantitative sample size of a case/control study in terms 
of statistical power,  𝑁!"#$# is the number of cases and 𝑁!"#$%"&' is the number of 
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controls in a case/control study (Han and Eskin, 2011; Ma et al., 2013). For example, 
if a GWAS were performed for a binary trait on 10,000 cases and 20,000 controls, the 
equivalent quantitative sample size would be 26,667. If we have an equal split of 
cases and controls, say 10,000 of each, then the equivalent quantitative sample size 




We collect summary statistic data for the largest available univariate GWAS on 19 
traits. These traits are: Alzheimer’s Disease (AD) (Lambert et al., 2013), Birth length 
(BL) (Valk et al., 2015), Bipolar Disorder (BPD) (Psychiatric GWAS Consortium 
Bipolar Disorder Working Group, 2011), Birth weight (BW) (Horikoshi et al., 2013), 
Childhood obesity (CO) (The Early Growth Genetics (EGG) Consortium, 2012), 
College Yes/No (CY) (Rietveld et al., 2013), Extreme hip-waist ratio (EHW) (Berndt 
et al., 2013), Fasting glucose (GLU) (Dupuis et al., 2010), High-density lipoprotein 
(HDL) (Global Lipids Genetics Consortium, 2013), Height (Wood et al., 2014), Infant 
head circumference (IHC) (Taal et al., 2012), Low-density lipoprotein (LDL) (Global 
Lipids Genetics Consortium, 2013), Major Depressive Disorder (MDD) (Ripke et al., 
2013), Obesity class 1: BMI ≥  30 kg/m2 (OC1), Obesity class 2: BMI ≥  35 kg/m2 
(OC2), Obesity class 3: BMI ≥  40 kg/m2 (OC3) (Berndt et al., 2013), Schizophrenia 
(SCZ) (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 
2014), Ever/never smoked (SM) (The Tobacco and Genetics Consortium, 2010) and 
Triglycerides (TG) (Global Lipids Genetics Consortium, 2013). We perform multi-trait 





4.2.4 Correlated-set analyses 
 
In addition to performing multi-trait analyses on all traits jointly, we perform multi-trait 
analyses on sub-sets of correlated traits. From our comparison study in Chapter 3, 
we observed that the summary statistic GWAS methods could lose power when 
many traits are analysed jointly, due to increasing the degrees of freedom. All real 
data analyses, apart from those performed on all GWAS results jointly, were 
performed on groups of phenotypes with a priori known genetic correlations as 
established by the application of LD Score regression (B. Bulik-Sullivan et al., 2015). 
The groups of correlated traits to which the multi-trait methods are applied are listed 
in Table 7.  
 
Correlated-sets No. Traits 
AD, CY 2 
LDL, TG 2 
BPD, MDD, SCZ 3 
EHW, HDL, TG 3 
HDL, LDL, TG 3 
BL, BW, Height, IHC 4 
BPD, CY, MDD, SCZ 4 
CO, OC1, OC2, OC3 4 
CY, EHW, HDL, LDL, TG 5 
CY, OC1, OC2, OC3, SM 5 
GLU, HDL, OC1, OC2, OC3 5 
BW, GLU, HDL, OC1, OC2, OC3 6 
CO, Height, HDL, OC1, OC2, OC3 6 
AD, BPD, CY, HDL, OC1, OC2, OC3, TG 8 
CO, CY, GLU, HDL, OC1, OC2, OC2, SM 8 
CY, EHW, GLU, HDL, OC1, OC2, OC3, TG 8 
All phenotypes 19 
 




4.2.5 Summary statistics 
 
Beta coefficients, standard errors and P-values for all SNPs genome-wide are 
obtained from the largest publicly available GWAS on each phenotype (stored, for 
example, here: https://www.med.unc.edu/pgc/results-and-downloads). These are 
used to compute the corresponding t-statistics to perform multi-trait GWAS using the 
MetaHom, MetaHet and Cattle methods (other methods not applied based on 
simulation results; see 4.3.1) as described above. Chromosome and physical 
position of all SNPs are made consistent across data sets by assigning all to human 
genome build hg19 using the UCSC Genome Browser, and only those SNPs present 
across all 19 GWAS data sets are analysed. Across all 19 traits there are complete 
summary data for 838,294 SNPs. For quantitative traits we use the sample size as 
reported in the individual studies, and for case/control phenotypes we convert to an 
effective sample size as given in Equation 3. For each group of traits to be analysed, 
we extract the corresponding t-statistics across all SNPs, and perform the analyses 
on these subsets.  
 
4.2.6 Independent and novel associations 
 
In order to compare the performance of the multi-trait analysis results to those of 
existing GWAS, the results are thinned according to linkage disequilibrium between 
SNPs to highlight only independent genome-wide significant associations. By 
chromosome, we used a 500kb window centred on each genome-wide significant 
SNP to remove correlated SNPs, retaining the SNP in the region with the smallest P-
value. Significant associations were deemed to be novel in a multi-trait analysis if no 
SNP within the 500kb centred window on the multi-trait SNP had an association P-
value below 5 × 10!!  in any of the relevant single-trait GWAS. We repeat this 
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procedure for all analyses conducted, establishing the subset of novel independent 




4.3.1 Comparison of summary statistic GWAS methods 
 
We begin by performing a comparison between the summary statistic based multi-
trait GWAS methods MetaHom and MetaHet, which we have developed by extending 
previous methods to make them suitable for a mixture of continuous and case/control 
phenotype data and for negative genetic correlations, and the Cattle method (see 
Materials and Methods). In addition we include the min-P and TATES methods, 
which adjust univariate P-values, and CCA (mv-PLINK), which performs multi-trait 
analyses on individual-level genotype-phenotype data. We focus here on methods 
that perform SNP-by-SNP testing because, while there are methods for assessing 
pleiotropy at a locus-level (Pickrell et al., 2016), we wish to reveal single variant 
pleiotropic effects and produce results that are directly comparable to GWAS results 
on single phenotypes.  
 
Figure 35 and Figure 36 illustrate the results of comparing the multi-trait methods 
(TATES (van der Sluis et al., 2013), min-P (O’Reilly et al., 2012), MetaHom, MetaHet, 
Cattle (Bolormaa et al., 2014), CCA (mv-PLINK) (Ferreira and Purcell, 2009)) across 
a range of simulation scenarios. This comparison study, focusing on summary 
statistic methods, captures the most important aspects of method performance 
according to a more general multi-trait comparison study that we performed in 
Chapter 3. Figure 35 shows the results of our simulations on two traits for scenario 
S1 (see Chapter 2), where the genetic effects on each trait are both the same 
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(Figure 35a), of different magnitudes (Figure 35b), and where only one trait is 
affected by the genetic variant (Figure 35c). We see that for homogeneous genetic 
effects (Figure 35a), as expected, MetaHom is the best performing method, while 
performing comparably poorly for the heterogeneous genetic effect simulations of 
Figure 35c. In contrast, MetaHet performs more consistently across the different 
scenarios, and the Cattle method performs comparably to the individual-level method 
CCA. Slight inflation is observed for the univariate methods min-P and TATES for 
large positive and negative correlations, while the other methods perform as 
expected under the null (Figure 35d). Further details of these simulations are 
provided in Chapter 2 and Chapter 3.  
 
 
Figure 35. Simulation plots for scenario S1 with two phenotypes (as described in Chapter 2) for the 
summary statistic methods TATES, min-P, MetaHet, MetaHom and Cattle, as well as the individual-level 
method CCA (mv-PLINK): (a) same genetic effects, (b) different magnitude of genetic effects, (c) only 
one phenotype affected, (d) null effects. 
 
The simulations of Figure 36 are under the assumption that the genetic effects and 
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simulated to be highly correlated if the genetic effects are of the same magnitude 
(𝑟 = 0.6), moderately correlated if the effects are of different magnitudes (𝑟 = 0.2), 
and have a low correlation if there is only one trait influenced by the genetic variant 
(𝑟 = 0.05). For two traits, three genetic effects vectors are simulated, and for four or 
more traits, 10 genetic effect vectors are simulated (see Table 2 of Chapter 2). We 
observe that the univariate methods min-P and TATES consistently have the 
greatest performance. However as noted earlier, these methods are unable to 
achieve novel findings due to only performing adjustments on the univariate P-
values. These methods both perform as expected since when the genetic effects are 
reflective of the phenotypic correlations, there is no gain in power from analysing the 
traits jointly (as in the other methods) as there is less potential for additional residual 
variance explained. In these scenarios, these results suggest that there would be no 
gain in performing a multi-trait analysis over the standard univariate approach, and 
thus if there is a causal effect it will have already been identified in the single-trait 
study. Out of the other methods, MetaHom performs well in the more pleiotropic 
scenarios, for example Figure 36b for genetic effect vector 𝒗𝟏, where the magnitude 
of genetic effects are the same, and 𝒗𝟓 where the genetic effect on three quarters of 
the traits is 0.5% and 0.1% on the remaining quarter of traits. However, MetaHom 
performs poorly for the least pleiotropic scenarios, for example Figure 36d for 
genetic effect vector 𝒗𝟒, where the genetic variant is only affecting a quarter of the 
traits. The performance of MetaHet either matches the performance of the Cattle and 
CCA methods, or exceeds them across the different scenarios. 
 
We choose to highlight these simulation results in particular as they expose both the 
similarities and differences in method performance across different scenarios, 
enabling us to gain insight into how these methods should perform on real data. The 
results highlight sensitivity of method performance to modelling scenario, but also 
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show that irrespective of scenario, TATES and min-P have matching performance, 
as do Cattle and CCA (mv-PLINK). MetaHom or MetaHet is typically the best-
performing multi-trait method under pleiotropic and non-pleiotropic scenarios, 




Figure 36. Simulation plots for scenario S3 (as described in Chapter 2) for the summary statistic 
methods TATES, min-P, MetaHet, MetaHom and Cattle, as well as the individual-level method CCA 
(mv-PLINK) for (a) 2, (b) 4, (c) 8 and (d) 12 phenotypes. 
 
4.3.2 Summary statistic GWAS 
 
Based on the results of the simulation study, we applied MetaHom and MetaHet to 
publicly available GWAS summary statistic data on 19 traits (see Materials and 
Methods). We also applied the Cattle method to the same data to represent the 
performance of the other methods and to verify the prediction from the simulations 









































 TATES   
 min−P   
 MetaHet   
 MetaHom   
 Cattle   
 CCA   
 (a)  (b) 
 (c)  (d) 
 140 
4.3.2.1 Correlated-set analyses 
Our simulation study demonstrated that when these methods are applied to a large 
set of heterogeneous phenotypes the statistical power may be limited, and thus as 
well as application to all phenotypes we perform analyses on correlated-sets of traits. 
These correlated-sets were defined according to global estimates of genetic 
correlations from LD Score regression (see Materials and Methods) (B. K. Bulik-
Sullivan et al., 2015). The genetic correlations from LD Score regression quantify the 
shared genetic aetiology between traits; these provide an indication of the pairs of 
phenotypes that have pleiotropic genetic effects. Analysing sets of homogenous 
traits with respect to genetic effects should maximise the power of the MetaHom 
method. Table 8 displays the number of novel genome-wide significant SNPs 
identified for each of the 16 correlated-set analyses performed and for the analysis 
across all 19 traits jointly.  
  
 141 
Phenotypes MetaHom MetaHet Cattle 
AD, BPD, CY, HDL, OC1, OC2, OC3, TG 30 37 18 
AD, CY 1 1 0 
All phenotypes 48 12 39 
BL, BW, Height, IHC 68 12 10 
BPD, CY, MDD, SCZ 10 20 6 
BPD, MDD, SCZ 5 7 5 
BW, GLU, HDL, OC1, OC2, OC3 10 12 7 
CO, CY, GLU, HDL, OC1, OC2, OC2, SM 14 17 8 
CO, Height, HDL, OC1, OC2, OC3 28 28 18 
CO, OC1, OC2, OC3 2 0 0 
CY, EHW, GLU, HDL, OC1, OC2, OC3, TG 33 39 18 
CY, EHW, HDL, LDL, TG 31 44 44 
CY, OC1, OC2, OC3, SM 1 1 2 
EHW, HDL, TG 37 32 25 
GLU, HDL, OC1, OC2, OC3 12 10 5 
HDL, LDL, TG 38 45 50 
LDL, TG 22 20 26 
Total 390 337 281 
Total unique 244 169 151 
Table 8. Number of independent, novel genome-wide significant associations for the analyses of all 
phenotype subsets using the MetaHom, MetaHet and Cattle methods. 
 
As expected from the simulations, MetaHom and MetaHet are the best-performing 
methods, and so hereafter we refer only to their results. We observe that MetaHom 
performs best for the analyses of traits where we may expect greatest pleiotropic 
genetic effects, for example, BL, BW, Height, and IHC. Interestingly, in the analysis 
of all 19  traits, MetaHom is again the best performing method, with MetaHet 
performing comparatively poorly. This may be due to the sub-setting procedure of 
MetaHet; in the analysis of all 19 traits, many subsets are tested for association with 
each SNP based on their univariate test statistics. While this can lead to increased 
power when only a subset of the analysed traits are associated with the SNP, it also 
greatly increases the degrees of freedom of the MetaHet test statistic, leading to a 
reduction in power overall.  For the group of traits considered here, there are likely to 
be pleiotropic effects, for example between the lipids (HDL, LDL and TG) and obesity 
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measures (OC1, OC2 and OC3), as well as between the anthropometric traits such 
as height, birth length (BL), birth weight (BW) and infant head circumference (IHC), 
suggesting that MetaHom will perform well for the joint analysis of these traits. 
 
In total, MetaHom identifies 390 independent, novel SNP-phenotype associations. 
Novelty is defined here according to there being no genome-wide significant 
associations in any of the univariate GWAS of the traits analysed, within a 500kb 
window centered on each SNP (see Materials and Methods). For example, one 
such SNP is rs1473886 at ~20.4Mb on chromosome 2, identified by the MetaHom 
correlated-set analysis of HDL, LDL and TG, which has a MetaHom association 𝑃 =  1.11 × 10!!" ; thus, there are no genome-wide significant results between 
~20.15Mb and ~20.65Mb in any of the independent GWAS on HDL, LDL and TG 
conducted by the Global Lipids Genetics Consortium (Global Lipids Genetics 
Consortium, 2013). A summary of the joint association P-value and the univariate P-
values for this SNP is given in Table 9, and Figure 37 illustrates the association 
results for HDL, LDL, TG and MetaHom in the region of this finding, highlighting the 




HDL GWAS 1.14 x 10-5 
LDL GWAS 4.26 x 10-4 
TG GWAS 1.88 x 10-5 
Multi-trait GWAS of HDL, LDL and TG 1.11 x 10-19 
Table 9. Univariate P-values for the MetaHom top hit, rs1473886, from the univariate GWAS of HDL, 
LDL and TG, as well as the joint association P-value. 
 
We see that the univariate P-values for rs1473886 are around the genome-wide 
suggestive significance threshold of 1 × 10!!, and that the signal has been boosted 
to genome-wide significant in the multi-trait analysis. 
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Figure 37. Manhattan plot for the MetaHom association results for chromosome 2 where the top hit 
from the MetaHom analysis of HDL, LDL and TG (rs1473886; 𝑃 =  1.11 × 10!!") is located. Manhattan 
plots for the univariate GWAS on HDL, LDL and TG for the same region. 
 
4.3.2.2 Multiple-testing correction 
To adjust for multiple testing, for each method we calculated the correlation between 
the test statistics across all 16 correlated-set analyses and the analysis of all 19 
traits. We then applied a Nyholt correction (Nyholt, 2004) to calculate the number of 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































performed for each method and the adjusted significance threshold, which was also 
further adjusted to account for the application of three methods. 
 
Method Number of Tests Adjusted Threshold 
MetaHom 13.16 1.27 x 10-9 
MetaHet 12.57 1.33 x 10-9 
Cattle 12.60 1.32 x 10-9 
 
Table 10. Number of independent tests performed across the 17 analyses for each method, and the 
corresponding adjusted significance thresholds. 
 
Table 11 provides the adjusted number of novel, independent associations after 
correcting for multiple testing. 
 
Phenotypes MetaHom MetaHet Cattle 
AD, BPD, CY, HDL, OC1, OC2, OC3, TG 7 12 4 
AD, CY 0 0 0 
All phenotypes 11 2 8 
BL, BW, Height, IHC 1 0 2 
BPD, CY, MDD, SCZ 0 0 0 
BPD, MDD, SCZ 0 2 0 
BW, GLU, HDL, OC1, OC2, OC3 2 4 1 
CO, CY, GLU, HDL, OC1, OC2, OC2, SM 2 6 1 
CO, Height, HDL, OC1, OC2, OC3 8 9 4 
CO, OC1, OC2, OC3 1 0 0 
CY, EHW, GLU, HDL, OC1, OC2, OC3, TG 11 14 6 
CY, EHW, HDL, LDL, TG 11 17 11 
CY, OC1, OC2, OC3, SM 0 0 0 
EHW, HDL, TG 16 8 4 
GLU, HDL, OC1, OC2, OC3 2 3 0 
HDL, LDL, TG 13 18 11 
LDL, TG 4 3 4 
Total 89 98 56 
Total unique 50 45 34 
 
Table 11. Number of independent, novel hits at the multiple-testing significance threshold for the 
analyses of all phenotype subsets using the MetaHom, MetaHet and Cattle methods.  
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After adjusting for multiple testing, MetaHom still produces the largest number of 
novel findings overall. The Cattle method performs worse than both the MetaHom 
and MetaHet methods. Figure 38 provides a visual representation of the number of 
novel, independent genome-wide significant associations for the MetaHom and 
MetaHet methods across the correlated-set analyses, after adjusting for multiple 
testing. Table 12 and Table 13 provide details of the genome-wide significant 
associations (after multiple testing correction) for the multi-trait analyses of HDL, LDL 
and TG for the MetaHom and MetaHet methods respectively. 
 
 
Figure 38. Waffle plots displaying the proportions of the multiple-testing adjusted novel, independent 
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SNP CHR Position (Mb) P-value 
rs1473886 2 20.4 1.11 x 10-19 
rs10904908 10 17.3 9.42 x 10-15 
rs3779500 7 10.7 9.51 x 10-13 
rs7033354 9 16.9 2.78 x 10-12 
rs6505081 17 26.7 3.74 x 10-12 
rs1997243 7 1.08 6.25 x 10-12 
rs7947951 11 13.4 1.13 x 10-11 
rs1198433 1 23.8 1.16 x 10-10 
rs4933744 10 94.6 2.05 x 10-10 
rs12539895 7 107.1 2.30 x 10-10 
rs12137896 1 26.7 3.72 x 10-10 
rs1382567 8 11.4 5.86 x 10-10 
rs2936507 8 6.61 1.13 x 10-9 
 
Table 12. Novel, independent genome-wide significant SNPs (after multiple testing correction) for the 
multi-trait analysis of HDL, LDL and TG using the MetaHom method. 
 
SNP CHR Position (Mb) P-value 
rs1473886 2 20.4 9.25 x 10-19 
rs10904908 10 17.3 6.02 x 10-14 
rs3779500 7 106.8 5.39 x 10-12 
rs7033354 9 16.9 1.53 x 10-11 
rs6505081 17 26.7 2.04 x 10-11 
rs1997243 7 1.08 2.98 x 10-11 
rs7947951 11 13.4 5.97 x 10-11 
rs2862954 10 101.9 9.53 x 10-11 
rs2287623 2 169.8 2.13 x 10-10 
rs10928512 2 135.5 2.57 x 10-10 
rs10513801 3 185.8 4.23 x 10-10 
rs1198433 1 23.8 5.73 x 10-10 
rs4895441 6 135.4 7.94 x 10-10 
rs10861661 12 107.2 9.61 x 10-10 
rs4933744 10 94.6 9.97 x 10-10 
rs6968554 7 17.3 1.09 x 10-9 
rs12539895 7 107.1 1.11 x 10-9 
rs6901147 6 52.5 1.23 x 10-9 
 
Table 13. Novel, independent genome-wide significant SNPs (after multiple testing correction) for the 
multi-trait analysis of HDL, LDL and TG using the MetaHet method. 
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The top novel hit from the analysis of HDL, LDL and TG across both the MetaHom 
and MetaHet methods, rs1473886 on chromosome 2, was identified in a recent 
univariate analysis of total cholesterol from the Global Lipids Genetics Consortium (𝑃 = 5.06 × 10!!") (Global Lipids Genetics Consortium, 2013). Of the MetaHet hits 
that were not identified by the MetaHom method a range of other traits have been 
found to show the greatest level of association in previous studies. The association 
of rs2862954 with fatty liver disease and alanine aminotransferase (ALT) levels 𝑃 = 3.03 × 10!!"  (Feitosa et al., 2013) is the most significant currently recorded for 
that SNP in the PhenoScanner tool (Staley et al., 2016), which provides an online 
catalog of all published GWAS results. Among other associated traits with the 
MetaHet hits are BMI for rs10513801 (𝑃 = 1.94 × 10!!") (Locke et al., 2015), as well 
as coffee consumption 𝑃 = 7.00 × 10!!"  (Cornelis et al., 2015) and blood 
metabolite levels (𝑃 = 9.00 × 10!!")  (Shin et al., 2014) for rs6968554. Several 
known total cholesterol loci were identified in the MetaHom analysis of LDL, HDL and 
TG, such as ASAP3 (chr 1: 23.8Mb), GPR146 (chr7: 1.08Mb) and VIM-CUBN (chr10: 
17.3Mb) (Global Lipids Genetics Consortium, 2013). The MetaHet analysis, in 
addition, identified the ABCB11 (chr 2: 169.8Mb) and HBS1L (chr6: 135.4Mb) total 
cholesterol associated loci (Global Lipids Genetics Consortium, 2013). 
 
These observations provide validation for our findings and approach by replicating 
known total cholesterol hits, as well as highlighting the genetic link between the 
analysed traits and other traits known to be associated with the identified SNPs, such 
as the lipids and fatty liver disease. Our results also provide evidence that analysing 
components of traits in a multivariate model could lead to additional power gains, as 
was achieved here by analysing the lipids in a joint model instead of only total 
cholesterol. Furthermore, these findings indicate that multi-trait methods could not 
only be applied to gain additional power for identifying SNP-phenotype associations, 
 148 
but could also provide useful information for identifying sources of shared genetic 
aetiology between traits. 
In addition to the aim of identifying novel association signals by repurposing existing 
GWAS summary data, we also sought to compare how MetaHom and MetaHet 
perform in practice on real data. From these results, it would suggest that manually 
sub-setting the traits should be performed prior to combining them in a joint analysis, 
as done here using the LD score genetic correlations (B. Bulik-Sullivan et al., 2015), 
in order to yield greatest discovery. 
 
4.3.3 Validation using CADD scores 
 
To validate our findings, we used the CADD (Combined Annotation Dependent 
Depletion) score (Kircher et al., 2014). The CADD score quantifies how deleterious a 
SNP is likely to be based on estimated intensities of purifying selection across 
multiple functional annotation categories, and has been shown to be correlated with 
pathogenicity and disease severity (Kircher et al., 2014). We compared the CADD 
scores of both novel and all MetaHom and MetaHet hits with those of all independent 
genome-wide significant hits from the latest GWAS on schizophrenia (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014), height (Wood et al., 
2014), HDL and LDL (Global Lipids Genetics Consortium, 2013), and compared each 
of these with a set of randomly selected SNPs (see Table 14). 
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SNPs CADD Score No. SNPs P-value vs. Random 
MetaHom novel 4.39 236 7.45 x 10-4 
MetaHom all 4.55 1807 2.19 x 10-22 
MetaHet novel 4.58 165 1.23 x 10-3 
MetaHet all 4.50 1542 1.51 x 10-18 
SCZ GWAS 4.35 154 1.04 x 10-2 
HDL GWAS 4.97 123 4.86 x 10-3 
LDL GWAS 5.21 105 4.46 x 10-3 
Height GWAS 4.56 721 7.06 x 10-11 
Random SNPs 3.38 5000 - 
 
Table 14. Mean CADD scores for the MetaHom and MetaHet total independent hits and novel, 
independent hits, as well as for independent GWAS hits for SCZ, HDL, LDL and Height and a random 
set of SNPs.  
 
The CADD scores of the MetaHom and MetaHet results were similar to those of the 
published GWAS and significantly higher than those of the random SNPs (novel 
MetaHom vs. random: 𝑃 = 7.45 × 10!!; novel MetaHet vs. random 𝑃 = 1.23 × 10!!; 
all MetaHom vs. random 𝑃 = 2.19 × 10!!! ; all MetaHet vs. random 𝑃 = 1.51 × 10!!" ). These results, combined with those of the simulations showing that 
MetaHom and MetaHet have appropriate type 1 error (Figure 35d), strongly support 
the validity of our findings. 
 
Table 15 provides the mean CADD scores for the novel, independent genome-wide 
significant SNPs and the independent genome-wide significant SNPs, after adjusting 
for multiple testing. 
 
SNPs CADD score No. SNPs P-value vs. Random 
MetaHom novel 5.04 48 0.0322 
MetaHom all 4.70 1271 3.97 x 10-20 
MetaHet novel 5.30 43 0.0342 
MetaHet all 4.60 1027 7.72 x 10-15 
Table 15. Mean CADD scores for the MetaHom and MetaHet total independent and novel, independent 
hits after adjusting for multiple testing. 
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We observe that the mean CADD scores for the MetaHom and MetaHet SNPs after 
adjusting for multiple testing are significantly greater than the random SNPs, for both 
the independent and novel, independent SNPs.  
 
4.3.4 Boost to univariate signals 
 
As well as identifying novel genome-wide significant findings through performing 
multi-trait analyses on GWAS summary statistics, we observe that the univariate 
signals of previously identified genetic associations are typically boosted.  
Table 16 details the SNPs that were found to be genome-wide significant in the 
univariate LDL GWAS, and were also identified by the MetaHom method in the HDL, 
LDL and TG correlated-set analysis. Here we observe that the univariate P-values 
are generally boosted by the multi-trait analysis, with quite dramatic boosts observed 
for some SNPs. For example, rs4587594 on chromosome 1 has a univariate 
association P-value of 1.63 × 10!!" from the LDL GWAS, and achieves a multi-trait 
P-value of 1.21 × 10!!"#  from the MetaHom analysis. This same SNP has a 
univariate P-value of 3.50 × 10!!" from the TG GWAS, and was not identified as 
genome-wide significant in the HDL GWAS. 
 
SNP CHR Position (Mb) univariate P-value multi-trait P-value 
rs11206510 1 55.5 2.38 x 10-53 2.12 x 10-34 
rs207145 1 55.8 6.19 x 10-18 2.36 x 10-8 
rs2807834 1 221.0 1.19 x 10-15 2.07 x 10-31 
rs4587594 1 63.1 1.63 x 10-32 1.21 x 10-125 
rs518076 1 110.1 5.60 x 10-14 3.37 x 10-12 
rs558971 1 234.9 5.56 x 10-24 1.25 x 10-12 
rs660240 1 109.8 9.00 x 10-265 1.03 x 10-162 
rs2250802 10 113.9 3.94 x 10-13 5.98 x 10-40 
rs10832962 11 18.7 6.62 x 10-14 1.97 x 10-9 
rs1535 11 61.6 7.77 x 10-41 5.89 x 10-126 
rs4937122 11 126.2 1.81 x 10-20 2.70 x 10-19 
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rs964184 11 116.6 2.01 x 10-26 1.02 x 10-154 
rs10774625 12 111.9 8.31 x 10-11 4.72 x 10-21 
rs11066320 12 112.9 1.57 x 10-9 1.58 x 10-16 
rs17630235 12 112.6 5.61 x 10-11 1.17 x 10-18 
rs735396 12 121.4 5.36 x 10-16 8.66 x 10-14 
rs4942486 13 33.0 2.26 x 10-11 7.57 x 10-11 
rs8017377 14 24.9 2.52 x 10-15 3.99 x 10-8 
rs1532624 16 57.0 1.84 x 10-26 < 5 x 10-324 
rs217181 16 72.1 1.13 x 10-25 8.79 x 10-20 
rs3809868 17 45.8 4.30 x 10-10 5.06 x 10-23 
rs6504872 17 45.4 3.48 x 10-13 7.89 x 10-23 
rs10460181 19 45.1 2.25 x 10-28 4.99 x 10-35 
rs11881315 19 10.9 7.75 x 10-50 3.28 x 10-29 
rs16996148 19 19.7 1.97 x 10-45 7.99 x 10-54 
rs2075650 19 45.4 1.72 x 10-214 1.77 x 10-174 
rs2228603 19 19.3 4.43 x 10-44 6.06 x 10-48 
rs6511720 19 11.2 3.85 x 10-262 6.60 x 10-132 
rs676388 19 49.2 1.31 x 10-11 2.12 x 10-10 
rs10195252 2 165.5 3.81 x 10-8 3.10 x 10-23 
rs4988235 2 136.6 3.22 x 10-11 8.81 x 10-12 
rs6544713 2 44.1 4.84 x 10-83 1.85 x 10-39 
rs6730157 2 135.9 6.32 x 10-11 4.90 x 10-10 
rs6739502 2 21.5 5.27 x 10-25 9.44 x 10-17 
rs693 2 21.2 1.20 x 10-131 7.36 x 10-129 
rs6016381 20 39.2 6.85 x 10-20 2.66 x 10-16 
rs6102322 20 39.9 9.63 x 10-20 1.13 x 10-13 
rs11709504 3 12.7 4.60 x 10-8 1.36 x 10-12 
rs9875338 3 12.3 2.21 x 10-11 2.45 x 10-14 
rs1501908 5 156.4 1.12 x 10-28 3.49 x 10-27 
rs34358 5 75.0 8.77 x 10-31 8.55 x 10-28 
rs3935470 5 74.4 1.59 x 10-27 5.99 x 10-21 
rs6878990 5 74.7 5.83 x 10-63 1.60 x 10-45 
rs11753995 6 160.6 4.06 x 10-21 7.03 x 10-15 
rs1367211 6 161.1 7.23 x 10-9 5.64 x 10-12 
rs2294261 6 16.1 6.57 x 10-17 5.12 x 10-11 
rs868943 6 116.3 8.44 x 10-11 9.61 x 10-14 
rs12670798 7 21.6 4.81 x 10-14 4.25 x 10-8 
rs17725246 7 44.6 1.49 x 10-20 1.13 x 10-12 
rs4722551 7 26.0 3.95 x 10-14 5.72 x 10-28 
rs2126259 8 9.19 1.35 x 10-22 1.59 x 10-55 
rs2326077 8 59.4 5.00 x 10-17 6.00 x 10-17 
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rs6982502 8 126.5 4.70 x 10-46 2.58 x 10-120 
rs6993938 8 145.0 1.77 x 10-10 4.09 x 10-10 
rs1883025 9 107.7 6.14 x 10-11 4.48 x 10-104 
rs579459 9 136.2 2.42 x 10-44 9.24 x 10-52 
 
Table 16. P-values for the genome-wide significant SNPs in the univariate GWAS on LDL, and the joint 
association P-values for the joint analysis of HDL, LDL and TG using the MetaHom method. 
 
We do not observe a boost in all univariate P-values, however, suggesting that these 
SNPs may not have a pleiotropic effect on the analysed traits. 
 
Furthermore, we observe that SNPs that reached suggestive level of significance in 
the univariate GWAS often become genome-wide significant in the multi-trait 
analysis. Table 17 details the SNPs from the univariate LDL GWAS with 1 × 10!! ≤𝑃 <  5 × 10!! that were found to be genome-wide significant in the multi-trait GWAS 




SNP CHR Position (Mb) univariate P-value multi-trait P-value 
rs17162330 1 27.2 8.28 x 10-6 2.74 x 10-18 
rs2095403 1 62.9 9.27 x 10-6 9.57 x 10-10 
rs1260326 2 27.7 1.51 x 10-7 2.44 x 10-267 
rs2287623 2 169.8 5.40 x 10-8 2.13 x 10-10 
rs13315871 3 58.4 4.72 x 10-7 3.42 x 10-9 
rs6831256 4 3.5 9.07 x 10-7 5.77 x 10-14 
rs3891175 6 32.6 7.53 x 10-6 8.62 x 10-13 
rs2814993 6 34.6 2.87 x 10-7 5.68 x 10-18 
rs11755266 6 35.2 1.98 x 10-6 1.14 x 10-13 
rs6901147 6 52.5 7.72 x 10-7 1.23 x 10-9 
rs4895441 6 135.4 7.28 x 10-6 7.94 x 10-10 
rs4921914 8 18.3 1.92 x 10-7 1.52 x 10-18 
rs7033354 9 16.9 1.42 x 10-6 1.53 x 10-11 
rs10904908 10 17.3 3.14 x 10-7 6.02 x 10-14 
rs4933744 10 94.6 2.55 x 10-6 9.97 x 10-10 
rs1351452 11 116.9 4.16 x 10-7 2.15 x 10-89 
rs7117842 11 122.5 7.56 x 10-7 1.13 x 10-20 
rs4765219 12 124.4 8.90 x 10-6 2.46 x 10-19 
rs7193549 16 71.6 1.54 x 10-6 1.34 x 10-8 
rs2277862 20 34.2 1.30 x 10-6 4.36 x 10-8 
Table 17. Suggestive hits from the univariate LDL GWAS that were found to be genome-wide significant 
in the multi-trait analysis of HDL, LDL and TG using the MetaHom method. 
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SNP CHR Position (Mb) univariate P-value multi-trait P-value 
rs17162330 1 27.2 8.28 x 10-6 3.36 x 10-19 
rs1260326 2 27.7 1.51 x 10-7 1.65 x 10-62 
rs11688816 2 63.1 2.30 x 10-7 8.32 x 10-9 
rs6430552 2 135.6 1.15 x 10-6 3.43 x 10-8 
rs2287623 2 169.8 5.40 x 10-8 1.57 x 10-8 
rs13315871 3 58.4 4.72 x 10-7 4.51 x 10-9 
rs6831256 4 3.47 9.07 x 10-7 6.86 x 10-13 
rs3891175 6 32.6 7.53 x 10-6 1.45 x 10-13 
rs3800457 6 34.7 2.30 x 10-7 1.06 x 10-14 
rs11755266 6 35.2 1.98 x 10-6 2.97 x 10-9 
rs6901147 6 52.5 7.72 x 10-7 8.09 x 10-9 
rs4921914 8 18.3 1.92 x 10-7 1.83 x 10-19 
rs7033354 9 16.9 1.42 x 10-6 2.78 x 10-12 
rs10904908 10 17.3 3.14 x 10-7 9.42 x 10-15 
rs4933744 10 94.6 2.55 x 10-6 2.05 x 10-10 
rs7117842 11 122.5 7.56 x 10-7 1.33 x 10-12 
rs10744777 12 112.2 1.56 x 10-7 3.98 x 10-11 
rs4765219 12 124.4 8.90 x 10-6 2.86 x 10-20 
rs7193549 16 71.6 1.54 x 10-6 3.73 x 10-9 
Table 18. Suggestive hits from the univariate LDL GWAS that were found to be genome-wide significant 





By re-analysing existing GWAS results, combining information across traits, we have 
identified a large number of novel genotype-phenotype associations. While power 
can also be increased by additional sample size, this study provides a proof-of-
principle that no matter what the present sample sizes of GWAS, novel variants can 
be discovered by performing multi-trait analyses on GWAS summary data. This can 
be particularly beneficial for traits that are highly heterogeneous or for which sample 
collection is challenging, since their independent GWAS may have produced few 
findings and thus targets for further biological investigation or drug development. The 
variants with the strongest signals from our cross-trait analyses may point to causal 
variants that act as ‘hubs’ of phenotypic importance, deserving special biological 
investigation, which may unravel the mechanisms underlying the shared aetiology 
between the traits.  
 
Our results have demonstrated that performing multi-trait analyses of GWAS 
summary statistics can boost univariate signals. This may provide the increase in 
power required to identify genetic variants associated with traits that have few known 
genetic determinants to date. The resource of publicly available summary data is 
continually growing and there is now an online tool, PhenoScanner (Staley et al., 
2016), that collates summary statistics across a wide range of traits, further 
facilitating these types of analyses. The traits considered in this study could be 
considered to be rather homogenous in respect to genetic effects, thus further multi-
trait analyses should be performed to gain further insight into the interaction between 
genetic variation and correlated sets of traits. Here we also applied both the 
MetaHom and MetaHet methods, as our simulations suggested that a combination of 
the two methods produces the most novel findings when the causal genetic 
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relationships are not known. However, we did not test this inference formally and 
applying two methods increases the multiple testing burden, providing the motivation 
for methodology development into the identification of the type of causal genetic 
relationships that typically exist, so that the most appropriate method can be 
adopted. 
 
A detailed evaluation of our results can provide more general insights into the genetic 
aetiology underlying correlated traits; strong results for MetaHom compared to 
MetaHet, which we observe for most of the correlated-sets of traits here, are 
indicative of relatively uniform effects across the tested traits. The set of MetaHom 
and MetaHet GWAS results produced here, in particular the former, provide the field 
with a ‘pleiotropic GWAS’ resource, both relating to a wide range of phenotypes and 
more focused subsets. This can act as a unified GWAS results set, capturing effects 
across multiple traits into single measures of association. Such a resource is useful 
for testing the enrichment of, for example, regulatory features, genomic aberrations 
or putative selected loci, against a single set of GWAS signals. We expect multi-trait 
GWAS scans to be continually updated as univariate GWAS of larger sizes are 
performed and publicly released, and we believe that they will aid in our 
understanding of specific phenotypes and in the biological processes contributing to 










5.  Building a multi-trait predictive model of 
Major Depressive Disorder 
 
Major Depressive Disorder (MDD) is a common, polygenic disorder that is estimated 
to affect more than 350  million people worldwide, and is the leading cause of 
disability in the world (‘WHO | Depression’, Fact Sheet; Whiteford et al., 2013). MDD 
is characterised by low mood, loss of interest, feelings of guilt, reduced appetite, and 
disrupted sleep. While MDD has been shown to be highly heritable (ℎ! = 37%) 
(Sullivan et al., 2000), research efforts have discovered only a modest number of 
genetic markers associated with MDD (Ripke et al., 2013; Converge Consortium, 
2015; Hyde et al., 2016) compared to other psychiatric disorders such as 
schizophrenia (SCZ), for which there are 108 independent known loci (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014). Genome-wide 
association studies (GWAS) have often been limited by small sample sizes and/or 
high heterogeneity in phenotype, resulting in low statistical power to detect causal 
associations. A recent study by 23andMe (Hyde et al., 2016) identified 4 independent 
loci from a discovery GWAS on 326,113 individuals (84,847 cases). The 23andMe 
data were meta-analysed with the PGC MDD GWAS (Ripke et al., 2013), with this  
previous smaller GWAS failing to find any loci (Ripke et al., 2013). This demonstrates 
that due to the heterogeneous nature of MDD, extremely large sample sizes are 
required to achieve a well-powered study. 
 
Neuroticism is a personality trait, with high levels of neuroticism characterised by 
anxiety, worry, loneliness, feelings of guilt and sensitivity, and heritability is estimated 
to be between 15%  and 37%  (Smith et al., 2016). Neuroticism is considered a 
continuous measure, with the severity determined by 12 component measures; a 
neuroticism score between 0  and 12  is computed from answers to the Eysenck 
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Personality Questionnaire - Revised Short Form (EPQ-R-S) (Eysenck et al., 1985). 
High neuroticism scores are correlated with MDD (Jylhä and Isometsä, 2006), and a 
genetic correlation between neuroticism and MDD has been established (Smith et 
al., 2016).  
 
As MDD is a polygenic disorder, polygenic risk scores (PRS) are often constructed 
based on MDD GWAS results to quantify an individual’s genetic risk for MDD. The 
resulting PRS is a weighted sum of the risk alleles for MDD carried by an individual 
across the genome (Purcell et al., 2009; Dudbridge, 2013; Euesden et al., 2015). 
This technique allows exploration into the genetic aetiology of disease, and is often 
used as a tool for predicting case/control status. While the PRS approach has been 
successful in other complex disorders (Purcell et al., 2009; Selzam et al., 2016), the 
low power of MDD GWAS to date has meant that PRS for MDD generally explain a 
relatively small amount of the variance in MDD diagnosis. Heterogeneity of the MDD 
phenotype could also provide an explanation for the poor predictive power of the 
MDD PRS. 
 
In this chapter we build predictive models of MDD case/control status utilising the 
rich phenotyping available in the UK Biobank resource (http://www.ukbiobank.ac.uk/). 
Usually only PRS for MDD and SCZ are used as predictors of MDD (Ripke et al., 
2013; Euesden et al., 2015). Here we build PRS on additional phenotypes that 
associate with MDD, such as component measures of neuroticism, obesity and 
whether college/university was attended. We build multivariate predictive models of 
MDD using these PRS predictors, choosing the most predictive model by variable 
selection techniques. Furthermore, we consider two-way interactions between these 
PRS variables to gain further insight into the genetic aetiology of MDD and its 
associated outcomes. Previous genetic interactions have been explored on a SNP-
by-SNP basis; here we aim to capture broader genetic interaction using PRS as a 
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proxy for the overall genetic predisposition to the corresponding phenotype, which 
may present phenotypically even if not clinically.  
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5.1 Introduction  
 
We aim to build predictive models for Major Depressive Disorder (MDD) that exploit 
multiple predictors, with an assumption that MDD is best predicted by a number of 
component measures that together capture different forms of this highly 
heterogeneous disorder. Given the complexity of MDD we also include interactions 
between the component measures as potential predictors. While we use polygenic 
risk scores (PRS) based on GWAS on MDD and schizophrenia from the Psychiatric 
Genomics Consortium (PGC) (Ripke et al., 2013; Schizophrenia Working Group of 
the Psychiatric Genomics Consortium, 2014), we build all other PRS, and train and 
test our predictive models, using UK Biobank data. GWAS are performed on the set 
of component measures in 80% of the UK Biobank data, a further 10% of the data is 
used to train the predictive models, and the final 10% of the data is used to validate 
the most predictive models. As well as the 12 components of neuroticism for which 
we build PRS, we also build PRS on obesity and whether college was attended. 
These PRS, together with the PRS for MDD and SCZ, are included as predictors in 
the models, and age, sex and 15  genetic principal components (to control for 
population structure) are included as control variables.  
 
The first part of the chapter focuses on prediction of MDD from PRS alone. We first 
consider the main effect terms of the PRS, performing stepwise variable selection 
using both Akaike Information Criteria (AIC) and Bayesian Information Criteria (BIC) 
on the model as follows:  
 𝑀𝐷𝐷!"#"$! ~ 𝑀𝐷𝐷!"# +  𝑆𝐶𝑍!"# +  𝑁𝐸𝑈1!"#  +  𝑁𝐸𝑈2!"#  +  …  +  𝑁𝐸𝑈12!"#  +  𝑂𝑏𝑒𝑠𝑒!"# +  𝐶𝑜𝑙𝑙𝑒𝑔𝑒!"# +  𝐴𝑔𝑒 +  𝑆𝑒𝑥 +  𝑃𝐶!  +  𝑃𝐶!  +⋯+  𝑃𝐶!" 
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where  𝑁𝐸𝑈1!"# is the PRS for the first component measure of neuroticism (here 
‘mood swings’), 𝑁𝐸𝑈2!"#  is the PRS for the second component measure of 
neuroticism (here ‘miserableness’), and so on. 
 
Next we include interaction terms, exhaustively including all two-way interactions 
between each component PRS and age and sex, so that variable selection is applied 
to the model containing 153 interaction terms in addition to the 16 main effect terms 
and the control variables.  
 
We also consider phenotype-only prediction models, which do not include genetic 
data in the form of PRS as predictors. We perform variable selection in the same way 
as for the PRS models (using both AIC and BIC) on both main effect and two-way 
interaction models, as detailed below. 
 
The main effect model with phenotype predictors on which variable selection is 
performed is given by: 
 𝑀𝐷𝐷!"#"$! ~ 𝑁𝐸𝑈!  +  𝑁𝐸𝑈! +  …  +  𝑁𝐸𝑈!" +  𝑂𝑏𝑒𝑠𝑒 +  𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝐴𝑔𝑒 +  𝑆𝑒𝑥  
 
The two-way interaction model of the phenotype predictors on which variable 
selection is performed contains 120 interaction terms in addition to the 14 main effect 
terms and the age and sex control variables. 
 
Finally, we build predictive models of MDD using both genetic (PRS) and phenotypic 
predictors. We build models using only the main effects of the PRS and phenotype 
predictors, as well as allowing interactions between the genetic predictors, 
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interactions between the phenotype predictors, and interactions between the genetic 
and phenotype predictors. 
 
Below, we begin by detailing the materials and methods used in the study before 
describing the results.  
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5.2 Materials and Methods 
 
The UK Biobank (Sudlow et al., 2015) is a population-based resource of 
approximately 502,000 individuals aged between 39 and 73, for which recruitment 
took place between 2006 and 2010. The current release of genetic data (June 2015) 
includes genotype data on 152,249 individuals. Data on a huge variety of health and 
trait measures have been collected as part of the UK Biobank, such as physical 




Here we focus on MDD and its associated traits. In particular, for building polygenic 
risk scores (PRS) for prediction we focus on neuroticism due to its established 
genetic and phenotypic correlation with MDD (Smith et al., 2016; Kendler and Myers, 
2010). In addition to using the neuroticism score as defined by the 12-point Eysenck 
Personality Questionnaire - Revised Short Form (EPQ-R-S) (Eysenck et al., 1985), 
we also consider these 12 questions as endo-phenotypes and perform analyses on 
these binary traits individually. These 12 endo-phenotypes are: mood swings (MS), 
miserableness (M), irritability (I), sensitivity (S), fed-up feelings (FU), nervous feelings 
(N), worrier (W), tense feelings (T), worry too long after embarrassment (WTL), suffer 
from nerves (SFN), loneliness (L) and guilty feelings (G). Details of the questions 
asked to UK Biobank participants are given in Table 19. In addition, we produce PRS 
on obesity, defined as having BMI ≥ 30 kg/m2 (Yang et al., 2012), and on educational 
attainment (whether college/university was attended), due to the known relationships 




Component Abbr. Question  
Mood swings MS Does your mood often go up and down? 
Miserableness M Do you ever feel 'just miserable' for no reason? 
Irritability I Are you an irritable person? 
Sensitivity S Are your feelings easily hurt?  
Fed-up feelings FU Do you often feel 'fed-up'? 
Nervous feelings N Would you call yourself a nervous person? 
Worrier W Are you a worrier? 
Tense feelings T Would you call yourself tense or 'highly strung'? 
Worry too long WTL Do you worry too long after an embarrassing experience? 
Suffer from nerves SFN Do you suffer from 'nerves'? 
Loneliness L Do you often feel lonely? 
Guilty feelings G Are you often troubled by feelings of guilt? 
 
Table 19. Summary of the 12 neuroticism endo-phenotypes, the symbol we use to refer to them, and 
the question that was asked to UK Biobank participants to determine a diagnosis. Participants were 
assessed via a touchscreen questionnaire, and answered: yes, no, do not know, or prefer not to answer. 
 
As some of the phenotypes under study do not currently have publicly available 
GWAS summary statistics, and due to potential problems with sample overlap in the 
UK Biobank, we split our data into training and test datasets. We use 80% of the UK 
Biobank as the training data in which to perform the discovery GWAS, required to 
compute polygenic risk scores, on the 15 traits detailed above. We use 10% of the 
UK Biobank as the test dataset for building the PRS and for building the predictive 
model of MDD. We retain a further 10% of the UK Biobank as a validation dataset in 





Genotyping of the UK Biobank sample was performed by Affymetrix using the UK 
BiLEVE and UKB Axiom arrays, which are two customised microarrays that assay 






5.2.3 Genotype quality control 
 
Preliminary quality control (QC) was performed by Affymetrix and the UK Biobank 
(see http://www.ukbiobank.ac.uk/wpcontent/uploads/2014/04/UKBiobank_genotyping 
_QC_documentation-web.pdf). In addition, we performed study specific QC using 
PLINK-1.9 (Chang et al., 2015) as follows. We removed all markers with 𝑀𝐴𝐹 < 0.01, and a genotype missingness threshold of 0.05 was applied. Hardy-Weinberg 
Equilibrium (HWE) was tested at a threshold of 5 × 10!!. Individuals with genotype 
missingness greater than 0.1 were removed and sex discordant individuals were 
excluded from the analysis. We restrict our sample to unrelated individuals using a 
Kinship coefficient threshold of 0.05, and to those individuals with a homogeneous 
UK-dominated ancestry, as defined by a cross-section of 4-means clustering on the 
first two principal components from a principal components analysis on the full 
genome-wide data. We performed GWAS on non-imputed data, consisting of 498,104 SNPs after QC. 
 
5.2.4 MDD phenotyping 
 
We defined MDD cases as any reported primary diagnosis of MDD from inpatient 
hospital records, identified by ICD10 subchapters F32 and F33. In addition, an 
individual was defined as a case for MDD if they reported a visit to a GP or 
psychiatrist for stress, anxiety or depression, and at least one period of depression or 
anhedonia lasting at least two weeks (Smith et al., 2013). In both cases and controls, 
we excluded individuals who had a primary diagnosis or self-reported for Bipolar 
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Disorder (BPD), psychosis, multiple personality disorder, autism or intellectual 
disability. Furthermore, we removed any controls that were taking anti-depressants, 
anti-psychotics or lithium.   
 
5.2.5 Training data 
 
Table 20 details the sample characteristics for the 80% of the data used for the 
discovery GWAS, and Table 21 details the numbers of individuals for which 
phenotype data were available for the 15 traits on which GWAS were performed. 
 
  Training Data 
Total sample 100,478 
Proportion Female 51.7% 
Age 56.8 (8.01; 39 - 73) 
BMI 27.4 (4.74; 13.9 - 74.7) 
Neuroticism score 3.86 (3.15; 0 - 12) 




Phenotype Cases Controls Total  % Cases 
Neuroticism - - 82,069 - 
Mood swings 41,781 56,241 98,022 42.6% 
Miserableness 39,868 58,977 98,845 40.3% 
Irritability 26,145 70,069 96,214 27.2% 
Sensitivity 52,196 45,426 97,622 53.5% 
Fed-up feelings 38,176 60,331 98,507 38.8% 
Nervous feelings 20,917 77,172 98,089 21.3% 
Worrier 52,932 45,006 97,938 54.0% 
Tense feelings 14,976 82,587 97,563 15.4% 
Worry too long 44,068 52,390 96,458 45.7% 
Suffer from nerves 17,944 79,104 97,048 18.5% 
Loneliness 16,367 82,626 98,993 16.5% 
Guilty feelings 26,017 71,988 98,005 26.5% 
Obese Yes/No 24,205 76,007 100,212 24.2% 
College Yes/No 31,870 50,196 82,066 38.8% 
Table 21. Number of cases and controls (total sample only for the continuous neuroticism phenotype) 
for the 15 phenotypes on which GWAS were performed in the training dataset (80% of the UK Biobank). 
Cases here refer to the number of individuals answering yes to each neuroticism endo-phenotype 
question, who have a BMI ≥ 30 kg/m2 for the obesity phenotype, and who said they have a university 




We performed genome-wide association studies (GWAS) in the UK Biobank for the 12  neuroticism endo-phenotypes, the composite neuroticism score, obesity and 
whether college/university was attended. We performed linear regression for the 
neuroticism score GWAS and logistic regression for all other phenotypes, controlling 
for age, sex and the top 15 PCs in each model. GWAS were performed in PLINK-1.9 







5.2.7 Polygenic risk scoring 
 
Polygenic risk scores (PRS) were built using the PRSice software (Euesden et al., 
2015) at SNP P-value thresholds of 0.001, 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5. Age, sex and 
the top 15  PCs were controlled for in the association of the scores with the 
phenotype in order to establish the most predictive threshold. 
 
5.2.8 Test data PRS 
 
Using the beta coefficients from the discovery GWAS performed in 80% of the UK 
Biobank (𝑁 = 100,478), we built polygenic risk scores (PRS) on the test dataset 
consisting of 10% of the UK Biobank (𝑁 = 12,552). For MDD and SCZ, we used the 
PGC MDD (Ripke et al., 2013) and PGC SCZ (Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014) discovery GWAS. We were not able to use 
the summary statistics from the latest MDD GWAS (Hyde et al., 2016) as 23andMe 
do not release summary statistics due to data protection. We removed all individuals 
in the UK Biobank who were also part of the PGC MDD discovery GWAS (𝑁 = 8). 
For the neuroticism phenotypes, as well as obesity and college, we built the PRS, 
and chose the most predictive score, on the phenotype itself. For example, for 
miserableness we chose the most predictive score of the miserableness phenotype, 
as opposed to of MDD, in order to obtain a score that best reflects the genetics of 
miserableness. For MDD and SCZ we chose the score most predictive of MDD case-
control status, as SCZ PRS has previously been shown to be a better predictor of 
MDD than MDD PRS (Euesden et al., 2015). Table 22 details the sample 
characteristics of the test dataset, and Figure 39 details the correlations between 
MDD, the 12 neuroticism endo-phenotypes, obesity and college. 
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  Test Data 
Total sample 12,552 
Proportion Female 51.2% 
MDD cases 955 
Age 56.9 (7.96; 40 - 70) 
BMI 27.3 (4.73; 15.4 - 61.9) 
Neuroticism score 3.85 (3.15; 0 - 12) 
 
Table 22. Sample characteristics of the test dataset, which represents 10% of the UK Biobank. 
 
 







5.2.9 Validation data PRS 
 
Due to potential problems with over fitting of the predictive model(s) in the test 
dataset, we retained a further 10% of the UK Biobank data as a validation dataset. 
Again, we removed all individuals in the UK Biobank who were also part of the PGC 
MDD discovery GWAS (𝑁 = 11). We calculated the PRS for each individual on each 
phenotype in the validation dataset using the most predictive threshold as 
determined in the test data. Table 23 details the sample characteristics of the 
validation dataset. 
 
  Validation Data 
Total sample 12,549 
Proportion Female 51.2% 
MDD cases 953 
Age 56.8 (7.95; 40 - 70) 
BMI 27.5 (4.82; 14.5 - 66.2) 
Neuroticism score 3.84 (3.14; 0 - 12) 
 
Table 23. Sample characteristics of the validation dataset, which represents 10% of the UK Biobank. 
 
5.2.10 Prediction Models 
 
We built prediction models of MDD case-control status using the PRS built in the test 
dataset as predictors in a logistic regression. We first fit a model with all PRS 
predictors (and no interaction terms), controlling for age, sex and the top 15 PCs. A 
stepwise forward and backward variable selection procedure was then performed to 
determine the most predictive subset of predictors. We use both AIC and BIC as 
criteria for variable selection, and the most predictive model is chosen to be the one 
that minimises the criterion. We compare the fit of the model against the null model 
containing only the control variables using a likelihood ratio test (LRT) of the nested 
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models. We also compare to a “MDD null model” that contains the control variables 
as well as the MDD PRS, and a “MDD and SCZ null model” that contains MDD and 
SCZ PRS as well as the control variables. We compare the Nagelkerke’s psuedo-R2 
between the fitted and null models. We also consider two-way interaction terms 
between the PRS predictors, as well as allowing for interaction between them and 
the age and sex covariates. As with the main effects models, we use stepwise 
variable selection procedures to determine the most predictive models and compare 
to the null models using likelihood ratio tests (LRTs) and Nagelkerke’s pseudo-R2. 
 
In the validation data, we rebuild the models chosen to be the most predictive of 
MDD case-control status from the stepwise variable selection procedures in order to 
determine whether the models replicate in an independent dataset. 
 
We repeat the above procedure using phenotypic data as predictors, as opposed to 
the PRS predictors, in this case controlling for age and sex in our fitted models. We 
also consider a mixture of genetic (PRS) and phenotypic predictors, where the top 15 
PCs are controlled for in addition to age and sex. 
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GWAS were performed in the training dataset for the 12  neuroticism endo-
phenotypes, the neuroticism score (sum across all 12  questions), obesity and 
college, in order to obtain the beta coefficients from which to build the PRS in the test 
dataset. Table 24 details the number of independent genome-wide significant hits 
identified by each of the GWAS. Independence here is defined as there being no 
other genome-wide significant SNP within a 500kb window centered on that SNP. 
Figure 41 shows the Manhattan plots for the GWAS on neuroticism, worrier (W), 
obesity and college, which identified the largest number of genome-wide significant 
findings. 
 
Phenotype Sample Size GWAS Hits 
Neuroticism 82,069 11 
Mood swings 98,022 2 
Miserableness 98,845 3 
Irritability 96,214 0 
Sensitivity 97,622 0 
Fed-up feelings 98,507 0 
Nervous feelings 98,089 0 
Worrier 97,938 10 
Tense feelings 97,563 0 
Worry too long 96,458 1 
Suffer from nerves 97,048 0 
Loneliness 98,993 0 
Guilty feelings 98,005 1 
Obese Yes/No 100,212 12 
College Yes/No 82,066 5 
 
Table 24. Number of independent genome-wide significant associations identified by each of the GWAS 




Figure 41. Manhattan plots for the GWAS on neuroticism, worrier (W), obesity and college, performed 
in the training dataset (80% of the UK Biobank). The green points represent the independent, genome-
wide significant signals. 
 
Table 25 contains the genome-wide significant associations for the neuroticism 
GWAS, and Table 26 details the genome-wide significant associations for the worrier 
(W) GWAS. We observe that the same signal on chromosome 8 is present in both 




et al., 2016). The signal on chromosome 2 for neuroticism is not observed in the 
worrier (W) GWAS. 
 
SNP CHR Position (Mb) P-value 
rs12547493 8 8.66 3.01 x 10-16 
rs7826660 8 8.38 2.87 x 10-14 
rs12679529 8 10.8 5.25 x 10-13 
rs3808509 8 11.2 5.61 x 10-13 
rs2929453 8 9.08 8.17 x 10-12 
rs9969657 8 10.5 1.40 x 10-11 
rs11998678 8 11.8 2.89 x 10-11 
rs13280813 8 11.4 1.32 x 10-10 
rs2980437 8 8.09 5.31 x 10-10 
rs3088186 8 10.2 1.40 x 10-9 
rs2678890 2 58.2 7.21 x 10-9 
 
Table 25. Genome-wide significant, independent hits for the neuroticism GWAS performed in the 
training dataset (80% of the UK Biobank). 
 
SNP CHR Position (Mb) P-value 
rs12679529 8 10.8 3.19 x 10-17 
rs12547493 8 8.66 1.49 x 10-15 
rs3808509 8 11.2 2.52 x 10-14 
rs11998678 8 11.8 1.15 x 10-13 
rs9969657 8 10.5 2.18 x 10-13 
rs2976940 8 8.28 1.52 x 10-12 
rs13280813 8 11.4 1.82 x 10-11 
rs28649568 8 8.96 2.23 x 10-9 
rs3088186 8 10.2 2.56 x 10-9 
rs656319 8 9.81 3.06 x 10-8 
 
Table 26. Genome-wide significant, independent hits for the worrier (W) GWAS performed in the 
training dataset (80% of the UK Biobank). 
 
Table 27 details the genome-wide significant SNPs for the obesity GWAS, and  
Table 28 details the genome-wide significant SNPs for the college GWAS. 
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SNP CHR Position (Mb) P-value 
rs1421085 16 53.8 4.57 x 10-39 
rs2867125 2 0.62 8.11 x 10-16 
rs10871777 18 57.9 8.28 x 10-12 
rs12343000 9 131.0 1.92 x 10-9 
rs34783010 19 46.2 3.27 x 10-9 
rs543874 1 177.9 3.43 x 10-9 
rs1364063 16 69.6 6.55 x 10-9 
rs1061810 11 43.9 7.55 x 10-9 
rs10938397 4 45.2 9.70 x 10-9 
rs2061154 1 219.7 1.60 x 10-8 
rs4788190 16 29.9 4.63 x 10-8 
rs10484439 6 26.3 4.75 x 10-8 
 
Table 27. Genome-wide significant, independent hits for the obesity GWAS performed in the training 
dataset (80% of the UK Biobank). 
 
SNP CHR Position (Mb) P-value 
rs868891 3 49.9 6.46 x 10-13 
rs4625 3 49.6 1.14 x 10-10 
rs55663797 17 43.5 6.93 x 10-10 
rs12554512 9 23.4 4.02 x 10-9 
rs806794 6 26.2 4.77 x 10-8 
 
Table 28. Genome-wide significant, independent hits for the college GWAS performed in the training 
dataset (80% of the UK Biobank).  
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5.3.2 Test data PRS 
 
Polygenic risk scores (PRS) were built in the test dataset using the SNP coefficients 
determined by the GWAS performed in the training data. MDD and SCZ discovery 
GWAS from the Psychiatric Genomics Consortium (PGC) were also used (Ripke et 
al., 2013; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 
2014). Table 29 details the most predictive thresholds for each phenotype, as well as 
the phenotypic variance explained by this most predictive score and the 
corresponding P-value of association. 
 
Phenotype Sample Size Threshold P-value R2 No. SNPs 
Neuroticism 10,219 0.05 4.37 x 10-18 0.0071 18,721 
Mood swings 12,241 0.3 3.13 x 10-7 0.0028 82,856 
Miserableness 12,333 0.05 7.39 x 10-7 0.0026 18,426 
Irritability 12,006 0.3 5.77 x 10-10 0.0046 82,212 
Sensitivity 12,195 0.4 8.54 x 10-12 0.0049 103,413 
Fed-up feelings 12,297 0.2 1.03 x 10-13 0.0060 59,799 
Nervous feelings 12,227 0.5 6.64 x 10-12 0.0060 121,426 
Worrier 12,217 0.3 4.08 x 10-12 0.0051 82,249 
Tense feelings 12,195 0.5 1.94 x 10-9 0.0051 121,374 
Worry too long 12,050 0.5 1.22 x 10-13 0.0060 121,754 
Suffer from nerves 12,105 0.05 1.15 x 10-4 0.0020 17,242 
Loneliness 12,369 0.4 3.60 x 10-8 0.0041 102,784 
Guilty feelings 12,220 0.1 1.91 x 10-5 0.0021 32,499 
Obese Yes/No 12,521 0.2 1.20 x 10-48 0.0260 62,223 
College Yes/No 10,261 0.4 6.33 x 10-37 0.0213 104,799 
MDD 12,552 0.001 2.71 x 10-1 0.0002 134 
SCZ 12,552 0.3 1.94 x 10-2 0.0010 81,326 
 
Table 29. Most predictive polygenic risk score (PRS) thresholds for each phenotype, and the 
corresponding variance explained (R2) and P-value. For the neuroticism phenotypes, obesity and 
college, the threshold was chosen so that the PRS was most predictive of the same phenotype. For 
MDD and SCZ the threshold was chosen for the most predictive PRS of MDD. Tested thresholds were 




As shown in Table 29, the best threshold PRS for obese (yes/no) and college 
(yes/no) have the largest variance explained out of all traits considered here at 2.6% 
( 𝑃 = 1.20 × 10!!" ) and 2.13%  ( 𝑃 = 6.33 × 10!!" ) respectively. Interestingly the 
schizophrenia (SCZ) PRS, which has been shown to have a variance explained of 
around 2.1% (𝑃 = 2.10 × 10!!") for predicting MDD status in one sample (Euesden 
et al., 2015), only has an R2 of 0.1% (𝑃 = 1.94 × 10!!) in this sample. This is likely 
due to the low prevalence of SCZ in the UK Biobank cohort. While the neuroticism 
PRS only has a modest R2 of 0.71% (𝑃 = 4.37 × 10!!"), this is in line with previous 
studies (Smith et al., 2016). Of the component measures of neuroticism, fed-up 
feelings, nervous feelings and worry too long have the best predictive power (R2 = 0.6% ; 𝑃 = 1.03 × 10!!" , 𝑃 = 6.64 × 10!!"  and 𝑃 = 1.22 × 10!!"  respectively), while 
mood swings and miserableness have the lowest variance explained (R2 of 0.28% 
(𝑃 = 3.13 × 10!!) and 0.26% (𝑃 = 7.39 × 10!!) respectively). The highest variance 
explained that has been achieved by a behavioral trait PRS to date is 9%  for 
educational achievement (Selzam et al., 2016), which puts the modest prediction 
achieved for the neuroticism traits into context. However, educational achievement 
has been estimated to have a twin heritability of around 60% (Krapohl et al., 2014), 
suggesting a large genetic component that may not be replicated in other traits. The 
PRS with the smallest R2 in this sample is MDD at 0.02% (𝑃 = 0.271). In a recent 
mega-analysis, the MDD PRS has been shown to explain 0.6% of variance in MDD 
case/control status (𝑃 <  10!!) (Ripke et al., 2013), suggesting that the MDD PRS 
could be underpowered in this sample due to the heterogeneous nature of the MDD 
phenotype. 
The predictive power of the PRS in this sample are modest, though the relative 
performance of the MDD-correlated-trait PRS compared to that of MDD could 
suggest that these PRS may provide more predictive power than MDD itself. In 
particular, using a combination of the PRS in a multivariate model could leverage the 
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individually limited variance explained to identify an overall more predictive model of 
MDD. However, the low predictive power that we have observed here clearly 
indicates that these PRS have almost no direct clinical benefit as yet, but should 
instead be viewed as potentially providing insights into disease and trait aetiology, 
which may subsequently have clinical use.   
Figure 42 shows the PRSice (Euesden et al., 2015) bar plots corresponding to PRS 
on MDD (Figure 42a) and SCZ (Figure 42b) built in the test dataset, and predicting 
























Figure 42. PRSice bar plots for the PRS built in the test dataset for: (a) MDD and (b) SCZ, illustrating 
the different SNP P-value thresholds and their prediction of MDD case-control status. 
 
Figure 43 shows the PRSice (Euesden et al., 2015) bar plots for the most predictive 





Figure 43. PRSice bar plots for the most predictive PRS as determined in the test dataset, across all 




5.3.3 Prediction models of MDD using multiple PRS predictors 
 
Previous analyses have shown that the PRS for MDD has limited predictive power of 
MDD case-control status (Ripke et al., 2013). Here we aim to build a more powerful 
predictive model of MDD using both MDD and SCZ PRS, and PRS for other 
correlated traits. We use variable selection techniques to find the most predictive 
models, and consider both the PRS main effects and two-way interactions between 
PRS. We first build a predictive model in the test dataset, with an independent 
dataset reserved for cross-validation. 
 
5.3.3.1 PRS: Main effect predictors 
We fit a logistic regression model with all PRS included as predictors, and include 
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𝑀𝐷𝐷!"#"$! ~ 𝑀𝐷𝐷!"# + 𝑆𝐶𝑍!"# + 𝑁𝐸𝑈!"# +𝑀𝑆!"# +𝑀!"# + 𝐼!"# + 𝑆!"# + 𝐹𝑈!"#+ 𝑁!"# +𝑊!"# + 𝑇!"# +𝑊𝑇𝐿!"# + 𝑆𝐹𝑁!"# + 𝐿!"# + 𝐺!"# + 𝑂𝑏𝑒𝑠𝑒!"#+ 𝐶𝑜𝑙𝑙𝑒𝑔𝑒!"# +  𝐴𝑔𝑒 + 𝑆𝑒𝑥 + 𝑃𝐶! +⋯+ 𝑃𝐶!" 
 
Using the forward and backward stepwise variable selection procedure, the most 
predictive model of MDD using Akaike Information Criterion (AIC) to assess model fit 
was: 𝑀𝐷𝐷!"#"$! ~ 𝑀𝐷𝐷!"# + 𝑆𝐶𝑍!"# + 𝑁!"# +𝑊!"# + 𝑇!"# +𝑊𝑇𝐿!"# + 𝐿!"#                              + 𝐴𝑔𝑒 + 𝑆𝑒𝑥 + 𝑃𝐶! +⋯+ 𝑃𝐶!" 
 
We compared the fit of this model to that of the null model, containing only age, sex 
and the top 15 PCs as covariates. We also compared to the MDD null model, which 
in addition includes the MDD PRS as a predictor, and to the MDD and SCZ null 
model, which includes the MDD and SCZ PRS as predictors in addition to the control 
variables. We compare to the MDD null and MDD/SCZ null in order to determine 
whether there is any gain over the standard approach of using the MDD PRS, or 
indeed the MDD and SCZ PRS, in predicting MDD case/control status. The 
corresponding Nagelkerke’s pseudo-R2 and likelihood ratio test P-values are given in 
Table 30. 
 
Model R2 P-value 
Main effects (AIC) vs. Null model 0.00877 2.90 x 10-5 
Main effects (AIC) vs. MDD null model 0.00776 6.06 x 10-5 
Main effects (AIC) vs. MDD and SCZ null model 0.00697 8.67 x 10-5 
Table 30. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) main 




We also performed the same procedure but instead using the Bayesian Information 
Criterion (BIC) to assess model fit. BIC is similar to AIC, but penalises the inclusion 
of additional predictors in the model more severely. The resulting model from the 
stepwise procedure using BIC is: 
 𝑀𝐷𝐷!"#"$! ~ 𝐿!"# +  𝐴𝑔𝑒 + 𝑆𝑒𝑥 + 𝑃𝐶! +⋯+ 𝑃𝐶!" 
 
L here refers to the loneliness neuroticism endo-phenotype. As the MDD and SCZ 
PRS were not retained in the model after the variable selection procedure, we 
compared the fit of this model only to that of the null model, the results of which are 
given in Table 31. 
 
Model R2 P-value 
Main effects (BIC) vs. Null model 0.00252 2.14 x 10-3 
Main effects (BIC) vs. MDD null model - - 
Main effects (BIC) vs. MDD and SCZ null model - - 
Table 31. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) main 
effect model compared to the null model. The MDD and SCZ PRS were not retained in the model, so 
comparisons with the MDD null model and the MDD and SCZ null model were not possible. 
 
 
5.3.3.2 PRS: Two-way interaction models 
We next fit a logistic regression model with all the same predictors as in the previous 
main effects model, but we also include two-way interactions between the PRS 
predictors, as well as interactions between them and the age and sex covariates. 
There are a total of 171 two-way interaction terms in the model in addition to the 
main effects terms, on which the variable selection procedure is performed. 
 
The stepwise variable selection two-way interaction best-fit model as determined by 
AIC is (PRS subscript omitted here for ease of reading): 
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𝑀𝐷𝐷!"#"$!  ~  𝑀𝑆 +  𝑀 +  𝑆 +  𝐹𝑈 +  𝑁 +  𝑊 +  𝑇 +  𝑊𝑇𝐿 +  𝑆𝐹𝑁 +  𝐿 +  𝐺 +  𝑁𝐸𝑈 +  𝑀𝐷𝐷 +  𝑆𝐶𝑍 +  𝑂𝑏𝑒𝑠𝑒 +  𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝐴𝑔𝑒:𝑀 +  𝐴𝑔𝑒:𝐹𝑈 +  𝐴𝑔𝑒:𝑊 +  𝐴𝑔𝑒: 𝑆𝐶𝑍 +  𝐴𝑔𝑒:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝑆𝑒𝑥:𝑀 +  𝑆𝑒𝑥:𝐹𝑈 +  𝑆𝑒𝑥:𝑇 +  𝑆𝑒𝑥: 𝑆𝐹𝑁 +  𝑀𝑆:𝑀 +  𝑀𝑆:𝐹𝑈 +  𝑀𝑆:𝑊𝑇𝐿 +  𝑀: 𝐿 +  𝑆:𝑊𝑇𝐿 +  𝑆:𝐺 +  𝑆:𝑁𝐸𝑈 +  𝑆: 𝑆𝐶𝑍 +  𝑆:𝑂𝑏𝑒𝑠𝑒 +  𝐹𝑈:𝑁 +  𝐹𝑈:𝑊 +  𝐹𝑈:𝑇 +  𝐹𝑈:𝑊𝑇𝐿 +  𝐹𝑈:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝑁:𝐺 +  𝑁: 𝑆𝐶𝑍 +  𝑁:𝑂𝑏𝑒𝑠𝑒 +  𝑊: 𝐿 +  𝑊:𝐺 +  𝑊:𝑁𝐸𝑈 +  𝑊: 𝑆𝐶𝑍 +  𝑇:𝑊𝑇𝐿 +  𝑇: 𝐿 +  𝑇:𝑁𝐸𝑈 +  𝑆𝐹𝑁: 𝐿 +  𝑆𝐹𝑁:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝐿: 𝑆𝐶𝑍 +  𝑁𝐸𝑈:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝑀𝐷𝐷:𝑂𝑏𝑒𝑠𝑒 +  𝐴𝑔𝑒+ 𝑆𝑒𝑥 + 𝑃𝐶! +⋯+ 𝑃𝐶!" 
 
We compare this two-way interaction model to the three null models as defined 
previously. The results of the likelihood ratio tests (LRTs) and comparison of 
Nagelkerke’s pseudo-R2 between these models are given in Table 32. 
 
Model R2 P-value 
Interaction model (AIC) vs. Null model 0.0414 8.51 x 10-12 
Interaction model (AIC) vs. MDD null model 0.0403 1.75 x 10-11 
Interaction model (AIC) vs. MDD and SCZ null model 0.0396 2.73 x 10-11 
Table 32. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) two-
way interaction model compared to the null model, the MDD null model and the MDD and SCZ null 
model.  
The stepwise variable selection two-way interaction model as determined by BIC is: 
 𝑀𝐷𝐷!"#"$! ~  𝐹𝑈 +  𝐴𝑔𝑒:𝐹𝑈 +  𝐴𝑔𝑒 + 𝑆𝑒𝑥 + 𝑃𝐶! +⋯+ 𝑃𝐶!" 
 
FU here refers to the fed-up neuroticism endo-phenotype. The results of the 
likelihood ratio tests (LRTs) and comparison of Nagelkerke’s pseudo-R2 between this 
model and the null models are given in Table 33. 
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Model R2 P-value 
Interaction (BIC) vs. Null model 0.00349 1.48 x 10-3 
Interaction (BIC) vs. MDD null model - - 
Interaction (BIC) vs. MDD and SCZ null model - - 
Table 33. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) two-
way interaction model compared to the null model. The MDD and SCZ PRS were not retained in the 
model, so comparisons with the MDD null model and the MDD and SCZ null model were not possible. 
 
 
5.3.4 Validation of PRS prediction models 
 
PRS were rebuilt in the validation dataset using the most predictive thresholds as 
determined in the test data. The SNP coefficients were obtained in the discovery 
GWAS performed in the training data and from the PGC for MDD and SCZ (Ripke et 
al., 2013; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 
2014). Figure 44 shows the PRSice (Euesden et al., 2015) bar plots for the most 
predictive thresholds across all phenotypes for which PRS were built in the validation 






Figure 44. PRSice bar plots for the most predictive PRS as determined in the test dataset and built in 
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Phenotype Sample Size Threshold P-value R2 No. SNPs 
Neuroticism 10,203 0.05 1.44 x 10-17 0.00690 18,721 
Mood swings 12,264 0.3 3.81 x 10-9 0.00376 82,856 
Miserableness 12,345 0.05 2.37 x 10-7 0.00284 18,426 
Irritability 11,997 0.3 1.09 x 10-7 0.00335 82,212 
Sensitivity 12,187 0.4 6.31 x 10-13 0.00547 103,413 
Fed-up feelings 12,309 0.2 1.53 x 10-16 0.00743 59,799 
Nervous feelings 12,235 0.5 2.09 x 10-15 0.00796 121,426 
Worrier 12,233 0.3 1.17 x 10-11 0.00491 82,249 
Tense feelings 12,162 0.5 4.74 x 10-9 0.00489 121,374 
Worry too long 12,032 0.5 5.29 x 10-11 0.00469 121,754 
Suffer from nerves 12,078 0.05 1.49 x 10-4 0.00193 17,242 
Loneliness 12,363 0.4 4.51 x 10-3 0.00112 102,784 
Guilty feelings 12,212 0.1 1.69 x 10-8 0.00370 32,499 
Obese Yes/No 12,520 0.2 1.21 x 10-46 0.02463 62,223 
College Yes/No 10,215 0.4 3.40 x 10-36 0.02094 104,799 
MDD 12,549 0.001 7.13 x 10-1 0.00003 134 
SCZ 12,549 0.3 4.02 x 10-2 0.00080 81,326 
 
Table 34. Most predictive polygenic risk score (PRS) thresholds for each phenotype as determined in 
the test dataset. Scores were then rebuilt at these thresholds in the validation dataset, and the 
corresponding variance explained (R2) and P-value for each phenotype are given here. 
 
The models that were determined to be most predictive of MDD case-control status 
in the test dataset by the stepwise variable selection procedures were then applied to 
the validation dataset using the PRS as detailed in Table 34. 
 
5.3.4.1 PRS: Main effect predictors 
The Nagelkerke’s pseudo-R2 and likelihood ratio test (LRT) P-values from the 
comparison of the stepwise (AIC) main effects model as fitted in the validation 






Model R2 P-value 
Main effects (AIC) vs. Null model 0.00154 0.567 
Main effects (AIC) vs. MDD null model 0.00154 0.450 
Main effects (AIC) vs. MDD and SCZ null model 0.00076 0.723 
Table 35. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) main 
effect model as determined in the test dataset and fitted in the validation dataset, compared to the null 
model, the MDD null model and the MDD and SCZ null model. 
 
The Nagelkerke’s pseudo-R2 and liikehood ratio test (LRT) P-values from the 
comparison of the stepwise (BIC) main effect model as fitted in the validation dataset 
are given in Table 36. 
 
Model R2 P-value 
Main effects (BIC) vs. Null model 0.000104 0.532 
Main effects (BIC) vs. MDD null model - - 
Main effect (BIC) vs. MDD and SCZ null model - - 
Table 36. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) main 
effect model as determined in the test dataset and fitted in the validation dataset, compared to the null 
model. 
 
We observe that neither the AIC or BIC selected main effect models show significant 
prediction in the validation dataset compared to the null model containing only the 
control variables. In addition, the AIC main effect model is not significant when 
compared to the MDD null model and the MDD and SCZ null model.  
 
5.3.4.2 PRS: Two-way interactions 
The Nagelkerke’s pseudo-R2 and likelihood ratio test (LRT) P-values from the 
comparison of the stepwise (AIC) two-way interaction model as fitted in the validation 




Model R2 P-value 
Interaction model (AIC) vs. Null model 0.0125 0.740 
Interaction model (AIC) vs. MDD null model 0.0125 0.707 
Interaction model (AIC) vs. MDD and SCZ null model 0.0118 0.775 
Table 37. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) two-
way interaction model as determined in the test dataset and fitted in the validation dataset, compared to 
the null model, the MDD null model and the MDD and SCZ null model. 
 
The Nagelkerke’s pseudo-R2 and likelihood ratio test (LRT) P-values from the 
comparison of the stepwise (BIC) two-way interaction model as fitted in the validation 
dataset are given in Table 38. 
 
Model R2 P-value 
Interaction model (BIC) vs. Null model 0.00114 0.119 
Interaction model (BIC) vs. MDD null model - - 
Interaction model (BIC) vs. MDD and SCZ null model - - 
Table 38. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) two-
way interaction model as determined in the test dataset and fitted in the validation dataset, compared to 
the null model. 
 
Again, we observe that neither the AIC nor BIC selected two-way interaction models 
replicate significantly in the validation dataset when compared to the null model. 
Likewise, for the AIC two-way interaction model compared to the MDD null model 
and the MDD and SCZ null model. 
 
5.3.5 Prediction models of MDD using phenotype-only data 
 
We now repeat the same procedure as for the PRS analyses above but using 
phenotype predictors instead, to test whether we can obtain better prediction with 
phenotype data alone. 
 
 190 
5.3.5.1 Neuroticism multi-trait analyses 
We first compare the use of the continuous neuroticism score (NEU) to that of using 
the 12 neuroticism endo-phenotypes in the prediction of MDD. Complete phenotype 
data across all 12 neuroticism endo-phenotypes were available on 10,219 individuals. 
We fit a logistic regression model of NEU predicting MDD case-control status, 
controlling for age and sex: 
 𝑀𝐷𝐷!"#"$! ~ 𝑁𝐸𝑈 + 𝐴𝑔𝑒 + 𝑆𝑒𝑥 
 
We compare this model to the null model containing only the age and sex covariates 
in a likelihood ratio test (LRT), as well as comparing the Nagelkerke’s pseudo-R2 
(see Table 39). 
 
Model R2 P-value 
NEU model vs. Null model 0.0561 1.33 x 10-56 
Table 39. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the neuroticism score 
model compared to the null model. 
 
Next, we fit a logistic regression model of the 12  neuroticism endo-phenotypes 
predicting MDD case/control status, controlling for age and sex:  
 𝑀𝐷𝐷!"#"$!  ~ 𝑀𝑆 +𝑀 + 𝐼 + 𝑆 + 𝐹𝑈 + 𝑁 +𝑊 + 𝑇 +𝑊𝑇𝐿 + 𝑆𝐹𝑁 + 𝐿 + 𝐺 + 𝐴𝑔𝑒 + 𝑆𝑒𝑥 
 
Table 40 details the comparison of this model with the null model in a likelihood ratio 






Model R2 P-value 
NEU component model vs. Null model 0.0650 2.23 x 10-55 
Table 40. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the neuroticism endo-
phenotype model compared to the null model. 
 
We also performed stepwise variable selection procedures on this model using both 
AIC and BIC as inclusion criterion. The resulting model from the AIC procedure is: 
 𝑀𝐷𝐷!"#"$!  ~ 𝑀𝑆 +𝑀 +𝑊 + 𝑇 + 𝑆𝐹𝑁 + 𝐿 + 𝐺 + 𝐴𝑔𝑒 + 𝑆𝑒𝑥 
 
The likelihood ratio test (LRT) P-value of the comparison of this model with the null 
model is given in Table 41, along with Nagelkerke’s pseudo-R2 for this model. 
 
Model R2 P-value 
NEU component model (AIC) vs. Null model 0.0644 1.26 x 10-58 
Table 41. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) 
neuroticism endo-phenotype model compared to the null model. 
 
The best-fitting model from the BIC variable selection procedure is: 
 𝑀𝐷𝐷!"#"$! ~ 𝑀𝑆 +  𝑀 +  𝑆𝐹𝑁 +  𝐺 +  𝐴𝑔𝑒 +  𝑆𝑒𝑥 
 
Table 42 details the likelihood ratio test (LRT) of the comparison of this model with 
the null model along with Nagelkerke’s pseudo-R2. 
 
Model R2 P-value 
NEU component model (BIC) vs. Null model 0.0613 2.43 x 10-58 
Table 42. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) 




We observe that for the model with all 12  neuroticism endo-phenotypes as 
predictors, and for both the models containing a subset of these predictors as 
determined by AIC and BIC variable selection criterion, the prediction of MDD 
case/control status is greater than that of using the continuous neuroticism score 
alone (these models all achieve a larger phenotypic variance explained). This 
suggests that taking a multivariate approach may yield better prediction, and that 
using stepwise variable selection procedures can inform us as to the subtypes of 
phenotypes that most correlate with the disease outcome and that should not be 
merely over-fit. 
 
5.3.5.2 Prediction of MDD using phenotype data 
Here we build predictive models of MDD case-control status using phenotype data 
alone. The phenotypes we consider are the 12 neuroticism endo-phenotypes, obesity 
and whether college was attended, and age and sex are used as control variables. 
Complete phenotype data were available for 8,459 individuals. 
 
5.3.5.3 Main effects models 
We perform the same variable selection procedures as with the PRS predictors but 
instead using the phenotype data to predict MDD case-control status. First we fit a 
logistic regression model with all phenotypes as predictors, controlling for age and 
sex: 
 𝑀𝐷𝐷!"#"$!  ~ 𝑀𝑆 +𝑀 + 𝐼 + 𝑆 + 𝐹𝑈 + 𝑁 +𝑊 + 𝑇 +𝑊𝑇𝐿 + 𝑆𝐹𝑁 + 𝐿 + 𝐺 + 𝑂𝑏𝑒𝑠𝑒+ 𝐶𝑜𝑙𝑙𝑒𝑔𝑒 + 𝐴𝑔𝑒 + 𝑆𝑒𝑥 
 
A forward and backward variable selection procedure was applied to this full model 
using both AIC and BIC criterion. The model selected based on AIC is: 
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𝑀𝐷𝐷!"#"$!  ~ 𝑀𝑆 +𝑀 + 𝑁 +𝑊 + 𝑇 + 𝑆𝐹𝑁 + 𝐿 + 𝐺 + 𝑂𝑏𝑒𝑠𝑒 + 𝐶𝑜𝑙𝑙𝑒𝑔𝑒 + 𝐴𝑔𝑒 + 𝑆𝑒𝑥 
 
We compare the fit of this model to that of the null model containing only the age and 
sex covariates in a likelihood ratio test (LRT). Table 43 details the results of the LRT 
as well as Nagelkerke’s pseudo-R2 for this model. 
 
Model R2 P-value 
Main effects (AIC) vs. Null model 0.0608 2.19 x 10-43 
Table 43. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) endo-
phenotype, obesity and college model compared to the null model. 
 
The best-fitting model selected based on BIC is: 
 𝑀𝐷𝐷!"#"$! ~ 𝑀𝑆 +  𝑆𝐹𝑁 +  𝐺 +  𝐴𝑔𝑒 +  𝑆𝑒𝑥 
 
Table 44 details the comparison of the fit of this model to that of the null model in a 
likelihood ratio test (LRT), as well as Nagelkerke’s pseudo-R2 for this model. 
 
Model R2 P-value 
Main effects model vs. Null model 0.0523 3.12 x 10-42 
Table 44. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) endo-
phenotype, obesity and college model compared to the null model. 
 
 
5.3.5.4 Two-way interactions 
We next fit a logistic regression model with all the same predictors as in the previous 
main effects model, but we also include two-way interactions between the 
phenotypes, as well as with the age and sex covariates. There are a total of 120 two-
way interaction terms in the model in addition to the 16 main effect terms and the 
control variables, on which the variable selection procedure is performed. 
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The stepwise variable selection two-way interaction model as determined by AIC is: 
 𝑀𝐷𝐷!"#"$! ~ 𝑀𝑆 +  𝑀 +  𝐼 +  𝑆 +  𝐹𝑈 +  𝑁 +  𝑊 +  𝑇 +  𝑊𝑇𝐿 +  𝑆𝐹𝑁 +    𝐿 +  𝐺  +  𝑂𝑏𝑒𝑠𝑒 +  𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝑀𝑆:𝑁 +  𝑀𝑆:𝐺 +  𝑀𝑆:𝐴𝑔𝑒 +  𝑀:𝑁 +  𝑀:𝑊 +  𝑀:𝑇 +  𝑀: 𝐿 +  𝑀: 𝑆𝑒𝑥 +  𝐼: 𝑆𝐹𝑁 +  𝐼: 𝐿 +  𝑆:𝐴𝑔𝑒 +  𝐹𝑈: 𝑆𝐹𝑁 +  𝐹𝑈:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝑁:𝑊 +  𝑇: 𝑆𝐹𝑁 +  𝑊𝑇𝐿: 𝐿 +  𝑊𝑇𝐿: 𝑆𝑒𝑥 +  𝑊𝑇𝐿:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 + 𝐿:𝐺 +  𝐿:𝐴𝑔𝑒 +  𝐺: 𝑆𝑒𝑥 +  𝐺:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝐴𝑔𝑒:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝑆𝑒𝑥:𝑂𝑏𝑒𝑠𝑒 +  𝐴𝑔𝑒 +  𝑆𝑒𝑥 
 
We compare the fit of this model to that of the null model containing only the age and 
sex covariates using a likelihood ratio test (LRT) and compare Nagelkerke’s pseudo-
R2 (see Table 45), as well as comparing with the full main effect model (all 
phenotypes included as predictors), and the AIC selected main-effect model. 
 
Model R2 P-value 
Interaction model (AIC) vs. Null model 0.0902 2.39 x 10-50 
Interaction model (AIC) vs. Full model 0.0289 4.46 x 10-13 
Interaction model (AIC) vs. Main effects (AIC) model 0.0295 3.78 x 10-12 
Table 45. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) 
neuroticism endo-phenotype, obesity and college two-way interaction model compared to the null 
model, the full model and the stepwise (AIC) model. 
 
The stepwise variable selection two-way interaction model as determined by BIC is: 
 𝑀𝐷𝐷!"#"$! ~ 𝑀𝑆 +  𝑀 +  𝐹𝑈 +  𝑁 +  𝑊𝑇𝐿 +  𝑆𝐹𝑁 +  𝐺 +  𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝑀:𝑁                                   + 𝐹𝑈:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝑊𝑇𝐿:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝐴𝑔𝑒 +  𝑆𝑒𝑥   
 
Table 46 details the comparison of this model to that of the null model containing 
only the age and sex covariates using a likelihood ratio test (LRT) and Nagelkerke’s 
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pseudo-R2, as well as a comparison with the BIC selected main effect model. We did 
not compare to the full model here, as not all predictors were retained in the model. 
 
Model R2 P-value 
Interaction model (BIC) vs. Null model 0.0639 3.79 x 10-45 
Interaction model (BIC) vs. Main effects (BIC) model 0.0115 6.14 x 10-7 
Table 46. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) 
neuroticism endo-phenotype, obesity and college two-way interaction model compared to the null model 
and the stepwise (BIC) model. 
 
 
5.3.6 Validation of phenotype models 
 
As with the PRS predictive models, we now aim to validate the models built in the 
test dataset using the phenotypic data only. 
 
5.3.6.1 Neuroticism multi-trait models 
We perform the same comparison models of the total neuroticism score (NEU) 
predicting MDD and the 12  neuroticism endo-phenotypes predicting MDD in the 
validation dataset. 
 
The likelihood ratio test (LRT) of the NEU score model compared to the null model 
containing only age and sex as predictors, as well as Nagelkerke’s pseudo-R2 for this 
model, are given in Table 47. 
 
Model R2 P-value 
NEU model vs. Null model 0.0484 4.55 x 10-48 
Table 47. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the neuroticism score 




The likelihood ratio test (LRT) for the model with the 12  neuroticism endo-
phenotypes as predictors compared to the null model, as well as Nagelkerke’s 
pseudo-R2 for this model, are given in Table 48. 
 
Model R2 P-value 
NEU component model vs. Null model 0.0580 1.35 x 10-47 
Table 48. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the neuroticism endo-
phenotype model compared to the null model in the validation dataset. 
 
Table 49 details the likelihood ratio test (LRT) results and the Nagelkerke’s pseudo-
R2 for the AIC selected neuroticism endo-phenotype model as fitted in the validation 
dataset. 
 
Model R2 P-value 
NEU component model (AIC) vs. Null model 0.0572 1.54 x 10-50 
Table 49. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the AIC selected 
neuroticism endo-phenotype model compared to the null model in the validation dataset. 
 
Table 50 details the likelihood ratio test (LRT) results and the Nagelkerke’s pseudo-
R2 for the BIC selected neuroticism endo-phenotype model as fitted in the validation 
dataset. 
 
Model R2 P-value 
NEU component model (BIC) vs. Null model 0.0515 1.07 x 10-47 
Table 50. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the BIC selected 
neuroticism endo-phenotype model compared to the null model in the validation dataset. 
 
We see that in all cases the models replicate in the independent validation dataset, 
and that the models built using the 12 neuroticism endo-phenotypes (and subsets) 
provide better prediction of MDD case/control status than using the total neuroticism 
score. 
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5.3.6.2 Main effect models 
We now rebuild the phenotype predictor models of MDD case/control status in the 
validation dataset. 
 
The Nagelkerke’s pseudo-R2 and likelihood ratio test (LRT) P-values from the 
comparison of the stepwise (AIC) main effect model with the null model as fitted in 
the validation dataset are given in Table 51. 
 
Model R2 P-value 
Main effects model (AIC) vs. Null model 0.0646 8.65 x 10-47 
Table 51. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) 
neuroticism endo-phenotype, obesity and college model compared to the null model in the validation 
dataset. 
 
Similarly, the results of the likelihood ratio test (LRT) of the BIC selected main effect 
model from the test dataset as fitted in the validation dataset are given in Table 52. 
 
Model R2 P-value 
Main effects model (BIC) vs. Null model 0.0450 1.88 x 10-36 
Table 52. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) 
neuroticism endo-phenotype, obesity and college model compared to the null model in the validation 
dataset. 
 
We observe that for both the AIC and BIC selected main effect models, the models 
are significantly replicated in the independent validation dataset, and from these 
results the AIC penalty appears to be most appropriate because the model from the 
AIC procedure is more predictive than that from the BIC. 
 
5.3.6.3 Two-way interactions 
Next we fit the AIC selected two-way interaction model in the independent validation 
dataset, and compare this model to the null model containing only age and sex 
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covariates, as well as the full model that includes all phenotype predictors and the 
stepwise main effects model, which was the result of the AIC variable selection 
procedure in the test dataset. The Nagelkerke’s pseudo-R2 and likelihood ratio test 
(LRT) P-values from these comparisons are given in Table 53. 
 
Model R2 P-value 
Interaction model (AIC) vs. Null model 0.0728 8.69 x 10-38 
Interaction model (AIC) vs. Full model 0.00695 0.317 
Interaction model (AIC) vs. Main effects (AIC) model 0.00812 0.309 
Table 53. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) 
neuroticism endo-phenotype, obesity and college two-way interaction model compared to the null 
model, the full model and the stepwise (AIC) model in the validation dataset. 
 
We perform the same validation for the BIC selected two-way interaction model, this 
time comparing only to the null model and the BIC selected stepwise main effect 
model (see Table 54). We do not compare to the full model here as not all phenotype 
predictors were retained in the model. 
 
Model R2 P-value 
Interaction model (BIC) vs. Null model 0.0595 5.18 x 10-42 
Interaction model (BIC) vs. Stepwise model 0.0146 3.42 x 10-9 
Table 54. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) 
neuroticism endo-phenotype, obesity and college two-way interaction model compared to the null model 
and the stepwise (BIC) model in the validation dataset. 
 
We observe that, while the AIC selected two-way interaction model offers 
significantly greater prediction when compared to the null model in the validation 
dataset, the prediction is not significantly greater than the full main effects model 
(containing all phenotype predictors), or the AIC selected main effect model. This 
suggests that the model chosen by the AIC variable selection procedure in the test 
dataset was over fit, and thus does not replicate in an independent dataset. 
 199 
For the BIC selected two-way interaction model, we see that for both the comparison 
with the null model and with the BIC selected main effect model, the BIC selected 
two-way interaction model offers better prediction of MDD case-control status. Using 
BIC as selection criteria is a more stringent approach, and will most often result in 
fewer predictors being retained in the model. This reduces the chance of over fitting, 
thus maximising the chance of replication in an independent dataset. However, when 
fitting main effects models we observed that using AIC lead to a more predictive 
model than the BIC interaction model. These results suggest that the AIC selected 
main effect model would be the best, and most reliable, model for future prediction. 
 
5.3.7 Prediction models of MDD using phenotypes and MDD PRS  
 
Given the significant replication of the MDD prediction models using only phenotype 
predictors, we next build predictive models with phenotype data, but also including 
the MDD PRS. We follow the same procedure as described earlier, testing both main 
effect and interaction models. We first build predictive models using the 12 
neuroticism endo-phenotypes, obesity and college phenotypes, and the MDD PRS, 
since the next step to improve prediction of MDD over the MDD PRS could 
conceivably be to add in correlated phenotype predictors. We also investigate 
building a predictive model using the 12 neuroticism endo-phenotypes and multiple 
genetic predictors, specifically the MDD, SCZ, obesity and college PRS, as we are 
interested in investigating whether the interaction between ‘environmental’ predictors, 
such as the neuroticism endo-phenotypes, and genetic factors can improve the 





5.3.7.1 Main effect models 
We fit a logistic regression model of the 12 neuroticism endo-phenotypes, obesity 
and college phenotypes, and MDD PRS predicting MDD case/control status, 
controlling for age and sex and the top 15 PCs:  
 𝑀𝐷𝐷!"#"$!  ~ 𝑀𝑆 +𝑀 + 𝐼 + 𝑆 + 𝐹𝑈 + 𝑁 +𝑊 + 𝑇 +𝑊𝑇𝐿 + 𝑆𝐹𝑁 + 𝐿 + 𝐺 + 𝑂𝑏𝑒𝑠𝑒+ 𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +𝑀𝐷𝐷!"# + 𝐴𝑔𝑒 + 𝑆𝑒𝑥 + 𝑃𝐶! +⋯+ 𝑃𝐶!" 
 
A forward and backward variable selection procedure was applied to this full model 
using both AIC and BIC criterion. The best-fitting model selected based on AIC is: 
 𝑀𝐷𝐷 !"#"$! ~  𝑀𝑆 +  𝑀 +  𝑁 +  𝑊 +  𝑇 +  𝑆𝐹𝑁 +  𝐿 +  𝐺 +   𝑂𝑏𝑒𝑠𝑒 +  𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝑀𝐷𝐷!"# +  𝐴𝑔𝑒 +  𝑆𝑒𝑥 +  𝑃𝐶! +⋯+ 𝑃𝐶!" 
 
We compare the fit of this model to that of the null model containing only the age, sex 
and top 15 PCs in a likelihood ratio test (LRT), as well as to the MDD null model 
containing the control variables and MDD PRS. Table 55 details the results of the 
LRT as well as Nagelkerke’s pseudo-R2 for this model.  
Model R2 P-value 
Main effects (AIC) vs. Null model 0.0617 8.12 x 10-44 
Main effects (AIC) vs. MDD Null model 0.0607 1.01 x 10-43 
Table 55. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) 
neuroticism endo-phenotype and MDD PRS model compared to the null model and MDD null model. 
 
The best-fitting model selected based on BIC is: 
 𝑀𝐷𝐷!"#"$!  ~  𝑀𝑆 +  𝑆𝐹𝑁 +  𝐺 +  𝐴𝑔𝑒 +  𝑆𝑒𝑥 +  𝑃𝐶! +⋯+ 𝑃𝐶!" 
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This model contains the same phenotype predictors as the best-fitting model based 
on the stepwise (BIC) procedure performed earlier on the 12  neuroticism endo-
phenotypes. We compare the fit of this model to that of the null model containing only 
the age, sex and top 15 PCs in a likelihood ratio test (LRT). Table 56 details the 
results of the LRT as well as Nagelkerke’s pseudo-R2 for this model. 
 
Model R2 P-value 
Main effects (BIC) vs. Null model 0.0519 3.57 x 10-42 
Table 56. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) 
neuroticism endo-phenotype and MDD PRS model compared to the null model. 
 
 
5.3.7.2 Two-way interactions 
We next fit a logistic regression model with the same predictors as in the previous 
main effects model, but we also include two-way interactions between the 
phenotypes and PRS predictors, as well as with the age and sex covariates. There 
are a total of 136 two-way interaction terms in addition to the 15 main effect terms 
and the control variables in the model, on which the variable selection procedures 
are performed. 
 
The stepwise variable selection two-way interaction model as determined by AIC is: 
 𝑀𝐷𝐷!"#"$! ~ 𝑀𝑆 +  𝑀 +  𝐼 +  𝑆 +  𝐹𝑈 +  𝑁 +  𝑊 +  𝑇 +  𝑊𝑇𝐿 +  𝑆𝐹𝑁 +  𝐿 +  𝐺 +  𝑂𝑏𝑒𝑠𝑒 +  𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝑀𝐷𝐷!"# +  𝑀𝑆:𝐴𝑔𝑒 +  𝑆:𝐴𝑔𝑒 +  𝐿:𝐴𝑔𝑒 +  𝐴𝑔𝑒:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝑀: 𝑆𝑒𝑥 +  𝑇: 𝑆𝑒𝑥 +  𝐺: 𝑆𝑒𝑥 +  𝑆𝑒𝑥:𝑂𝑏𝑒𝑠𝑒 +  𝑀𝑆:𝑁 +  𝑀𝑆:𝐺 +  𝑀𝑆:𝑀𝐷𝐷!"#  +  𝑀:𝑁 +  𝑀:𝑊 +  𝑀:𝑇 +  𝑀: 𝐿 +  𝐼: 𝑆𝐹𝑁 +  𝐼: 𝐿 +  𝐹𝑈: 𝑆𝐹𝑁 +  𝐹𝑈:𝐺 +  𝐹𝑈:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝑁:𝑊 +  𝑇: 𝑆𝐹𝑁 +  𝑊𝑇𝐿:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝑊𝑇𝐿:𝑀𝐷𝐷!"# +  𝐺:𝐶𝑜𝑙𝑙𝑒𝑔𝑒 +  𝐺:𝑀𝐷𝐷!"# +  𝐴𝑔𝑒 +  𝑆𝑒𝑥 +  𝑃𝐶! +⋯+ 𝑃𝐶!" 
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We compare the fit of this model to that of the null model, the MDD null model and 
the stepwise (AIC) model of main effects. Table 57 details the results of the LRTs as 
well as Nagelkerke’s pseudo-R2 for this model. 
 
Model R2 P-value 
Interaction model (AIC) vs. Null model 0.0949 6.14 x 10-53 
Interaction model (AIC) vs. MDD null model 0.0939 1.10 x 10-52 
Interaction model (AIC) vs. Main effects (AIC) model 0.0332 4.06 x 10-14 
Table 57. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) 
neuroticism endo-phenotype and MDD PRS two-way interaction model compared to the null model, 
MDD null model and the stepwise (AIC) main effect model. 
 
The stepwise variable selection two-way interaction model as determined by BIC is: 
 𝑀𝐷𝐷!"#"$! ~ 𝑀𝑆 +  𝑀 +  𝑁 +  𝑆𝐹𝑁 +  𝐺 +  𝑀𝐷𝐷!"#  +  𝑀:𝑁 +  𝐺:𝑀𝐷𝐷!"#  +  𝐴𝑔𝑒 +  𝑆𝑒𝑥 +  𝑃𝐶! +⋯+ 𝑃𝐶!" 
 
We compare the fit of this model to that of the null model, the MDD null model and 
the stepwise (BIC) model of main effects. Table 58 details the results of the LRTs as 
well as Nagelkerke’s pseudo-R2 for this model. 
 
Model R2 P-value 
Interaction model (BIC) vs. Null model 0.0621 2.60 x 10-46 
Interaction model (BIC) vs. MDD null model 0.0611 2.75 x 10-46 
Interaction model (BIC) vs. Main effects (BIC) model 0.0103 2.09 x 10-7 
Table 58. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) 
neuroticism endo-phenotype and MDD PRS two-way interaction model compared to the null model, 





5.3.8 Validation of phenotype and MDD PRS models 
 
As with the PRS predictive models and phenotype predictive models, we now aim to 
validate the models built in the test dataset using the phenotype data and MDD PRS. 
 
5.3.8.1 Main effect models 
The Nagelkerke’s pseudo-R2 and likelihood ratio test (LRT) P-values from the 
comparison of the stepwise (AIC) main effect model with the null model as fitted in 
the validation dataset are given in Table 59. 
 
Model R2 P-value 
Main effects (AIC) vs. Null model 0.0645 3.92 x 10-46 
Main effects (AIC) vs. MDD null model 0.0645 7.74 x 10-47 
Table 59. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) 
neuroticism endo-phenotype and MDD PRS model compared to the null model and MDD null model in 
the validaton dataset. 
 
Similarly, the results of the likelihood ratio test (LRT) of the BIC selected main effect 
model from the test dataset as fitted in the validation dataset are given in Table 60. 
 
Model R2 P-value 
Main effects (BIC) vs. Null model 0.0449 1.83 x 10-36 
Table 60. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) 
neuroticism endo-phenotype and MDD PRS model compared to the null model in the validation dataset. 
 
We observe that both the AIC and BIC selected main effect models are significantly 
replicated in the independent validation dataset. These results would suggest that 
the AIC penalty appears to be most appropriate as the model selected based on AIC 




5.3.8.2 Two-way interactions 
The Nagelkerke’s pseudo-R2 and likelihood ratio test (LRT) P-values from the 
comparison of the stepwise (AIC) interaction model with the null model, MDD null 
model and the stepwise (AIC) main effect model as fitted in the validation dataset are 
given in Table 61. 
 
Model R2 P-value 
Interaction model (AIC) vs. Null model 0.0735 3.31 x 10-37 
Interaction model (AIC) vs. MDD null model 0.0735 1.24 x 10-37 
Interaction model (AIC) vs. Main effects (AIC) model 0.00901 0.252 
Table 61. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) 
neuroticism endo-phenotype and MDD PRS two-way interaction model compared to the null model, 
MDD null model and the stepwise (AIC) main effect model in the validation dataset. 
 
The Nagelkerke’s pseudo-R2 and likelihood ratio test (LRT) P-values from the 
comparison of the stepwise (BIC) interaction model with the null model, MDD null 
model and the stepwise (BIC) main effect model as fitted in the validation dataset are 
given in Table 62. 
 
Model R2 P-value 
Interaction model (BIC) vs. Null model 0.0564 9.00 x 10-42 
Interaction model (BIC) vs. MDD null model 0.0564 1.57 x 10-42 
Interaction model (BIC) vs. Main effects (BIC) model 0.0116 2.06 x 10-8 
Table 62. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) 
neuroticism endo-phenotype and MDD PRS two-way interaction model compared to the null model, 
MDD null model and the stepwise (BIC) main effect model in the validation dataset. 
 
We observe that the AIC selected interaction model is significant when compared to 
the null model and MDD null model in the validation dataset, but is not significant 
when compared to the stepwise AIC selected main effect model. The BIC selected 
interaction model significantly replicates in the validation dataset when compared to 
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the null model, the MDD null model and the stepwise BIC selected main effect 
model. These results further suggest that the BIC penalty appears to be most 
appropriate when considering interaction terms as the BIC selected interaction model 
provides additional variance explained on the BIC selected main effect model, and 
replicates in independent data. The AIC selected main effect model does, however, 
explain a greater amount of variance than the BIC selected interaction model, 
suggesting that the AIC main effect model would provide the greatest prediction of 
MDD case/control status. 
 
5.3.9 Prediction models of MDD using phenotypes and multiple PRS 
 
In the previous stepwise procedures, we see that building predictive models of MDD 
using only PRS predictors does not lead to replication in independent data, despite 
the individual PRS replicating. In contrast, when we use phenotype predictors only, 
the predictive models replicate in independent data, and when we use phenotype 
predictors and include the MDD PRS as a predictor, we also observe replication 
(though not for the AIC stepwise interaction model). 
 
We next extend the predictive models of the previous section to use the neuroticism 
endo-phenotype predictors and PRS predictors for MDD, SCZ, obesity and college. 
We follow the same procedure as described earlier, testing both main effect and 
interaction models. 
 
5.3.9.1 Main effect models 
We fit a logistic regression model with the 12 neuroticism endo-phenotypes and PRS 
for MDD, SCZ, obesity and college predicting MDD case/control status, controlling 
for age and sex and the top 15 PCs:  
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𝑀𝐷𝐷 !"#"$! ~ 𝑀𝑆 +  𝑀 +  𝐼 +  𝑆 +  𝐹𝑈 +  𝑁 +  𝑊 +  𝑇 +  𝑊𝑇𝐿 +  𝑆𝐹𝑁 +  𝐿 +  𝐺 +   𝑀𝐷𝐷!"# +  𝑆𝐶𝑍!"# +  𝑂𝑏𝑒𝑠𝑒!"# +  𝐶𝑜𝑙𝑙𝑒𝑔𝑒!"# +  𝐴𝑔𝑒 +  𝑆𝑒𝑥 +  𝑃𝐶!+⋯+ 𝑃𝐶!" 
 
A forward and backward variable selection procedure is applied to this full model 
using both AIC and BIC criterion. The best-fitting model selected based on AIC is: 
 𝑀𝐷𝐷 !"#"$! ~ 𝑀𝑆 +  𝑀 +  𝑁 +  𝑊 +  𝑇 +  𝑆𝐹𝑁 +  𝐿 +  𝐺 +   𝑀𝐷𝐷!"# +  𝐴𝑔𝑒 +  𝑆𝑒𝑥 +  𝑃𝐶! +⋯+ 𝑃𝐶!" 
 
We compare the fit of this model to that of the null model and the MDD null model. 
Table 63 details the results of the likelihood ratio test (LRT) as well as Nagelkerke’s 
pseudo-R2 for this model. 
 
Model R2 P-value 
Main effects (AIC) vs. Null model 0.0582 2.25 x 10-42 
Main effects (AIC) vs. MDD null model 0.0572 2.60 x 10-42 
Table 63. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) 
neuroticism endo-phenotype, MDD, SCZ, Obese and College PRS model compared to the null model 
and MDD null model. 
 
The best-fitting model selected based on BIC is: 
 𝑀𝐷𝐷!"#"$! ~ 𝑀𝑆 +  𝑆𝐹𝑁 +  𝐺 +  𝐴𝑔𝑒 +  𝑆𝑒𝑥 +  𝑃𝐶! +⋯+ 𝑃𝐶!" 
 
This model is the same BIC selected main effect model as in the previous section, as 
well as containing the same predictors from the BIC variable selection procedure on 
the phenotype predictor main effect model. We compare the fit of this model to that 
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of the null model and Table 64 details the results of the LRT as well as Nagelkerke’s 
pseudo-R2 for this model. 
 
Model R2 P-value 
Main effects (BIC) vs. Null model 0.0519 3.57 x 10-42 
Table 64. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) 
neuroticism endo-phenotype, MDD, SCZ, Obese and College PRS model compared to the null model 
and MDD null model. 
 
 
5.3.9.2 Two-way interactions 
We next fit a logistic regression model with all the same predictors as in the previous 
main effects model, but we also include two-way interactions between the 
phenotypes and PRS predictors, and with the age and sex covariates. There are a 
total of 153 two-way interaction terms in the model in addition to the 16 main effect 
terms and the control variables, on which the variable selection procedure is 
performed. 
 
The stepwise variable selection two-way interaction model as determined by AIC is:  𝑀𝐷𝐷!"#"$! ~ 𝑀𝑆 +  𝑀 +  𝐼 +  𝑆 +  𝐹𝑈 +  𝑁 +  𝑊 +  𝑇 +  𝑊𝑇𝐿 +  𝑆𝐹𝑁 + 𝐿 +  𝐺 +   𝑀𝐷𝐷!"#  +  𝑆𝐶𝑍!"#  +  𝑂𝐵𝐸𝑆𝐸!"#  +  𝐶𝑂𝐿𝐿𝐸𝐺𝐸!"#  +  𝑀𝑆:𝐴𝑔𝑒 +  𝑆:𝐴𝑔𝑒 +  𝐿:𝐴𝑔𝑒 +  𝐴𝑔𝑒:𝐶𝑂𝐿𝐿𝐸𝐺𝐸!"#  +  𝑀: 𝑆𝑒𝑥 +  𝑀𝑆:𝑁 +  𝑀𝑆:𝑊𝑇𝐿 +  𝑀𝑆:𝐺 +  𝑀𝑆:𝑀𝐷𝐷!"#  +  𝑀:𝑁 +  𝑀:𝑊 +  𝑀:𝑇 +  𝑀: 𝐿 +  𝑀: 𝑆𝐶𝑍!"#  +  𝐼: 𝑆𝐹𝑁 +  𝐼: 𝐿 +  𝐼: 𝑆𝐶𝑍!"#  +  𝐼:𝐶𝑂𝐿𝐿𝐸𝐺𝐸!"#  +  𝑆: 𝑆𝐶𝑍!"#  +  𝑆:𝑂𝐵𝐸𝑆𝐸!"#  +  𝐹𝑈: 𝑆𝐹𝑁 +  𝐹𝑈:𝐺 +  𝐹𝑈: 𝑆𝐶𝑍!"#  +  𝑁:𝑊 +  𝑁:𝑂𝐵𝐸𝑆𝐸!"#  +  𝑊:𝑂𝐵𝐸𝑆𝐸!"#  +  𝑇: 𝑆𝐹𝑁 +  𝑇:𝐶𝑂𝐿𝐿𝐸𝐺𝐸!"#  +  𝑊𝑇𝐿: 𝐿 +  𝑊𝑇𝐿:𝑀𝐷𝐷!"#  +  𝐿: 𝑆𝐶𝑍!"#  +  𝐺:𝑀𝐷𝐷!"#  +  𝐺:𝑂𝐵𝐸𝑆𝐸!"#  +  𝑀𝐷𝐷!"#:𝑂𝐵𝐸𝑆𝐸!"# + 𝐴𝑔𝑒 +  𝑆𝑒𝑥 +  𝑃𝐶! +⋯+ 𝑃𝐶!" 
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We compare the fit of this model to that of the null model, the MDD null model, the 
MDD and SCZ null model, and the stepwise (AIC) selected main effect model. The 
results of the LRT as well as Nagelkerke’s pseudo-R2 for this model are given in  
Table 65. 
 
Model R2 P-value 
Interaction model (AIC) vs. Null model 0.0957 2.02 x 10-49 
Interaction model (AIC) vs. MDD null model 0.0947 3.82 x 10-49 
Interaction model (AIC) vs. MDD and SCZ null model 0.0939 4.99 x 10-49 
Interaction model (AIC) vs. Main effects (AIC) model 0.0376 1.55 x 10-13 
Table 65. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) 
neuroticism endo-phenotype, MDD, SCZ, Obese and College PRS two-way interaction model compared 
to the null model, the MDD null model, and the stepwise (AIC) main effect model. 
 
The best-fitting model selected based on BIC is: 
 𝑀𝐷𝐷!"#"$! ~ 𝑀𝑆 +  𝑀 +  𝑁 +  𝑇 +  𝑆𝐹𝑁 +  𝐺 +  𝑀𝐷𝐷!"#  +  𝐶𝑂𝐿𝐿𝐸𝐺𝐸!"#  +  𝑀:𝑁 +  𝑇:𝐶𝑂𝐿𝐿𝐸𝐺𝐸!"#  +  𝐺:𝑀𝐷𝐷!"# + 𝐴𝑔𝑒 + 𝑆𝑒𝑥 + 𝑃𝐶! +⋯+ 𝑃𝐶!"    
We compare the fit of this model to that of the null model, the MDD null model and 
the stepwise (BIC) selected main effect model. The results of the LRT and 
Nagelkerke’s pseudo-R2 for this model are given in Table 66.  
Model R2 P-value 
Interaction model (BIC) vs. Null model 0.0657 5.70 x 10-47 
Interaction model (BIC) vs. MDD null model 0.0646 6.92 x 10-47 
Interaction model (BIC) vs. Main effects (BIC) model 0.0138 1.17 x 10-8 
Table 66. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) 
neuroticism endo-phenotype, MDD, SCZ, Obese and College PRS two-way interaction model compared 




5.3.10 Validation of phenotype and multiple PRS models 
 
We now rebuild the models fitted in the test dataset in the validation dataset to 
investigate whether they replicate in independent data. 
 
5.3.10.1 Main effect model 
We compare the fit of the AIC selected main effect model to the null model and the 
MDD null model as fitted in the validation dataset. The results of the LRTs and 
Nagelkerke’s pseudo-R2 for the model are given in Table 67. 
 
Model R2 P-value 
Main effects (AIC) vs. Null model 0.0617 2.84 x 10-45 
Main effects (AIC) vs. MDD null model 0.0617 5.07 x 10-46 
Table 67. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) 
neuroticism endo-phenotype, MDD, SCZ, Obese and College PRS model compared to the null model 
and MDD null model in the validation dataset. 
 
We compare the fit of the BIC selected main effect model to the null model as fitted 
in the validation dataset. The results of the LRT and Nagelkerke’s pseudo-R2 for the 
model are given in Table 68. 
 
Model R2 P-value 
Main effects (BIC) vs. Null model 0.0449 1.83 x 10-36 
Table 68. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) 
neuroticism endo-phenotype, MDD, SCZ, Obese and College PRS model compared to the null model 
and MDD null model in the validation dataset. 
 
5.3.10.2 Two-way interactions 
We compare the fit of the AIC selected interaction model to the null model, the MDD 
null model, the MDD and SCZ null model and the stepwise AIC main effect model as 
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fitted in the validation dataset. The results of the LRTs and Nagelkerke’s pseudo-R2 
for the model are given in Table 69. 
 
Model R2 P-value 
Interaction model (AIC) vs. Null model 0.0756 5.03 x 10-35 
Interaction model (AIC) vs. MDD null model 0.0756 2.06 x 10-35 
Interaction model (AIC) vs. MDD and SCZ null model 0.0748 2.84 x 10-35 
Interaction model (AIC) vs. Main effects (AIC) model 0.0139 0.0909 
Table 69. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (AIC) 
neuroticism endo-phenotype, MDD, SCZ, Obese and College PRS two-way interaction model compared 
to the null model, the MDD null model, and the stepwise (AIC) main effect model in the validation 
dataset. 
 
We compare the fit of the BIC selected interaction model to the null model, the MDD 
null model, and the stepwise BIC main effect model as fitted in the validation dataset. 
The results of the LRTs and Nagelkerke’s pseudo-R2 for the model are given in  
Table 70. 
 
Model R2 P-value 
Interaction model (BIC) vs. Null model 0.0594 5.09 x 10-42 
Interaction model (BIC) vs. MDD null model 0.0594 1.05 x 10-42 
Interaction model (BIC) vs. Main effects (BIC) model 0.0145 3.44 x 10-9 
Table 70. Nagelkerke's pseudo-R2 and likelihood ratio test (LRT) P-value for the stepwise (BIC) 
neuroticism endo-phenotype, MDD, SCZ, Obese and College PRS two-way interaction model compared 
to the null model, the MDD null model, and the stepwise (BIC) main effect model in the validation 
dataset. 
 
Here we see the same pattern of replication as in the previous section. The AIC and 
BIC selected main effect models both replicate in the independent validation dataset. 
However, for the interaction models, the AIC and BIC models are significant 
compared to the null models, but only the BIC model provides significantly better 
prediction over the corresponding main effect model in the validation dataset.  That 
said, the AIC main effect model is again the model that provides the greatest 
 211 
variance explained out of all the replicated models, suggesting that the AIC selected 






In this study we applied stepwise variable selection procedures to logistic regression 
with multiple predictors, both genetic (PRS) and phenotypic, in order to establish a 
prediction model of MDD case/control status from UK Biobank data. We used both 
AIC and BIC criterion for variable selection in order to compare the approaches, and 
considered two-way interaction terms between our predictors. 
 
We built PRS for MDD, SCZ and for MDD comorbid traits: neuroticism (total score 
and the 12 endo-phenotypes), obesity and whether college was attended. Previous 
analyses into the predictive power of the MDD PRS have yielded disappointing 
results, and the SCZ PRS has even been shown to be a better predictor of MDD 
case/control status (Euesden et al., 2015). We therefore explored the use of multiple 
PRS as predictors of MDD case/control status. In order to investigate whether the 
interaction between the genetics of, for example, MDD and obesity associates with 
MDD case/control status, we considered the interaction between PRS. While the 
results from the prediction models in the test dataset seemed promising with greater 
phenotypic variance explained than the MDD PRS alone, the models did not 
replicate in the independent validation dataset. This suggests that both the AIC and 
BIC stepwise variable selection procedures produced models that were over-fit to the 
test data. Particularly with the two-way interaction terms, there is a substantial 
possibility that there are low numbers of individuals to which each interaction is 
applicable, thus potentially leading to over-fitting of the model. Furthermore, given 
such large sample sizes in the UK Biobank even small effects potentially have the 
power to be detected, which then have a low probability of being validated in 
independent data, since validation datasets are likely to be of a much smaller sample 
size and thus potentially underpowered to detect the same magnitude of effect. 
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Given that there are known phenotypic correlations between MDD and neuroticism, 
obesity and educational attainment (Smith et al., 2016; Okbay et al., 2016; Hung et 
al., 2015; Rivera et al., 2012; Bjelland et al., 2008), we also performed the same 
variable selection procedures using only the phenotype data. In contrast to the PRS 
predictive models, the phenotype main effect models (both AIC and BIC selected) did 
replicate in an independent dataset. While the AIC selected two-way interaction 
model did not replicate, the BIC selected two-way interaction model did. This 
suggests that using the more stringent BIC to determine the predictors to be included 
in the model, particularly when considering interaction terms, may yield a more 
robust predictive model with greater probability of replication in an independent 
dataset. Though generally the models resulting from BIC variable selection had lower 
pseudo-R2 values than the AIC selected equivalents, meaning that they explained 
less variance in MDD case/control status, the BIC selected models are likely to be 
more widely applicable.  
 
Finally, we investigated the use of a combination of phenotype and genetic predictors 
of MDD case/control status. For both the models using phenotypes and MDD PRS 
predictors, and the models using phenotypes, MDD, SCZ, obesity and college PRS 
predictors, we observed replication for both the AIC and BIC main effect models, 
while only the BIC interaction models replicated.  
 
From our investigation of building predictive models of MDD case/control status 
using PRS predictors and phenotype predictors, there was much greater replication 
of the predictive models when using the phenotype data. Given that the MDD PRS 
itself provides only modest prediction of MDD case/control status, building a 
predictive model of MDD using PRS of correlated traits is likely to be less powerful 
than using only the phenotypic data due to the genetic heterogeneity of MDD. 
Although our attempts to build a predictive model of MDD by considering 𝑃𝑅𝑆 × 𝑃𝑅𝑆 
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interactions did not replicate, we did achieve replication for models including 𝑃𝑅𝑆 × 𝑒𝑛𝑣𝑖𝑟𝑜𝑛𝑚𝑒𝑛𝑡 and 𝑒𝑛𝑣𝑖𝑟𝑜𝑛𝑚𝑒𝑛𝑡 × 𝑒𝑛𝑣𝑖𝑟𝑜𝑛𝑚𝑒𝑛𝑡 interaction terms. In the two-
way interaction (BIC) phenotype predictor model, we observed interactions of the 
fed-up feelings and worry too long phenotypes with the college phenotype; in the 
two-way interaction (BIC) phenotype and MDD PRS model, we retained interaction 
terms between miserableness and nervous feelings, and guilty feelings and the MDD 
PRS; finally, in the two-way interaction (BIC) phenotype and multiple PRS predictor 
model we observed interactions between the miserableness and nervous feelings 
phenotypes, the tense feelings phenotype and the college PRS, and the guilty 
feelings phenotype and the MDD PRS. Within genetic epidemiology, most research 
into interactions has involved the testing and discovery of 𝑔𝑒𝑛𝑒𝑡𝑖𝑐 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 × 𝑒𝑛𝑣𝑖𝑟𝑜𝑛𝑚𝑒𝑛𝑡 interactions (Caspi et al., 2003), but there has been minimal focus on 
investigating how the genome-wide genetic burden interacts with the environment 
(Mullins et al., 2016; Keers et al., 2016). The findings presented here provide an 
indication that these interactions may in fact often exist and contribute to the variance 
in human phenotypes. Therefore, this work highlights the need for further 
investigation into this, starting with replication using different phenotypes and data, to 
explore what impact interactions between genome-wide genetic burdens for certain 
traits and environmental risk factors have on physical disease and psychiatric 
disorders.  
 
Considering future developments in population-level genotyping and the growing 
surge towards ‘precision medicine’, it is likely that predictive models of disease will 
become more frequently developed and applied, which provided the motivation for 
this study. Genetic risk score approaches have been shown to provide improved 
prediction over existing predictors of type 2 diabetes risk (Läll et al., 2016), 
demonstrating the utility of this approach for the prediction of disease risk. The 
results from the phenotype data prediction models suggest that there is potentially 
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statistical power to be gained from performing multi-trait analyses on components 
and symptoms of major phenotypes rather than using binary summaries of them. 
However, the general challenge in predicting MDD from genetic data may have 
resulted in insufficient power in this study to demonstrate directly the benefit of multi-
trait PRS prediction of MDD. Although our PRS-only predictive models did not 
replicate in an independent dataset, if the same procedure were applied to a more 




6.  Discussion 
 
We have presented a variety of research developments and applications under the 
multiple phenotype theme, ranging from adjustments of univariate GWAS summary 
statistics to obtain multi-trait association P-values, to building prediction models of 
disease that incorporate genetic and environmental interactions. In each instance, 
we have demonstrated the utility in taking a multivariate approach to statistical 
modelling, taking care to account for the complexities introduced when transitioning 
from single-phenotype analyses. Overall, our findings suggest that taking a 
multivariate approach yields increased statistical power and greater understanding of 
the relationships underlying multiple correlated traits than single phenotype analyses 
alone. Considering phenotypes jointly can expose previously unknown connections 
that can aid in shaping the direction of future analyses, and bring us closer to the 
ultimate goal of understanding how the complex biological network underlying 
multiple diseases and traits operates. 
 
6.1 Multivariate simulation framework 
 
In Chapter 2, we set up a modelling framework for exploring the implications of 
modelling multiple phenotypes in the context of genome-wide association studies 
(GWAS). Motivated by the recent developments in multi-trait GWAS methodology 
and the lack of understanding into their relative performance in the field, we 
developed a simulation framework for generating multi-trait GWAS data with known 
causal genetic relationships for the benchmarking of multi-trait GWAS methods. 
When modelling only one trait with a causal genetic relationship relating to one SNP, 
the important considerations for genetic association testing are the sample size, the 
minor allele frequency of the SNP and the magnitude (and direction) of the genetic 
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effect from the SNP to the trait. Modelling multiple traits, however, produces extra 
dimensionality: the phenotypic correlation structure, and the interplay between these 
correlations and the combination of genetic effects on the traits. 
 
We developed a series of simulation scenarios that aimed to capture a large portion 
of the multivariate data landscape, in order to expose the similarities and differences 
between current multi-trait GWAS methodology. We built simulation scenarios where 
the genetic effects and phenotypic correlations were varied in a structured way, 
where they were varied more freely, and where the phenotypic correlations were 
reflective of the genetic effects on the traits. To perform simulations that closely 
matched reality, we also exploited publicly available summary data from univariate 
GWAS to inform the genetic effects, and used phenotypic correlations extracted 
directly from the Northern Finland Birth Cohort (NFBC1966). The main data-
generating model considered direct effects between the SNP and multiple 
quantitative traits, but we also modelled indirect genetic effects as well as binary 
traits. 
 
The simulation framework developed here is available as an open-source command 
line program to act as an aid in method development and benchmarking. We also 
provide an R shiny web-application (www.MultiTraitGWAS.kcl.ac.uk) that generates 
multivariate datasets that can be used for applications similar to those presented 
here. With minor modifications, data can be generated using our open-source 
software for any application concerning multiple correlated variables with some 
common associated factor.  
 
While we aimed to make the simulation scenarios implemented in our framework as 
extensive as possible, it inevitably could not be exhaustive, especially for multivariate 
simulations where there are infinite combinations of phenotypic correlations and 
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genetic effects. These limitations formed part of the motivation for creating the 
associated software package, so that it can be utilised by researchers in the future, 
and scenarios can be expanded upon as required. We also did not consider the 
simulation of correlated SNP data in linkage disequilibrium (LD). The focus of this 
study was single-SNP, multi-trait methods in order to isolate the methodological 
advances made by modelling multiple traits jointly, in comparison to the standard 
univariate approach. However, the software could be modified to model such data, 
and the performance of multi-SNP, multi-trait methods can thus be compared in a 
similar way. 
 
6.2 Multi-trait GWAS methods comparison 
 
The focus of Chapter 3 was to perform a comparison of the leading multi-trait GWAS 
methods by utilising the simulation framework developed in Chapter 2. Previous 
publications introducing new methodology (O’Reilly et al., 2012; van der Sluis et al., 
2013; Zhu et al., 2015; Aschard et al., 2014), or previous comparison studies 
(Galesloot et al., 2014), considered only a few methods or a small number of 
simulation scenarios, making it difficult to fully dissect and contrast the performance 
of existing methodology. This provided the motivation to develop a rigorous set of 
simulation scenarios, presented in Chapter 2, to fully test the performance of the 
methodology, thereby demystifying user choice and enabling higher-powered multi-
trait analyses in the future. 
 
In this comparison study, we compared the leading multi-trait GWAS methodology, 
consisting of two types of method: those that exploit existing GWAS summary 
statistics (O’Reilly et al., 2012; van der Sluis et al., 2013; Zhu et al., 2015) and those 
that utilise individual-level genotype-phenotype data (Ferreira and Purcell, 2009; 
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Nath and Pavur, 1985; O’Reilly et al., 2012; Aschard et al., 2014; Stephens, 2013; 
Marchini et al., 2007). Ten methods were compared in total, though further methods 
can be easily incorporated into our open-source software package. These methods 
were compared across all four scenarios implemented in the simulation framework, 
for varying numbers of traits, genetic effects and phenotypic correlations. 
 
The results of the comparison study suggest that the methods that utilise individual-
level genotype-phenotype data will, generally, optimise discovery power, based on 
the final, most realistic, scenario in the simulation framework where it was estimated 
that individual-level methods could yield twice the discovery of genetic variants over 
the summary statistic methods. However, summary data are likely to be available on 
much larger sample sizes than available in multi-trait GWAS panels, in particular in 
relation to case/control data. From simulations at a larger sample size for the 
summary statistic methods, we observed a substantial increase in power over the 
individual-level methods, suggesting that if summary statistics are available on much 
larger sample sizes then these methods will provide optimal discovery power. That 
said, the emergence of population-wide resources such as the UK Biobank means 
that multi-trait analyses on individual-level data will soon be able to match, and even 
exceed, the sample sizes of summary data, making the development of individual-
level multi-trait methods still an important area of research. As sample sizes grow, 
the main consideration in methodology development will be in reducing computation 
time to ensure methods are computationally feasible for application in these large 
population cohorts, especially since our results suggest that optimal power for multi-





6.3 Summary statistic GWAS 
 
Motivated by the results from our comparison study, where we observed that 
summary statistic GWAS methods could often achieve similar discovery power as 
methods that exploit individual-level data, and greater power with larger data publicly 
available, we performed a series of multi-trait analyses on publicly available GWAS 
summary statistics. From simulations of scenario S4b on two traits, as presented in 
Chapter 3, we observe in Figure 45 that with only modest gains in sample size the 




Figure 45. Power of the summary statistic method SHet from simulations of scenario S4b on two traits for 
varying sample sizes – the dotted line represents the power of the individual-level multi-trait GWAS 
methods for 5,000 samples. 
 
In recent years the availability of GWAS summary data has increased, though up to 
this point the main utility for these data has been in meta-analyses of the same trait 
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2012; Global Lipids Genetics Consortium, 2013), as well as for assessing the shared 
genetic aetiology between traits using polygenic risk scores (PRS) (Purcell et al., 
2009; Euesden et al., 2015; Dudbridge, 2013; Selzam et al., 2016; Krapohl et al., 
2015; Power et al., 2015) and the LD Score regression method (B. Bulik-Sullivan et 
al., 2015; B. K. Bulik-Sullivan et al., 2015). Multi-trait methods that exploit summary 
data to perform meta-analyses across traits have now been developed (Zhu et al., 
2015; Bolormaa et al., 2014; Zhu and Stephens, 2016), enabling existing data to be 
repurposed to boost the power to detect causal variants through the joint analysis of 
multiple correlated traits. 
 
We collected summary statistics from the largest GWAS to date on 19  traits, 
consisting of anthropometric, metabolic and psychiatric phenotypes. Next we 
developed our own summary statistic based multi-trait GWAS methods, MetaHom 
and MetaHet, introduced in this thesis, by extending existing methods to make them 
applicable to a mixture of quantitative and binary traits, while allowing for opposing 
directions of genetic effect on different traits (Zhu et al., 2015). Here we focused on 
the application of these two methods in particular, because the results of a 
comparison of several summary statistic methods that we conducted showed that 
MetaHom has greatest power when pleiotropic genetic effects exist, and MetaHet 
has highest power when heterogeneous genetic effects exist. By using a combination 
of these two methods, we expect to maximise our potential to uncover novel causal 
variants when the underlying genetic aetiology of the traits is unknown prior to the 
analyses. Multi-trait GWAS were performed on 16 correlated sets of traits, as well as 
on all 19 traits jointly. Novel associations were identified across the analyses, which 




Since performing this study, summary data on many more phenotypes has been 
made publicly available, meaning that the potential for further multi-trait analyses has 
expanded. The PhenoScanner online tool (Staley et al., 2016) will, in addition, 
facilitate the pooling of summary data across many traits, further aiding the utilisation 
of such data. Furthermore, with the release of the UK Biobank data, there is likely to 
be vast amounts of summary data resulting from univariate studies of this resource, 
aiding follow-up analyses and potentially leading to novel discoveries as 
demonstrated here. While we performed analyses on many traits, the phenotypes 
under study in this chapter are likely to be quite homogenous, for example the lipids 
and obesity measures. Thus, further multi-trait analyses across many more 
phenotypes will help to further paint the picture as to the performance of multi-trait 
summary statistic GWAS methods. 
 
This study highlights the utility of summary statistic data, and demonstrates that 
additional signal can be extracted by multi-trait analyses, and by applying the most 
appropriate summary statistic method for identifying genotype-phenotype 
relationships.  We can also gain further insight into the biology underlying multiple 
traits from such analyses; for example, MetaHom is highly powered to detect 
pleiotropic genetic effects, and so any genetic variant identified by the application of 
this method is likely to be a pleiotropic SNP, thus providing insight beyond that 
obtained from univariate GWAS. 
 
6.4 Prediction modelling using PRS 
 
An ultimate aim of genetics research is to understand the human genome sufficiently 
to be able to predict phenotypes given an individual’s DNA. If we are able to 
completely understand the biological network, its interactions with internal and 
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external factors, and the link between genetic variation and phenotypic outcomes 
then, in theory, we could build a highly powerful predictive model for any disease 
outcome. The field, however, is not at this point yet and as it stands there is still a 
large amount of phenotypic variance and heritability left unexplained. Polygenic risk 
scores (PRS), however, have shown signs of success for the prediction of diseases 
and traits from information on genetic risk of disease (Selzam et al., 2016; Krapohl et 
al., 2015; Power et al., 2015; Vassos et al., 2016). The most successful prediction of 
a behavioural trait using PRS has been in educational attainment, where the PRS for 
educational attainment was found to explain 9%  of the variance in educational 
achievement at age 16 (Selzam et al., 2016). The twin heritability of educational 
achievement has been estimated to be around 60% (Krapohl et al., 2014), and so the 
upper limit on the amount of variance a highly-powered PRS could explain is around 
this figure. While 9% may seem rather modest, this compares to ~1% of the variance 
explained by sex, and shows that the field is making real progress as larger sample 
sizes are obtained and as studies become more powerful. In contrast, similar 
success has not been observed for phenotypes such as MDD; the MDD PRS 
currently only explains 0.6% of the variance in MDD case/control status (Ripke et al., 
2013). Most PRS prediction models have been performed either within phenotype or 
between two phenotypes to assess their shared genetic aetiology (Purcell et al., 
2009; Euesden et al., 2015; Selzam et al., 2016). Given the multi-dimensionality of 
heterogeneous traits, taking a multivariate approach to prediction could yield greater 
success. 
 
In Chapter 5 we built predictive models of MDD using multiple PRS predictors 
computed from the UK Biobank, as well as comparing this approach to building 
predictive models using only phenotype data. We considered both the main effects 
and two-way interactions between the predictors in order to establish the most 
 224 
predictive model of MDD. We built models consisting of only PRS predictors, only 
phenotype predictors, and of a combination of PRS and phenotype predictors, 
implementing variable selection procedures to determine the most predictive models 
(AIC and BIC). We then replicated the models in an independent subset of the UK 
Biobank. We found that, although the PRS built in the validation dataset significantly 
predicted the trait that they were built on, the prediction models of MDD did not 
replicate, for both the main effects and the interaction models. Replication, however, 
was observed for the models using only phenotype predictors and the models using 
a combination of phenotypes and PRS, both for the main effects models and the BIC 
selected interaction models. There was no instance where the AIC selected 
interaction model replicated, suggesting that these models were over-fit to the test 
dataset. This also suggests that when considering interaction terms on these type of 
data, BIC may be the most appropriate variable selection criterion to prevent over-
fitting and improve the generalisability of the predictive model. When considering the 
interaction between different PRS, interaction terms could be retained in a model yet 
apply to only a small number of individuals in the dataset, thus leading to over-fitting. 
Furthermore, the size of the UK Biobank resource means there is sufficient power to 
detect small effects that are very specific to a subgroup of the total population. These 
particular issues are amplified when studying such a heterogeneous disorder as 
MDD, as there is likely to exist many subtypes that can be highlighted by interaction 
terms, but not be widely applicable to MDD as a whole. This approach applied to a 
more homogenous trait may achieve greater success. 
 
Even though the multiple PRS-only models did not replicate, we did achieve success 
using the phenotype data alone, as well as the models built using a combination of 
PRS and phenotype predictors. One of the phenotypes of particular interest in this 
study was neuroticism, due to its known association with MDD and their high 
phenotypic correlation (Smith et al., 2016; Kendler and Myers, 2010). The 
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neuroticism score is made up of 12 components, assessing different aspects of 
neuroticism. We performed analyses to assess whether greater prediction of MDD 
could be achieved from using these component measures as multiple predictors, 
instead of the one aggregated neuroticism score. We performed both AIC and BIC 
variable selection on the model with all 12 neuroticism components as predictors, 
and both of the resulting models offered greater prediction of MDD; the neuroticism 
score model explained 4.8% variance in MDD, whereas the AIC selected neuroticism 
component model explained 5.8% variance in MDD. By decomposing traits into their 
components, we can not only improve prediction but also gain greater understanding 
into the biology of the traits. The AIC variable selection procedure retained only a 
subset of the neuroticism components in the most predictive model, providing insight 
into the components that most associate with MDD. This information can be used to 
further guide the analysis of MDD as a phenotype, and highlight important factors for 
phenotyping and subtype analyses. Multivariate analyses, such as those presented 




6.5 Future work 
 
The field of genetic epidemiology is evolving rapidly. With new methodology being 
developed and new discoveries being made at a rapid pace, both now in relation to 
genetic association and genetic prediction, researchers must work dynamically as we 
learn more and more about the human genome. Due to such advances in 
understanding, there is always more to uncover with follow up analyses. One 
question answered can lead to the creation of several more as we delve further into 
the analysis of the genetic determinants of disease. 
 
6.5.1 Multi-SNP simulation and methods comparison 
 
Having developed a simulation framework as a platform for the comparison of multi-
trait, single-SNP GWAS methods, the next step is to extend this framework to 
incorporate the simulation of multiple SNPs associated with multiple phenotypes. The 
focus of multi-SNP methods (Bottolo et al., 2013; Zhou and Stephens, 2012; Kim et 
al., 2016) is to gain additional power by considering the association between sets of 
SNPs and multiple traits by reducing residual variation. Simulation of independent 
SNPs associated with multiple traits would be a simple extension of the main data-
generating model of Chapter 2. Instead here, for example, we may generate, say, 100 SNPs each explaining 0.01% of the variance in each trait (thus ℎ!   =  1% in 
total), ensuring that the residual error term accounts for 99% of the phenotypic 
variance. This holds under the assumption of small total ℎ!, but to simulate SNPs of 
larger total effect we would not be able to continue to approximate the phenotypic 
correlation by the residual correlation and instead would need to construct a proper, 
non-approximate, model using conditional expectations via application of Bayes’ 
formula. Alternatively, vast individual-level data resources, such as the UK Biobank, 
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could also be exploited to generate a large amount of highly realistic simulation data, 
for example by selecting SNPs at random and constructing traits by assuming a 
causal effect of the SNP(s) with certain heritability. The performance of multi-SNP, 
multi-trait methods can then be explored and help to guide the future direction of 
GWAS methodology. Given that there is a highly connected network of genetic 
interactions underlying most common diseases and traits, multi-SNP methods have 
the potential to uncover further insight into how these genetic interactions influence 
human diseases. As technology advances and modelling interactions between 
millions of SNPs across the genome becomes more computationally feasible, multi-
SNP methods will have an important role to play in the analysis of the effect genetic 
variation has on phenotypic outcomes. 
 
6.5.2 Multi-trait GWAS in the UK Biobank 
 
The results of our comparison of multi-trait GWAS methods suggested that, taking 
sample size into account, summary statistic GWAS methods were likely to provide 
the greatest discovery power. This provided the motivation for the application of 
summary statistic GWAS methods to publicly available summary data in Chapter 4. 
The application of these methods led to the identification of novel associations, which 
the separate univariate analyses did not have power to detect. However, the 
emergence of the UK Biobank resource, which has currently collected genotype data 
on around 140,000 individuals and is set to release genotype data on the full sample 
(around 500,000 individuals) in January 2017, will facilitate highly powered multi-trait 
analyses of individual-level data, exceeding the sample sizes of available summary 
data. The results of our simulations suggest that applying an individual-level data 
method on these data would optimise discovery power. We plan to perform multi-trait 
analyses on this resource using a range of individual-level methods, to act as a 
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further comparison of these methods on real data, but also to boost discovery power 
for the identification of causal genetic variants. We are particularly interested in 
building upon our analyses presented here to help leverage underpowered 
phenotypes, such as MDD, in order to further understand the genetic aetiology of 
heterogeneous disorders. An important challenge in the future will be fully exploiting 
both multi-trait individual-level resources, such as the UK Biobank, and summary 
data available from large-scale GWAS meta-analyses simultaneously, rather than 
using only one resource; multi-trait methods will be required to perform multi-trait 
analyses on each data type in a way that optimises power for each, and then 
appropriately combine the two sets of results to produce an overall result. 
 
6.5.3 Prediction modelling  
 
As the understanding of the human genome increases, prediction modelling will 
become an important area of research in genetic epidemiology, and research has 
been performed into the predictive utility of polygenic models (Chatterjee et al., 2013, 
2016). Relatively modest prediction has been achieved to date for heterogeneous 
disorders, such as MDD (Ripke et al., 2013), though large resources of genetic data 
will help to facilitate this. From our study focused on building a predictive model of 
MDD we were able to significantly predict MDD using only phenotype data, or a 
combination of phenotypes and genetic factors (PRS). However, the predictive 
models built only on PRS did not replicate in an independent validation dataset. We 
concluded that due to the heterogeneity of MDD, variable selection procedures on 
the PRS predictors were more likely to lead to over-fitting of the prediction models, 
though there are several other factors that could be contributing to lack of power. 
Diagnosis of MDD, for example, is challenging due to varying severities of the 
disorder, and the stigma associated with mental health and the barriers this causes 
in seeking medical help. In addition, while the pooling of individuals with mild single 
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episode depression with those who have lifelong problems will increase the sample 
size, this may not be the optimum study design, and it could be that treating them as 
two separate disorders may lead to increased power. As larger resources of data are 
collected, stratified analyses can be performed to identify more homogenous clinical 
sub-types. Given that our genetic prediction models did not replicate, we plan to 
apply the same approach to more homogenous disorders and those that have 
already shown reasonable predictive power from genetics, such as educational 
attainment, schizophrenia and obesity, to further explore the utility of multiple PRS 
predictors in predicting disease status. 
 
6.5.4 Rare variant analyses 
 
The GWAS study design has been shown to be a successful tool for the identification 
of common variants associated with complex disorders, yet despite the identification 
of thousands of genetic variants there still remains the problem of missing heritability 
(Manolio et al., 2009; Eichler et al., 2010; Lee et al., 2011). For type 2 diabetes, for 
example, GWAS have identified more than 70 genetic loci, yet only ~11% of the 
heritability is explained by these common variants (Morris et al., 2012; Lee et al., 
2014). Rare variants play an important role in Mendelian disorders, and there is now 
empirical evidence that rare variants could contribute to complex disorders (Rivas et 
al., 2011; Gudmundsson et al., 2012). The cost of whole-genome sequencing (WGS) 
now makes it possible to explore the effects of rare variants, but performing genome-
wide analyses of WGS data poses many statistical challenges and questions. There 
are many additional factors that come with WGS, one such example being read-
depth, and the trade-off between greater depth and larger sample size (Pasaniuc et 
al., 2012). In terms of methodology, the challenges arise in applying a method that 
can detect variants of low frequency. In theory the single variant design, as is 
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implemented in current GWAS, could be applicable for the study of rare variants. 
However, large sample sizes would be required in order to have sufficient statistical 
power, which in turn incurs extra cost. Instead a region or gene based approach is 
likely to yield greater success, based on the assumption that a locus containing one 
causal variant is likely to contain other causal variants nearby, as detailed in a review 
of current rare variant methodology (Lee et al., 2014). In the same way, a genetic 
variant or locus affecting one phenotype is likely to affect another correlated 
phenotype, as evidenced by recent research into genome-wide pleiotropy (Visscher 
and Yang, 2016; Solovieff et al., 2013). Therefore, multi-trait approaches could be 
even more beneficial in the analysis of rare variants, for which this sharing of 
information across different variants and traits may make the critical difference in 
power to produce discovery. As WGS becomes more frequently performed, the 
associated methodology should be rigorously benchmarked, as presented here, for 
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